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 Prefácio 
 
Eu acredito que cada pessoa tem a sua própria filosofia. Na minha filosofia há uma 
grande disposição para absorver a experiência da vida e com ela apreciar o mundo. 
Grande parte da minha satisfação pessoal provém das minhas opções profissionais. 
Há cinco anos atrás lancei um desafio. Candidatei-me a um programa doutoral. E 
tracei o meu caminho. Ao longo dele encontrei fraquezas, encontrei esperanças. E 
fui guardando tudo o que vi, tudo o que fiz. A minha tese reflecte o meu percurso 
destes cinco anos. 
Comecei o meu projecto de doutoramento no grupo Cancer Biology no IPATIMUP, 
o qual reportou uma elevada prevalência de mutações BRAF em carcinomas 
papilares da tiróide esporádicos e linhas celulares derivadas destes carcinomas. A 
procura de factores adicionais que explicassem a tumorigénese do cancro da 
tiróide potencialmente relacionadas com as mutações do BRAF e a descoberta de 
mutações no promotor da telomerase permitiram ao grupo explorar estas últimas 
mutações nas várias séries existentes no banco de tumores. Entretanto, enquanto 
outros elementos do grupo procuravam perceber mecanisticamente o efeito das 
mutações no promotor da telomerase, eu foquei-me no desenvolvimento de um 
modelo animal que permitisse inicialmente compreender o efeito de alterações 
frequentemente encontradas no cancro da tiróide (mutações nos genes BRAF e p53) 
e futuramente estudar factores adicionais que agora se sabem terem um papel 
relevante na tumorigénese tais como as mutações no promotor da telomerase. Por 
esta altura foi estabelecida uma colaboração com o grupo Telomeres and Genome 
Stability no IGC passando de uma ciência translacional para uma ciência básica. O 
desenvolvimento de um modelo para o estudo do efeito das mutações nos genes 
BRAF e p53 em peixe-zebra foi o fruto dessa colaboração. Deixarei um legado de 
ferramentas que muitos poderão usufruir.  
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Abstract 
 
Thyroid diseases are extremely frequent and are most often of benign nature. 
Thyroid cancer is the most common endocrine malignancy in humans and the 
majority of tumors harbor genetic alterations such as the BRAF mutation. Most of 
this mutation is an activating mutation in the kinase domain of the BRAF. In 
sporadic papillary thyroid carcinomas (PTCs), BRAF gene mutations are found in 
29%-83% of all cases and almost never co-exist with RAS mutations or RET 
(RET/PTC) and NTRK1 rearrangements. As a result of BRAF mutation, the MAPK 
pathway is activated and cellular processes such as proliferation, survival, motility 
and invasion are promoted. Recently, mutations in the telomerase reverse 
transcriptase (TERT) promoter have been described in thyroid cancer and 
considered one of the possible mechanisms that underlies TERT reexpression in 
several types of human tumors including those of the thyroid. 
In the first part of the thesis, I describe the study regarding TERT promoter 
mutations in which I was deeply involved. Our study highlighted the presence of 
recurrent somatic mutations in the TERT promoter in cancers of the central nervous 
system (43%), bladder (59%), thyroid (follicular cell-derived, 10%) and skin 
(melanoma, 29%). Concerning thyroid cancer, the presence of TERT promoter 
mutations was found to be significantly associated with higher TERT mRNA 
expression and with older age of the patients. We concluded that TERT promoter 
mutations are relatively frequent in several specific types of human cancer and that 
such mutations may enhance expression of telomerase. 
Over the years, thyroid cancer has been studied using mice models. These models 
have provided evidence showing that thyroid-specific expression of BRAFV600E 
induced goiter as well as invasive PTCs which progress to poorly differentiated 
carcinoma closely recapitulating some human thyroid tumor phenotypes. Very 
successful, mice models of thyroid cancer are being used to explore molecular 
mechanisms involved in thyroid tumorigenesis. Mice models can also be used to 
monitor tumors and to perform drug screening in the setting of thyroid cancer but 
such tasks remain time-consuming. 
In the second part of the thesis, I developed a thyroid-targeted BRAFV600E-
expressing transgenic zebrafish and evaluated the thyroid tissue phenotypes 
x 
 
during all stages of development up to 12 months of age. I observed that thyroid-
specific expression of BRAFV600E induced abnormal thyroid morphogenesis early in 
life that developed later on into hyperplasia by ~2-3 months of age and colloid 
goiter by 12 months of age. BRAFV600E–expressing cells disclosed upregulation of 
proliferation, concomitant with MAPK pathway activation, and there was promotion 
of apoptosis. High levels of p53 suggested that this protein may be restraining 
progression to malignancy. Loss of WT p53 using a tp53M214K zebrafish prevented 
impairment of thyroid morphogenesis induced by BRAFV600E and surprisingly no 
evidence of thyroid hyperplasia, goiter and/or neoplasia was detected in those 
animals up to 12 months of age. tp53M214K BRAFV600E–expressing cells were low 
proliferative, consistent with downregulation of the MAPK pathway; suppression of 
apoptosis was also observed. 
In conclusion, my work showed that TERT promoter mutations are relatively 
frequent in specific types of human cancer, including those of the thyroid, and that 
may enhance telomerase expression. Also, thyroid-specific expression of BRAFV600E 
induces hyperplasia and colloid goiter in zebrafish and together with the absence 
of WT p53, BRAFV600E was not able to develop thyroid cancer. This data provides 
evidence that BRAF activation is sufficient for thyroid cell transformation and that 
BRAF and p53 pathways must interact genetically in zebrafish thyroid.  
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Resumo 
 
As doenças na tiróide são extremamente frequentes e são geralmente de natureza 
benigna. O cancro da tiróide é o tumor endócrino maligno mais comum em 
humanos e a maioria destes tumores possui alterações genéticas tais como a 
mutação no gene BRAF. A maioria das mutações do BRAF activam o domínio de 
cinase da proteína BRAF. Em carcinomas papilares da tiróide (CPT) esporádicos, as 
mutações no gene BRAF são encontradas em 29% a 83% do total de casos e quase 
nunca co-existem com as mutações do RAS e rearranjos do RET (RET/PTC) e 
NTRK1. Como resultado das mutações do BRAF, a via de sinalização das MAP 
cinases é activada e processos celulares, tais como proliferação, sobrevivência, 
motilidade e invasão, são promovidos. Recentemente, foram descritas mutações 
no promotor da telomerase transcriptase reversa (TERT) e estas são consideradas 
um dos possível mecanismos de reexpressão da telomerase em vários tipos de 
cancro humano incluindo os da tiróide.  
Na primeira parte da tese eu descrevo o estudo relativo às mutações no promotor 
da TERT no qual eu estive envolvida. O nosso estudo realçou a presença de 
mutações somáticas recorrentes no promotor da TERT em tumores como os do 
sistema nervoso central (43%), da bexiga (59%), da tiróide com origem nas células 
foliculares (10%) e da pele (melanoma) (29%). Relativamente ao cancro da tiróide, 
foi encontrada uma associação significativa entre a presença de mutações no 
promotor da TERT e níveis elevados de expressão de mRNA e também uma 
associação com pacientes mais velhos. Concluímos que as mutações no promotor 
da TERT são relativamente frequentes em determinados tipos de cancro humanos 
e que estas mutações podem aumentar a expressão da TERT. 
Ao longo dos anos, o cancro da tiróide tem sido estudado usando modelos de 
ratinho. Estes modelos deram evidências que demonstram que a expressão 
específica de BRAFV600E induziu bócio bem como CPT invasivos que progrediram 
para carcinomas pouco diferenciados recapitulando alguns dos fenótipos dos 
tumores de tiróide humanos. Os modelos de ratinho ainda são usados para 
explorar mecanismos moleculares envolvidos na tumorigénese da tiróide. Estes 
modelos podem também ser usados para monitorizar tumores e para realizar 
ensaios de drogas no contexto do cancro da tiróide mas estas tarefas são morosas. 
xii 
 
Na segunda parte do tese eu desenvolvi uma linha transgénica com expressão 
específica de BRAFV600E na tiróide de peixe-zebra e avaliei os fenótipos na tiróide 
durante todos os estádios de desenvolvimento e até aos doze meses de idade. 
Observei que a expressão específica de BRAFV600E na tiróide induziu uma 
morfogénese anormal deste tecido em estádios iniciais que se desenvolvem em 
hiperplasia aos 2-3 meses de idade e bócio colóide ao fim de 12 meses. Células 
da tiróide que expressavam BRAFV600E tinham uma sobreregulação da proliferação, 
concomitante com a activação da via de sinalização das MAP cinases, e foi 
observada indução da apoptose. Nível elevados de p53 sugerem que esta proteína 
pode ter contido a progressão para malignidade. Perda da proteína selvagem de 
p53, usando uma linha homozigota para a mutação M214K do tp53, preveniu 
morfogénese anormal da tiróide induzida pelo BRAFV600E e surpreendentemente não 
foram encontradas evidências de hiperplasia, bócio e/ou carcinomas em peixes até 
doze meses de idade. Células da tiróide que expressavam BRAFV600E eram pouco 
proliferativas, consistente com desregulação da via de sinalização das MAP cinases, 
e foi observada supressão da apoptose. 
Em conclusão, o meu trabalho demonstrou que as mutações no promotor da TERT 
são relativamente frequentes em determinados tipos de cancro humanos, incluindo 
os da tiróide, e podem aumentar a expressão da TERT. A expressão específica de 
BRAFV600E induziu hiperplasia e bócio colóide em peixe-zebra e que em conjunto 
com a ausência da proteína p53, o BRAFV600E não foi capaz de induzir cancro na 
tiróide. Estas observações demonstram evidências de que a activação do BRAF é 
suficiente para a transformação de células da tiróide e que as vias de sinalização 
da qual fazem parte o BRAF e o p53 devem interagir geneticamente na tiróide do 
peixe-zebra. 
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THE HUMAN ENDOCRINE SYSTEM comprises part of the body’s communication 
system connecting the brain to the organs which in turn control the metabolism, 
growth and reproduction. Tight control of the system is possible through complex 
feedback mechanisms that maintains homeostasis. Any disruption to an endocrine 
gland or to the feedback mechanisms may result in endocrine disturbance. 
Ultimately, cancer may either contribute or be the outcome of such disturbance.  
 
I.1 Thyroid gland 
The human thyroid gland is a butterfly-shaped gland located on the trachea and 
comprises two lobes connected by an isthmus (VanPutte et al., 2010). The gland is 
highly vascularized and is one of the largest endocrine glands in the human body 
(VanPutte et al., 2010). The thyroid gland comprises numerous and varying sized 
follicles consisting of a thin-layer of cuboidal epithelial cells and a central lumen. 
The lumen is filled with a homogeneous protein-rich colloid named thyroglobulin 
which is essential to thyroid hormone (TH) synthesis (Manson et al., 1973; VanPutte 
et al., 2010). Two hormones are produced in the thyroid gland by the follicular cells 
in response to thyroid-stimulating hormone (TSH) released from the pituitary: tri-
iodothyronine (T3) and thyroxine (T4). These hormones have an effect on all body 
systems at all stages of life regulating the basal metabolic rate and tissue growth 
and maturation (Manson et al., 1973; Kumar et al., 2005; VanPutte et al., 2010). 
Parafollicular cells secreting calcitonin are also found in clusters surrounding the 
follicles and in the connective tissue (VanPutte et al., 2010). 
 
I.1.1 Thyroid physiology 
Thyroid follicles are the factory and the storage of THs. The presence of TSH is 
indispensable for the synthesis and secretion of THs as well as an adequate iodide 
nutrition.  
The first step in the synthesis of THs is the uptake of iodide by sodium-iodine 
symporter (NIS) which is converted to iodine and then condensed onto tyrosine 
residues from the backbone of thyroglobulin, a protein produced inside the thyroid 
cells. The newly formed iodothyroglobulin can be either mono-iodinated or di-
iodinated. When coupled, two di-iodotyrosine molecules result in the formation of 
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T4 whereas a di-iodotyrosine coupled with a mono-iodotyrosine results in T3. 
Although the T3 is more biologically active than the T4, the production of T3 occurs 
preferentially outside the thyroid gland by peripherical conversion from T4. THs 
are stored inside the thyroid follicles composing the majority of the colloid 
material. T3 and T4 are released by proteolysis from the thyroid to the bloodstream 
where they bind to TH binding proteins namely the thyroxin binding globulin (TBG) 
(Figure 1) (Kumar et al., 2005; Brix et al., 2011). 
 
 
 
Figure 1. TH synthesis. TSH signaling via the TSH receptor controls TH synthesis. NIS at 
the basolateral membrane takes up iodide from the blood. Iodide is organified in the tyrosyl 
residues of tg in a reaction catalyzed by thyroid peroxidase (TPO). T3, and T4 are stored in 
colloid until they are released into the blood. 
 
I.1.2 Thyroid disorders 
Thyroid disorders can range from an enlarged thyroid gland that does not need 
treatment to thyroid cancer. The most common thyroid problems include goiter 
and benign thyroid nodules. Also relatively frequent, and clinically more evident, is 
the abnormal production of TH that can be classified into two groups: 
hyperthyroidism and hypothyroidism (Manson et al., 1973; VanPutte et al., 2010).  
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In hyperthyroidism, the thyroid gland is overactive producing high levels of thyroid 
hormones and speeding up the metabolism. Graves’ disease also known as toxic 
diffuse goiter is the most common cause of hyperthyroidism (Manson et al., 1973; 
VanPutte et al., 2010). In hypothyroidism, the thyroid gland is underactive 
producing inadequate levels of thyroid hormones and slowing down the 
metabolism. Hashimoto’s thyroiditis, congenital hypothyroidism and irradiation 
are some of the causes of hypothyroidism (Manson et al., 1973; VanPutte et al., 
2010). 
The proper treatment of hyperthyroidism and hypothyroidism depends on the 
symptoms of the disease and the aetiology. In hyperthyroidism, treatments include 
thiouracils or thioamides, radioiodine therapy, thyroidectomy, radioactive iodine 
and/or beta blockers. In hypothyroidism, levothyroxine is a hormone replacement 
used for treatment (VanPutte et al., 2010).  
 
I.1.2.1 Goiter 
A goiter is an enlarged thyroid gland, it can be either diffuse or nodular and it may 
extend into the retrosternal space with or without substantial anterior enlargement 
(Kumar et al., 2005; Lam et al., 2014).  
A deficiency in iodine intake or in TH synthesis leads to an increased TSH 
production which in turn sustains increased cellularity and hyperplasia of the 
thyroid gland as an attempt to normalize the levels of the TH. TH deficiency can be 
due to defects on hormone synthesis, iodine deficiency and goitrogens (Figure 2). 
Also, a goiter may appear as a result of the stimulation of the thyroid gland by 
thyroid stimulating hormone receptor (TshR) agonists such as TSH receptor 
antibodies, pituitary resistance to thyroid hormone, adenomas of the 
hypothalamus or pituitary gland and human chorionic gonadotropin-producing 
tumours (Kumar et al., 2005; Lam et al., 2014).  
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Figure 2. Relation between hypothalamus-pituitary-thyroid (HPT) axis and human 
goiter development. Iodine deficiency and/or goitrogens disrupt the TH synthesis in many 
ways. Upon insufficient TH levels, the negative feedback inhibition is lost resulting in 
increased secretion of tropic hormones (TRH and TSH). High TSH levels stimulate thyroid 
cells promoting goiter. Also, TSH receptor agonists can ilicitly mimick the biological activity 
of TSH.  
 
Small benign euthyroid goiters do not require any treatment, however their size 
may be reduced with levothyroxine suppressive therapy. Large and complicated 
goiters usually require surgical and/or radiation treatment followed by TH 
replacement (Kumar et al., 2005; Lam et al., 2014). 
 
I.1.2.2 Neoplasias 
Thyroid cancer is the 16th most common cancer worldwide and accounts for 
approximately 2% of total of human malignancies with around 298.000 new cases 
diagnosed in 2012 worldwide (latest data reported) (Nikiforov, 2012; Ferlay et al., 
2013). Incidence rates of thyroid cancer are highest in Northern America and other 
developed countries and lowest in western Africa but this is partly due to data 
quality and reflects different prevalence of risk factors and screening and 
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diagnostic methods used (Nikiforov, 2012; Ferlay et al., 2013). Although incidence 
rates have increased in most countries, mortality rates have decreased and 
remained low. There were approximately 37.800 deaths worldwide from thyroid 
cancer in 2012 corresponding to 0.5% of total cancer deaths (Nikiforov, 2012; 
Ferlay et al., 2013).  
Thyroid cancer represents the most common type of endocrine malignancy 
although it is relatively rare when compared to benign thyroid tumors. Thyroid 
cancer occurs primarily in youngsters and middle aged adults whilst in children is 
rare. The incidence of thyroid cancer is four times higher in females than in males 
and this sex difference it less pronounced in children and older adults (DeLellis et 
al., 2004; Nikiforov, 2012). 
 
According to the current World Health Organization (WHO) classification, thyroid 
tumors can be subdivided into primary and secondary or metastatic tumors 
(DeLellis et al., 2004). While most of the primary tumors are epithelial and 
originated from the thyroid follicular cells, a lower number of cancers derive from 
neural crest-derived parafollicular C cells. Follicular thyroid cell-derived tumors 
can be benign (follicular adenomas) or malignant (well differentiated follicular and 
papillary carcinomas, poorly differentiated and undifferentiated/anaplastic 
carcinomas) and tumors with an uncertain malignant potential (Soares et al., 2011; 
Nikiforov, 2012) (Figure 3). Also found are the medullary carcinomas which have a 
C-cell origin (DeLellis et al., 2004). Among malignant tumors, papillary thyroid 
carcinomas (PTC) constitute about 80% of all thyroid cancer cases and the increased 
incidence observed in thyroid cancer is mostly due to PTCs. The follicular thyroid 
carcinomas (FTC) represent 15% and medullary and anaplastic carcinomas about 
3% and 2%, respectively, of all thyroid cancer cases. For these tumors, the incidence 
has not changed significantly (DeLellis et al., 2004; Nikiforov, 2012). 
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Figure 3. Follicular thyroid cell-derived tumors and its putative progression. Scheme 
of step-wise dedifferentiation of follicular cell-derived thyroid cancer from benign to 
malignant tumors. 
 
Conventional surgical thyroidectomy and adjuvant ablation by radioiodine 
treatment are the standard treatments for follicular thyroid cell-derived tumors. 
These treatments are not curative in all cases and a big effort is still being made 
towards understanding the molecular pathogenesis of thyroid cancer, namely of 
those that show clinical progression (DeLellis et al., 2004; Nikiforov, 2008; 
Nikiforov, 2012). 
 
Papillary thyroid cancer 
The PTC is a malignant epithelial tumor that shows evidence of follicular cell 
differentiation and is characterized histologically by distinctive nuclear features 
(DeLellis et al., 2004; Kumar et al., 2005; Nikiforov, 2012).  
PTCs are rare in childhood but still are the most common pediatric thyroid tumor. 
Incidence of PTCs begins to rise in the second decade of life up to the fifth and 
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sixth decades. Female to male ratio is as high as 4:1 but in older adults the 
prevalence for females is less pronounced (DeLellis et al., 2004; Kumar et al., 2005; 
Nikiforov, 2012). Increased accuracy in the diagnosis and changes in the 
histological WHO criteria have contributed to a very high prevalence of the papillary 
type among other thyroid carcinomas (DeLellis et al., 2004). Nevertheless, one 
cannot exclude a real increase in the incidence of PTCs due to iodine 
supplementation or exposure to radiation and endocrine disruptors especially 
during childhood (Farahati et al., 2004; Tronko et al., 2006; Frasca et al., 2008; 
Almeida et al., 2013). Indeed, development of PTC is linked to environmental 
(mainly radiation exposure), genetic, hormonal factors and interactions between 
them. Radiation either external or internal from radioactive iodine is a major risk 
factor and children are the most susceptible as thyroid gland grows during 
childhood (DeLellis et al., 2004; Kumar et al., 2005; Nikiforov, 2012; Almeida et 
al., 2013). 
PTC is presented as a cold mass on radioactive scan or as a cervical 
lymphadenopathy. On gross examination, PTCs present a variety of patterns but 
most masses are grey-white and firm with irregular borders that may infiltrate the 
surrounding thyroid tissue. Tumor size ranges from less than 1mm to several 
centimeters and multicentricity and cystic change are commonly observed (DeLellis 
et al., 2004; Kumar et al., 2005; Nikiforov, 2012).   
The diagnosis of a PTC relies mainly in the cytological features observed in the 
nuclei and on the architecture. This includes enlargement, oval shape, elongation 
and overlapping of the nuclei, chromatin clearing, irregular nuclear contours, 
nuclear pseudoinclusions and nuclear grooves. Papillary growth pattern with 
branching is frequently seen but not required for diagnosis. Also found are 
intratumoral sclerosis, peritumoral lymphocytic infiltration and psamomma bodies 
(DeLellis et al., 2004; Kumar et al., 2005; Nikiforov, 2012).   
Some PTCs present particular features which represent specific histological 
variants. The two most frequent variants are the papillary microcarcinomas (30-
40%) usually found incidentally and with a tumor size less than 1cm and the 
follicular variant (15-20%) which has a follicular pattern instead of a papillary 
pattern, very often absent. Other variants, exhibiting variable clinical behaviors, are 
less prevalent (solid, tall-cell, sclerosing, etc.) (DeLellis et al., 2004; Kumar et al., 
2005; Lloyd et al., 2011; Nikiforov, 2012). 
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Prognosis is overall excellent with a 20-year survival of 98% and a mortality rate of 
less that 1% (DeLellis et al., 2004). However, rate of recurrence is highly variable 
ranging from 5% to 40%. Commonly, PTCs metastasize via lymphatic vessels often 
in the cervical lymph nodes and rarely to the lungs and bones as bilateral, small 
and diffuse lesions (DeLellis et al., 2004; Kumar et al., 2005; Nikiforov, 2012). 
Treatment of PTCs remains surgical. Total thyroidectomy is advised for tumors 
greater that 1cm and since well-differentiated PTCs are radiosensitive, iodine-131 
ablation may be employed as adjuvant therapy (DeLellis et al., 2004; Kumar et al., 
2005; Nikiforov, 2012). 
 
Molecular genetics of papillary thyroid cancer 
The rapidly understanding of cancer molecular genetics has led not only to a deep 
insight of cell biology but also to seek prevention and new treatments for cancer. 
In thyroid cancer as in other human cancers, the success of molecular genetics to 
further contribute with novel therapeutic approaches, such as targeted molecular 
therapy, is yet to be fully achieved.  
PTCs are characterized by nonoverlapping genetic alterations in more than 70% of 
the cases. These alterations include rearrangements in the tyrosine kinase (TK) 
receptors Rearranged-during-transfection (RET), Neurotrophic Tyrosine Kinase, 
Receptor, Type 1 (NTRK1), Anaplastic Lymphoma Receptor Tyrosine Kinase (ALK) 
and A Kinase (PRKA) Anchor Protein 9/B-type Raf kinase (AKAP9/BRAF) and also 
point mutations in Rat Sarcoma Viral Oncogene Homolog (RAS) and BRAF genes. 
Ultimately, most cases will lead to an aberrant activation of the RAS-RAF-MEK-ERK 
kinase pathway (DeLellis et al., 2004; Kumar et al., 2005; Nikiforov, 2012). 
Despite the high frequency of chromosomal rearrangements in PTCs, the 
predisposition of follicular thyroid cells to undergo those rearrangements is not 
fully understood. Chromosomal rearrangements are likely to reflect the sensitivity 
of the follicular thyroid cells to ionizing radiation and/or the intrinsic capacity of 
cells to repair radiation-induced deoxyribonucleic acid (DNA) double-strand 
breaks and proneness to aberrant DNA repair instead of apoptosis (Galleani et al., 
2014). 
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BRAF mutations BRAF serine-threonine kinase belongs to the RAF family together 
with A-Raf Proto-Oncogene, Serine/Threonine Kinase (ARAF) and C-Raf Proto-
Oncogene, Serine/Threonine Kinase (CRAF). BRAF is an intracellular effector 
mediating the response to growth factor signaling through the Mitogen-Activated 
Protein Kinases (MAPK) pathway which controls cell proliferation and differentiation 
(McKay et al., 2007). From all the RAF proteins, BRAF has the highest basal kinase 
activity and it is the most potent activator of the MAPK signaling pathway (Marais 
et al., 1997). 
Most mutations in BRAF are activating mutations in the kinase domain. In sporadic 
PTCs, BRAF gene mutations are found in 29%-83% of the cases and are almost 
exclusive to RAS mutations, RET (RET/PTC) and NTRK1 rearrangements (Soares et 
al., 2003; Xing, 2005; Frasca et al., 2008).  
Up to 90% of the BRAF gene mutations are a thymine-to-adenosine transversion at 
position 1799 in exon 15 of the BRAF gene leading to the substitution of a valine 
(V) by glutamic acid (E) at the residue 600 (V600E) of the protein (Garnett et al., 
2004; Frasca et al., 2008). When BRAF is in its inactive and dephosphorylated 
conformation, the adenosine triphosphate (ATP)-binding site and the 
phosphoregulatory activation loop are bound through hydrophobic interactions 
and the kinase domain of BRAF is closed. In the mutant form of BRAF, glutamic acid 
introduces a negative charge adjacent to the Thr599 residue mimicking 
phosphorylations at Thr599 and Ser602 residues. This disrupts the hydrophobic 
interactions and allows new interactions that maintain the protein in a catalytically 
competent conformation resulting in a continuous phosphorylation of MAP Kinase 
1 (MEK), a downstream effector (Dhillon et al., 2004; Wan et al., 2004). 
BRAFV600E mutation are highly frequent in classical PTCs and in the tall-cell variant 
but rare in the follicular variant of PTCs. Additionally, BRAFV600E mutation is found 
in poorly differentiated and undifferentiated carcinomas arising from preexisting 
PTCs which may still contain well-differentiated areas (Nikiforova et al., 2003; 
Begum et al., 2004; Soares et al., 2004; Frasca et al., 2008).  
BRAFV600E mutation is also found in many other human cancers with a high 
prevalence in cutaneous melanoma and in a smaller subset of serous ovarian 
carcinoma and colorectal carcinoma (Davies et al., 2002). 
Besides the BRAFV600E mutation, other rare BRAF mutations are found comprising 
nucleotides around the codon 600 which also constitutively activate the BRAF 
kinase (Soares et al., 2003; Xu et al., 2003). One example is the BRAFK601E mutation 
11 
 
which lead to the substitution of a lysine (K) by glutamic acid (E) at the residue 601 
(K601E). This mutation has a higher prevalence in the follicular variant of PTCs 
(Trovisco et al., 2005).  
 
BRAFV600E and thyroid tumorigenesis The initial evidence that BRAFV600E is required 
for the cell proliferation, transformation and tumorigenicity of follicular thyroid 
cells was demonstrated in a xenograft mice model (Liu et al., 2007) although many 
studies had already supported the role of that BRAF mutation in tumor initiation.  
By stably and specifically knocking down BRAF using small interfering ribonucleic 
acid (siRNA) expression vectors in BRAF mutation-harboring papillary thyroid cells, 
suppression of cell proliferation, colony formation in monolayer culture and 
anchorage-independent cell growth in soft agar was achieved (Liu et al., 2007). 
Furthermore, it was observed inhibition of in vivo tumorigenicity and tumor growth 
of BRAF mutation-harboring papillary thyroid cells after stable knockdown of BRAF 
and xenografted in nude mice. These data suggest that BRAFV600E is a maintainer of 
PTCs phenotype (Liu et al., 2007). 
Targeted expression of the BRAFV600E in follicular thyroid cells of transgenic FVB/N 
mice with a bovine thyroglobulin promoter was also studied. BRAF induced thyroid 
dysfunction which was compensated by increased levels of TSH and goiter 
development. In this model, multifocal tumors involving both lobes of the thyroid 
gland with mixed papillary and follicular growth pattern were observed in 12 and 
22-week-old mice. PTCs presented the classical architecture, tall-cell features and 
a high potential for invasiveness. Tumors from one of the transgenic lines 
progressed into poorly differentiated carcinomas (Knauf et al., 2005).  
PTCs were also observed in a thyrocyte-specific knock-in of BRAFV600E in mice but 
with a very short latency and complete penetrance by 3 weeks. When this model 
was crossed with a TshR knockout mice to genetically ablate TSH signaling, thyroid 
growth was reduced and low-grade PTCs were only observed by 9 weeks of age 
(Franco et al., 2011).  
Along with these observations, a study has explored the consequences of induced 
BRAFV600E expression in the thyroid of adult mice. Shortly after inducing BRAFV600E 
expression, one-month-old mice developed hypothyroidism and a dramatically 
enlarged, goiterous and hypercellular thyroid gland that was 10 times larger than 
controls and up to 300 times larger by 12 months. Only after 6-to-9 months, all 
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mice developed PTC that closely recapitulated the phenotype in humans. Strikingly, 
treatment of these mice with a MEK inhibitor reduced thyroid size, restored the 
production of THs and inhibited tumorigenesis (Charles et al., 2011). 
More evidence of BRAFV600E involvement in mice thyroid tumorigenesis was observed 
when BRAFV600E expression was induced in follicular thyroid cells in a doxycycline-
inducible manner. As early as one week after doxycycline treatment, development 
of highly penetrant and high-grade PTCs with poorly differentiated features and a 
reversible activation of the MAPK pathway were observed. Upon doxycycline 
withdrawal, follicular architecture was reestablished but a second induction not 
only resulted in hypothyroidism but also reduced thyroid-specific genes 
expression (Chakravarty et al., 2011).  
It is reasonable to assume that BRAFV600E is an early event in thyroid tumorigenesis 
due to a high prevalence of BRAFV600E in papillary microcarcinomas and development 
of tumors with histological features of human PTCs induced by expression of 
BRAFV600E in transgenic mice in the absence of any other genetic alterations (Park et 
al., 2010).  
Intriguingly, it has been showed that some human PTCs have intratumor 
heterogeneity of the BRAF genotype as there are two distinct cell populations either 
with the wild-type (WT) or the BRAFV600E. This may suggest that the clonal occurrence 
of BRAF mutation is a rare event, occuring only in a subpopulation of cells, and 
BRAF mutations are rather a late subclonal event in PTCs (Guerra et al., 2012).  
Also, genome-wide allelotyping and BRAF mutation analysis of foci in multifocal 
human PTCs showed that BRAFV600E mutation is an early event during clonal 
evolution in most but not all cases. In fact, BRAFV600E is not always present in all 
tumor foci which suggests that other genetic factors in the primary tumor clone 
may have triggered neoplastic transformation (Jovanovic et al., 2008). 
Nonetheless, in most mice studies BRAFV600E is expressed in all thyroid cells very 
early in life (fetal or during the first month) and BRAF-induced suppression of 
thyroid function led to TSH elevation which in turn promoted thyroid 
tumorigenesis. One particular study generated a model in which BRAFV600E 
expression was temporally and spatially restricted so that it can recapitulates the 
human sporadic PTC that usually arises postnatally from follicular cells under 
physiological serum TSH concentrations. With this approach, thyroid carcinomas 
under normal TSH levels were not found (Shimamura et al., 2013).  This shows that 
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the timing of BRAF activation may be the key to determine cell transformation as 
the induction of an oncogene in poorly dividing cells, such as the follicular thyroid 
cells, during adulthood may not trigger tumorigenesis (Shimamura et al., 2013).  
These data questions whether BRAFV600E initiates thyroid tumorigenesis or BRAFV600E 
is a consequence of tumor development and not a driver mutation. An alternative 
scenario is that BRAFV600E does initiate the formation of a PTC however as secondary 
genetic alterations and/or epigenetic changes take over to maintain tumor 
sustainability, BRAFV600E is no longer selected and/or important for tumor 
maintenance (Xing, 2012).   
 
RET/PTC and NTRK1 rearrangements The RET gene is a member of the cadherin 
superfamily and encodes one of the first TK receptors that were found to have a 
role in human cancer (Phay et al., 2010). RET ligands belong to the glial cell-derived 
neurotrophic factor family and, when bound to RET co-receptors (GFRα-1), brings 
together two RET molecules leading to the autophosphorylation of the intracellular 
tyrosine portion (Manie et al., 2001; Airaksinen et al., 2002; Trovisco et al., 2007). 
In turn, there is the recruitment and binding of adaptor proteins and subsequent 
activation of signaling pathways such as the MAPK pathway which are able to 
control cell proliferation, differentiation, motility and survival (Manie et al., 2001; 
Airaksinen et al., 2002; Trovisco et al., 2007). 
NTRK1 gene encodes a member of the neurotrophic TK receptor family. Upon 
neurotrophin binding, this membrane-bound receptor auto-phosphorylates and 
activates other members of the MAPK signaling pathway leading to cell 
differentiation (Teng et al., 2004; Trovisco et al., 2007). 
Rearrangements of RET and NTRK1 usually involve the fusion with heterologous 
genes resulting in RET/PTC and NTRK1 chimeric transcripts. The chimeric proteins 
have an aberrant and persistent activation of their TK domains (Trovisco et al., 
2007).  
Somatic rearrangements of RET gene are found in 3% and up to 60% of sporadic 
PTCs and lead to a de novo expression of the TK on RET domain in the cytoplasm 
of follicular thyroid cells (Nikiforov, 2002; Santoro et al., 2002; Frasca et al., 2008). 
The most common RET rearrangements are the RET/PTC1 and RET/PTC3. 
RET/PTC1 is by far the most prevalent type comprising 60-70% of all the 
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rearrangements however RET/PTC3 is the most frequent rearrangement found 
early after radiation exposure. RET/PTC1 and RET/PTC3 are paracentric 
rearrangements with CCDC6 (coiled-coil domain containing 6) and NCOA4 (nuclear 
receptor coactivator 4) genes, respectively (Trovisco et al., 2007). Another 
rearrangement, RET/PTC2, involves reciprocal translocations with the protein 
kinase, cAMP-dependent, regulatory, type I, alpha (PRKAR1A) gene. RET gene can 
still be involved in other rearrangements but it is mainly associated with radiation 
(Trovisco et al., 2007). RET/PTC fusions leave intact the TK domain of the RET 
receptor enabling the protein to induce activation of signaling cascades including 
MAPK and phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)-V-Akt murine 
thymoma viral oncogene homolog (AKT) pathways (Kuroda et al., 2003; Knauf et 
al., 2009).  
Rearrangements of NTRK1 gene are rare and are found in less than 10% of sporadic 
PTCs (Trovisco et al., 2007).  
 
RAS mutations The RAS gene encodes for a family of related proteins that stay at 
the center of a cascade of molecular interactions. Most proteins are activated by 
RAS upon phosphorylation as Ras switches between its “on” and “off” state. Usually, 
RAS binds to guanosine-5'-diphosphate (GDP) but upon a receptor activation, GDP 
is expelled allowing guanosine-5'-triphosphate (GTP) to bind. In turn, GTP causes 
a subtle rearrangement of the RAS protein ultimately leading to the activation of 
MAPK signaling pathway. As GTP is hydrolyzed to GDP, RAS turns itself “off”, self-
limiting its activity (Lodish et al., 2000).  
RAS mutations lead to a loss of the GTPase activity in RAS protein in such a way 
that it locks RAS in a constitutively active GTP-bound state which potentiate 
uncontrolled proliferative signals (Lodish et al., 2000). 
In PTCs, RAS gene mutations are more frequently found in the follicular variant of 
PTC (Zhu et al., 2003, Giordano et al., 2005, Frasca et al., 2008). The prevalence of 
RAS mutations in PTCs ranges from 0% to 16% and neuroblastoma RAS viral (v-ras) 
oncogene homolog (NRAS) gene is the most predominantly mutated namely on 
codon 61 (Zhu et al., 2003; Trovisco et al., 2007). 
 
PAX8-PPAR gamma rearrangements The paired box 8 (PAX8) gene encodes for 
a member of the paired box family of transcription factors involved in follicular 
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thyroid cell development and expression of thyroid-specific genes (Kimura, 2011). 
Peroxisome proliferator-activated receptor gamma (PPARG) gene encodes for a 
peroxisome proliferator-activated receptor that regulates the expression of target 
genes involved in cell proliferation, differentiation and immune and inflammatory 
responses (Kroll et al., 2000).  
PAX8-PPAR gamma rearrangements are tipically found in follicular thyroid 
adenomas, FTCs and on the follicular variant of PTCs, in the latter with a prevalence 
up to 38% (Castro et al., 2006). 
 
PTEN and PIK3CA mutations The phosphatase and tensin homolog (PTEN) gene 
encodes for a phosphatidylinositol-3,4,5-triphosphate 3-phosphatase which 
regulates dephosphorylation of phosphoinositide substrates thereby negatively 
regulating the PI3K-AKT signaling pathway (Sun et al., 1999; Hou et al., 2007). 
PTEN mutations are found in 1-2% of PTCs and mutations in this tumor suppressor 
gene activate the PI3K-AKT pathway (Hou et al., 2007). 
Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) 
encodes for a catalytic subunit that uses ATP to phosphorylate 
phosphatidylinositol-4-monophosphate and phosphatidylinositol-4,5-
diphosphate (Samuels et al., 2004). PIK3CA mutations have also a very low 
prevalence in PTCs (1-3%) and most are found in the helical and kinase domains of 
the p110α protein producing variants that are independent of the regulatory 
subunits and are capable of inducing cell proliferation, invasiveness and resistance 
to apoptosis (Gymnopoulos et al., 2007; Santarpia et al., 2010). PIK3CA copy gain 
prevalence goes up to 14% (Wang et al., 2007; Hou et al., 2007). Either mutations 
in the PIK3CA gene or increase in copy number result in the gain of function 
reflected by high or constitutive activation of the PI3K activity and promotion of 
tumorigenesis (Santarpia et al., 2010).   
 
p53 mutations The TP53 gene encodes for a protein that maintains genome 
integrity by binding specifically to a DNA consensus sequence to induce growth 
inhibitory genes or nonspecifically to damaged sites leading to DNA repair or 
apoptosis (Liu et al., 2001). The levels of p53 in normal cells are very low but upon 
p53 activation in response to environmental challenges such as cellular stress, p53 
protein is accumulated and stabilized (Liu et al., 2001). p53 is capable of arresting 
the cell cycle at G1, G2 or in S-phase by inducing p21 which in turn blocks the 
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cycling-dependent kinases (CDKs) responsible for checkpoint regulation and 
progression of the cell cycle (Bai et al., 2006). This allows time to repair damaged 
DNA or induce cell death (Bai et al., 2006). p53 is also an activator of the MDM2 
proto-oncogene, E3 ubiquitin protein ligase (MDM2) gene which negatively auto-
regulates p53 maintaining low levels of the p53 protein in normal cells (Bai et al., 
2006).   
At variance with other human tumors, TP53 mutations are not frequent in thyroid 
cancer (only 10%) and most have been documented in anaplastic carcinomas. 
Indeed, well-differentiated thyroid cancers do not harbor mutations in TP53 
suggesting a role on thyroid cancer progression to poorly differentiated and 
aggressive phenotypes (Morita et al., 2008). Of note, studies on thyroid tumor 
samples revealed an accumulation of p53 in poorly differentiated and anaplastic 
forms but also well-differentiated tumors in the absence of any p53 mutation 
suggesting that p53 inactivation may result from loss of interaction with MDM2 
(Soares et al., 1994). In thyroid cancer, TP53 mutations are commonly found at 
codons 213 and 238 and in anaplastic carcinomas are also found at codons 248 
and 273 (Bai et al., 2006). 
Modeling thyroid cancer in mice have shown that acquired mutations drive tumor 
progression and in general BRAFV600E is sufficient to initiate PTCs. Already 
demonstrated is evidence that p53 constrains progression from papillary to 
anaplastic thyroid carcinoma (Preto et al., 2004). By generating a thyroid-specific 
Cre recombinase-estrogen receptor (CreER) transgenic mouse and using a Cre-
regulated BRAFV600E and a conditional Trp53, it was found that p53 loss does enable 
progression to aggressive anaplastic thyroid cancer but additional events may be 
required for full anaplastic conversion (McFadden et al., 2014). 
 
Telomerase promoter mutations Telomerase is a ribonucleoprotein complex that 
adds telomeres repeats sequences to the ends of telomeric DNA. The protein 
component has reverse transcriptase (TERT) activity while the RNA component 
serves as a template for the telomere repeat (Capezzone et al., 2009; Hanahan et 
al., 2011). 
Telomerase is active in the vast majority of human cancer cells (80-90%) enabling 
their replicative immortality (Figure 4) (Hanahan et al., 2011) and sporadic thyroid 
carcinomas are no exception. In PTCs, telomerase activity measured by TRAP assay 
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ranged from 20% to 87.5% (Capezzone et al., 2009) but the high levels reported in 
some studies may be due to the presence of lymphocytic infiltration coexisting with 
the neoplasia (Brousset et al., 1997; Umbricht et al., 1997; Saji et al., 1999). Of 
note, telomerase activity in normal thyroid tissue is almost absent (Capezzone et 
al., 2009). 
 
 
Figure 4. Regulation of telomere length by telomerase. (A) In normal somatic cells, 
telomerase is absent and the telomere repeat sequence (light blue boxes) is lost everytime 
the cell divides. After many cell divisions, telomeres reach a critically short length triggering 
senescence and cessation of proliferation. (B) In cancer cells, reexpression of the 
telomerase expression bypasses senescence and telomere length is compatible with 
proliferation. Telomere elongation sustains cancer. 
 
Telomerase activity is considered the result of clonal selection as telomeres become 
critically shortened (Skvortzov et al., 2009). It was shown that genetic mechanisms 
that promote telomerase reactivation in human tumors include TERT alternative 
splicing, TERT gene amplification and TERT promoter mutations (Figure 5) 
(Skvortzov et al., 2009). As recently reported two recurrent, non-overlapping 
somatic mutations on chromosome 5, -124C>T (C228T) and -146C>T (C250T) 
(where -1 is the base just upstream of the ATG translation start site of the TERT 
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gene), in the TERT promoter are very frequent in sporadic melanoma (Huang et al., 
2013, Horn et al., 2013). These mutations were subsequently found in several 
tumors including thyroid cancer lines and either well-differentiated or poorly and 
anaplastic thyroid carcinomas (Vinagre et al., 2014). 
TERT promoter mutations create an eleven-base nucleotide stretch 5’-
CCCCTTCCGGG3’ which contains a new consensus binding site GGAA, generating 
de novo consensus binding motifs for E-twenty-six (erythroblast transformation-
specific –ETS- transcription factors). It was shown that it increases the 
transcriptional activity of the telomerase promoter by two-to-six-fold in human 
cancer cell lines (Huang et al., 2013; Horn et al., 2013; Liu et al., 2013). This is 
consistent with a mildly enhanced TERT expression with respect to normal tissues 
(Muzza et al., 2015). One of the transcription factors found to be recruited 
specifically to the mutant promoter is the multimeric GA-binding protein (GABP) 
(Bell et al., 2015).  
TERT promoter mutations are found in 8% to 22% of PTCs, being the  -124C>T 
mutation more prevalent (Liu et al., 2013; Landa et al., 2013; Vinagre et al., 2013; 
Melo et al., 2014; Liu et al., 2014; Wang et al., 2014; Muzza et al., 2015). 
Noticeably, 33% of PTCs with distant metastasis harbored TERT promoter mutations 
(Melo et al., 2014; Xing et al, 2014; Gandolfi et al., 2015). 
It was proposed that TERT promoter mutations may be more common in cancers 
derived from terminally differentiated cells which have a low self-renewing 
capacity. Indeed, follicular thyroid cells have a very low mitotic rate postnatally 
(proliferative rate lower than 0.1 in adults). Also, well-differentiated PTCs are 
usually indolent lesions with low rate of growth. A significant rate of TERT promoter 
mutations in those carcinomas suggests that thyroid cancer cells may benefit from 
this mechanism to maintain telomerase lengthening (Saad et al., 2006; Killela et 
al., 2013).   
Moreover, it was found a significant overrepresentation of TERT promoter 
mutations in thyroid tumors harboring alterations in BRAF or RAS genes. TERT 
promoter mutations seemed to be more frequent in BRAFV600E that in BRAFWT-PTCs 
(Liu et al., 2013; Melo et al., 2014; Xing et al., 2014). 
In differentiated thyroid carcinomas, TERT promoter mutations are associated with 
older age at diagnosis, tumor size and male gender and are correlated with a 
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reduced progression free survival and overall survival (Vinagre et al., 2013; Xing et 
al., 2014; Melo et al., 2014). 
This comes as no surprise that TERT promoter mutations are associated with older 
age at diagnosis which is consistent with a progressive shortening of telomeres in 
follicular cells during lifetime. When these cells acquire genetic alterations, such as 
the BRAFV600E mutation, and begin to reply to the oncogenic stimuli by inducing 
proliferation, very short telomeres also trigger telomere dysfunction which may be 
compensated by telomerase reactivation via TERT promoter mutations (Londoño-
Vallejo, 2008; Muzza et al., 2015). Furthermore, BRAF mutations leading to MAPK 
activation can be conceived as inducers of expression of members of the ETS 
transcription factor family. Having de novo consensus binding sites for ETS factors 
promoted by TERT promoter mutations, the lifespan of BRAF-driven clones is 
extended. Further accumulation of additional genetic defects is promoted which in 
turn allows progression to advanced tumor stages (Pratilas et al., 2009; Huang et 
al., 2013; Horn et al., 2013; Liu et al., 2013).  
These hypothesis could explain why well differentiated PTCs harboring BRAF 
mutations are more likely to harbor TERT promoter mutations than those PTCs 
without BRAF mutations. It is also consistent with an enrichment of TERT promoter 
mutations in poorly differentiated thyroid carcinomas and anaplastic thyroid 
carcinomas which have partially and completely lost differentiation, respectively, 
and are the most aggressive thyroid carcinomas (Landa et al., 2013; Liu et al., 
2013). Of note, TERT promoter mutations must be only one of the several 
mechanisms that illegitimately activate telomerase in human cancer. 
 
Signaling pathways altered in papillary thyroid carcinomas 
 
MAPK signaling pathway The MAPK pathway comprises evolutionarily conserved 
kinase modules that join extracellular signals to the machinery responsible for cell 
growth, proliferation, differentiation, migration and apoptosis. One of the groups 
of MAPK characterized in mammals is the extracellular signal-regulated kinase 
(ERK)1/2 (Dhillon et al., 2007).  
Constitutive activation of the MAPK signaling pathway is a frequent event in human 
cancers particularly in PTCs and melanomas (Xing, 2013).  
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For most cancers, constitutive activation of ERK signaling is established by 
sustained autocrine or paracrine production of activating ligands, overexpression 
and activating mutations of the TK receptor and activating mutations in RAS and 
BRAF (Dhillon et al., 2007; Knauf et al., 2009). In thyroid cancers, besides RAS and 
BRAF mutations, RET-PTC, NTRK1 and ALK mutations also mediate tumorigenesis 
via the MAPK pathway (Xing, 2013). 
In this pathway, ligand-mediated activation of TK receptor promote RAS GTPase 
conversion which recruits and activates RAF kinases to the plasma membrane. ERK1 
and ERK2 are activated upon phosphorylation by MEK1 and MEK2 which are 
themselves activated when phosphorylated by RAF proteins. Activated ERKs 
phosphorylate cytoplasmic and nuclear targets including kinases, phosphatases, 
transcription factors and cytoskeletal proteins (Figure 5) (Dhillon et al., 2007).  
The effect of ERK signaling activation is consistent to the cellular processes that 
itself regulates. Sustained ERK signaling promotes phosphorylation and 
stabilization of FBJ murine osteosarcoma viral oncogene homolog (Fos), Jun proto-
oncogene (Jun), V-Myc avian myelocytomatosis viral oncogene homolog (Myc) and 
ETS-Related (Erg-1) genes and also cyclin D1 thereby promoting cell-cycle entry 
and can repress genes responsible for inhibiting proliferation (Yamamoto et al., 
2006). On the other hand, high levels of ERKs can induce cell-cycle arrest by 
expression of CDK-inhibitor proteins such as p21 and p27 that must be 
counteracted by elevated RhO signaling or activation of AKT so that cells continue 
to proliferate (Dhillon et al., 2007). 
 
PI3K-AKT signaling pathway PI3Ks represent a family of kinases that 
phosphorylate the 3’-hydroxyl group of phosphatidylinositol inositides that are 
activated by many TK receptors. Class I of PI3Ks consists of heterodimers of 
regulatory (p85) and catalytic (p110) subunits. p110α and p110β subunits have an 
important role in tumorigenesis as RAS function is mediated by its interaction with 
the RAS-binding site present in those subunits. Also, activation of TK receptor by 
extracellular signals is itself sufficient to activate p110 subunits which in turn 
phosphorylates phosphatidylinositol (PtdIns)-3,4-P2 producing PtdIns-3,4,5-P3 
leading to the recruitment of AKT  to the cytosolic membrane. AKT is then 
phosphorylated and activated by PDK1 resulting in the phosphorylation of 
downstream effector such as the mammalian target of rapamycin (mTOR) (Figure 
21 
 
5). This result in a broad cascade of signaling responsible for cell growth and 
proliferation, glucose uptake, migration and apoptosis resistance (Saji et al., 2010). 
Constitutive activation of the PI3K-regulated signaling pathway is relevant in a wide 
variety of human tumors including thyroid cancer. This is particularly valid in 
Cowden’s syndrome, that present thyroid carcinomas, which is characterized by 
mutations in the PTEN gene that encodes a phosphatase that dephosphorylate 
PtdIns-3,4,5-P3 and thereby negatively regulates the PI3K-AKT pathway. 
Additionally, RAS mutations, RET/PTC rearrangements and PIK3CA and AKT1 
mutations are further evidences that PI3K signaling pathway has a fundamental role 
in thyroid tumorigenesis (Saji et al., 2010, Xing, 2010). 
 
mTOR signaling pathway mTOR is a serine/threonine kinase that belongs to the 
phosphoinositide 3-kinase (PI3K)-related kinase family and  functions as a 
regulator of cell growth-related processes.  mTOR can form two distinct complexes 
with other proteins, mTOR complex 1 (mTORC1) and complex 2 (mTORC2), that 
have different upstream inputs and downstream outputs. Regulation of mTOR by 
growth factors occurs through the PI3K/AKT pathway which is counteracted by 
PTEN. There is evidence of overactivation of AKT/mTOR pathway in PTCs when 
compared to other differentiated thyroid carcinomas and correlation with BRAFV600E 
mutation which could be explained by BRAF-induced phosphorylation of tumor 
suppressor liver kinase B1 (LKB1) Ser428, a main upstream kinase of AMP-activated 
protein kinase (Faustino et al., 2012). 
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Figure 5. MAPK and PI3K-AKT-mTOR signaling pathways. In green are the proteins from 
the MAPK pathway; in blue those belonging to the PI3K-AKT-mTOR pathway. These two 
classical pathways are associated to TK receptors at the cell membrane that transduces 
extracellular growth signals into intracellular signals downstream of the pathways. RAS 
protein can couples the signaling from the receptor to both MAPK and PI3K-AKT-mTOR 
pathways. These two pathways, driven by genetic alterations in one or more of their 
components, have a fundamental role in thyroid tumorigenesis. 
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THROUGHOUT HISTORY, ethical and religious considerations have prevented 
experimental studies of human biology. Most of the knowledge of human biology, 
physiology, endocrinology and pharmacology has come first from studies in animal 
models. Often practical, economical and scientific reasons are also crucial in 
understanding why animals are the best models for studies of biological 
phenomena. 
 
I.2 Zebrafish as a model system 
Zebrafish is a freshwater fish that was originally found in slow streams and rice 
paddies and in the Ganges River in East India and Burma. In these water, zebrafish 
rarely grow larger than 4 centimeters long (Clark et al., 2013). 
In comparison to other animal models, zebrafish has a far shorter relationship with 
research. Zebrafish started to be studied for developmental genetics by George 
Streisinger from the University of Oregon in the late 1960s. His idea was to apply 
mutational analysis to study zebrafish embryonic development as he thought this 
analysis was needed in vertebrates. Initially studies were set to study features of 
the organization and embryological development of the nervous system using 
mutant vertebrate strains (Grunwald et al., 2002; Clark et al., 2013).  
Zebrafish was and it still is an attractive model due to its brood size, short life 
cycle, transparent embryos, ex utero development of embryos, ease of keeping 
many fish in a small space, frequent mating possibility, sexual maturity at 3 months 
post fertilization (mpf) and conservation of vertebrate tissues (White et al., 2013; 
Liu et al., 2011). Zebrafish was only later used in large forward genetic screens that 
produced genetic mutants for virtually any phenotype (Dooley et al., 2000; Liu et 
al., 2011) and nowadays this model reached its full potential to study vertebrate 
biology and physiology as well as human diseases (Dooley et al., 2000). 
 
I.2.1 Zebrafish in Cancer Research 
The cancer field is heading towards a post-genomic state and, as most human 
cancers are being extensively sequenced, new tools are required so that the 
extensive genomic alterations found can be studied in a biological context and be 
translated into a more effective therapy (Mione et al., 2010; Liu et al., 2011; White 
et al., 2013).  
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Although no single model can fully reflect the complexity of cancer biology in vivo, 
zebrafish has been considered a great addition to animal models of human disease 
(Liu et al., 2011; White et al., 2013).  
In 1982, zebrafish was first proposed as a model for cancer with a study showing 
that exposure to carcinogens induced low-penetrance tumors (Pliss et al., 1982). 
Remarkably, despite over 300 million years of divergence between fish and 
humans, tumors in zebrafish strongly resemble human tumors at the histological, 
gene expression and genomic levels. Moreover, crucial genes and pathways 
involved in tumorigenesis are highly conserved between fish and humans 
(Amatruda et al., 2002). 
Two decades later more studies were able to demonstrate various neoplasms in 
zebrafish after mutagen exposure but the breakthrough came when T-cell 
leukemia was induced by expressing oncogenic myc under the control of rag2 in 
transgenic animals (Langenau et al., 2003). 
Since then, many zebrafish models of cancer expressing dominant-acting 
oncogenes have been established using various technologies. The two main 
approaches are either to select genetic alterations in human tumors and then test 
it in transgenic animals or to identify evolutionarily drivers conserved between 
human tumors and those tumors arising in transgenic animals (Liu et al., 2011; 
White et al., 2013). 
Taking into account the first approach, probably the most extensively studied 
transgenic zebrafish model of cancer is the melanoma model. Human melanoma is 
a lethal form of skin cancer with an incidence and mortality rates that are rapidly 
increasing (Wangari-Talbot, 2012). Molecular genetic analysis of precursor lesions 
such as the nevi and melanoma tumors have pointed to alterations in key genes of 
the RAS-RAF-MEK-ERK and PI3K-AKT pathways regulating signal transduction and 
other genes involved in cell cycle regulation such as the cyclin-dependent kinase 
inhibitor 2A (CDKN2A) (Wangari-Talbot, 2012). The majority of human melanomas 
exhibit mutations in BRAF, the same found in PTCs, and this may have a critical 
role in melanoma initiation (Wangari-Talbot, 2012).  
To study the role of activated BRAF, a transgenic zebrafish expressing BRAFV600E 
under the control of a melanocyte promoter was generated. Expression of the 
oncogene in the melanocytes lead to nevi which rapidly develop into invasive 
melanomas only in the absence of WT p53 (Patton et al., 2005). Furthermore, to 
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test for the ability of genes in a region of chromosome 1 (1q21) amplified in human 
melanomas to cooperate with BRAFV600E, the melanoma model described above was 
used to inject a rescuing-plasmid containing any of the genes present in the 1q21 
region. A single gene (SET Domain, Bifurcated 1-SETDB1) was found to cooperate 
with BRAFV600E in mediating melanoma growth in zebrafish and increase tumor 
aggressiveness (Ceol et al., 2011).  
An approach to compare common genetic alterations in human and zebrafish 
tumors is highlighted by the zebrafish T-cell acute lymphoblastic leukemia model 
(T-ALL). Almost 900 genes were found to have copy number alterations in 
zebrafish leukemia and when compared to human leukemia ten genes, that seemed 
to be true drivers of T-ALL, were repeatedly altered in the two species (Rudner et 
al., 2011). 
Besides classic transgenesis and comparative genomic studies, zebrafish has also 
the potential for tumor transplantation and xenotransplantation of human cells. In 
fact, transplantation models in zebrafish are being used to study cancer-related 
events such as invasion, metastasis, angiogenesis and cancer stem cell renewal 
which rely on in vivo imaging. More recently, zebrafish models were considered 
candidates for large-scale reverse genetics to identify tumor suppressors, for 
modeling multigenic alterations and epigenetic changes and for studying the 
immunological response and microenvironment (Liu et al., 2011; White et al., 
2013). 
 
I.2.2 Studies on zebrafish thyroid physiology and function 
The thyroid gland is responsible for producing THs in all vertebrates in order to 
regulate metabolism in the adult organism but also to control many processes 
during development (VanPutte et al., 2010). Despite some anatomical differences 
between fish and mammals, the hypothalamus-pituitary-thyroid (HPT) axis is 
conserved (VanPutte et al., 2010).   
The functional unit of teleost thyroid is the follicle (Fournie et al., 2005; Wendl et 
al., 2002). Thyroid follicles are scattered predominantly throughout the connective 
tissue of the pharyngeal region between the first gill arch and the bulbus arteriosus 
along the ventral aorta within the mesenchyme of the ventral head region. Adjacent 
muscle, cartilage or bone may also be surrounded by random follicles. Normal-
appearing thyroid follicles may also be found in the ocular choroid, kidney, spleen, 
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intestine, liver and heart. Indeed, this ectopic distribution could be due to the 
absence of a connective tissue barrier. Histologically, each thyroid follicle 
resembles that of other vertebrates (Fournie et al., 2005; Wendl et al., 2002). The 
follicles are usually round to oval and are lined by a single-layered epithelium 
consisting of endoderm-derived flat or cuboidal thyroid cells. Follicles are filled 
with colloid and the amount of colloid depends on the metabolic activity of thyroid 
cells and the extent of TSH production (Fournie et al., 2005; Wendl et al., 2002). 
Teleost follicles produce THs (T3 and T4) and their synthesis follows the iodine 
uptake and iodination of thyroglobulin and the release of the hormones into the 
blood stream (Wendl et al., 2002).  
Follicular thyroid cells in zebrafish, as in other vertebrates, express the orthologous 
transcription factors NK2 Homeobox 1a (nk2-1a) (Rohr et al., 2000), paired box 
gene 2.1 (pax2.1), pax8 and hematopoietically expressed homeobox (hhex) (Wendl 
et al., 2002) for thyroid differentiation and orthologous proteins such as solute 
carrier family 5 (sodium/iodide cotransporter), member 5 (slc5a5) and cathepsin B 
(ctsb) (Alt et al., 2006) important in TH synthesis, produce thyroglobulin (Wendl et 
al., 2002; Alt et al., 2006) and accumulate iodine (Elsalini et al., 2003).  
 
Development of thyroid in zebrafish In zebrafish development, classical steps 
shared with mammals include specification of follicular thyroid cells progenitors, 
budding of a thyroid anlage, migration of thyroid primordium and late thyroid 
morphogenesis and functional differentiation of follicles (Figure 6) (Alt et al., 2006; 
Porazzi et al., 2009).  
TH immunoreactivity appears faint at around 55 hours post fertilization (hpf) when 
the embryo hatches from the chorion. However, expression of thyroglobulin (tg) is 
first observed in the thyroid primordium as early as 32hpf (Alt et al., 2006). As the 
primordium grows along the midline of the ventral pharyngeal area, expression of 
slc5a5 and ctsb also initiates. T4 immunoreactivity is observed at about 80hpf in a 
group of cells that are not organized as follicles but lay at the base of the larva 
lower jaw (Alt et al., 2006). At 96hpf, the immunoreactivity increases as well as the 
number of cells which are localized caudally along the ventral aorta (Alt et al., 
2006). At 5 days post fertilization (dpf), three to five follicles can be observed and 
at 7dpf up to seven follicles arise. Larval follicles have a lumen filled with colloid 
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and vesicles at the apical surface of the follicular cells. These cells are usually round 
and their size is 5-10μm in diameter (Alt et al., 2006).  
 
 
 
 
Figure 6. Embryonic thyroid growth in zebrafish. The main steps are the following: (1) 
expression of developmental markers (nk2.1, hhex, pax2.1) in a field of the endoderm 
before a pharynx has formed; (2) and (3) evagination of the middle diverticulum; (4) 
differentiation of the first follicle at around 55hpf; (5) and (6) follicle growth with tissue 
added caually. The scale bar shows time of development in hpf. (Pink arrows indicate the 
onset of developmental gene expression and differentiation markers and blue arrows mark 
the onset of thyroid function judged by production of T4.  
 
The yolk of the larva contains maternal THs which explain the early onset of T4 and 
fast development (Wendl et al., 2002). Follicular thyroid cells do not fuse with the 
calcitonin-producing cells (Alt et al., 2006).  
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I.3 Aims 
Not so long ago cancer was seen as arising owing to the accumulation of mutations 
in critical genes that altered the normal programme of cell proliferation, 
differentiation and death. But the impact of such mutations, including those in the 
BRAF gene, is only part of the cancer paradigm, indeed many other mechanisms 
mediate tumorigenesis.  
One of the most novel mechanism is related to TERT promoter mutations. TERT 
promoter mutations were initially found at high frequency in human melanoma but 
not in nevi and are believed to illicitly contribute to telomerase reactivation in 
melanoma as in other cancers. I was involved in a study to investigate whether TERT 
promoter mutations were present in cancer types other than melanomas: thyroid, 
kidney, bladder, gastrointestinal stromal tumors (GIST), adrenal medulla and 
central nervous system (CNS) tumors. The frequency of TERT promoter mutations 
was assessed in the above-mentioned cancers and contributed to further studies 
to understand why those mutations are important in some cancers but not in others 
and how do they relate with additional genetic alterations. 
Virtually every breakthrough in the study of human diseases has been the direct 
result of using animal models. Although many alternative animal-replacing 
methods are also used, living systems remain a necessity in research.  
In thyroid cancer studies, mice models have provided enough evidence that 
thyroid-specific expression of BRAFV600E induced goiter and invasive PTCs which 
progress to poorly differentiated carcinomas that closely recapitulated the human 
PTC phenotypes. Those mice models are still used nowadays to disclose new 
mechanisms of thyroid tumorigenesis, however tumor imaging and translational 
studies namely drug screening are difficult and time-consuming. 
In the last years, zebrafish has proved to be a good addition to animal models of 
human cancer not only because they develop cancer spontaneously, after mutagen 
exposure or through transgenesis but also because tumors that arise resemble 
those of the humans at the histological, genetic and genomic levels. Taking 
advantage of this versatile animal model, I developed a novel transgenic line that 
expressed BRAFV600E specifically in thyroid cells of zebrafish to understand the effect 
of BRAFV600E in this tissue and validate a model useful to study thyroid disease. 
Upregulation of p53 was found to play an important role in the BRAFV600E-induced 
phenotype in that line. Also, human and mice data showed that p53 loss is essential 
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in tumor progression. Therefore, I developed a transgenic line that expressed 
BRAFV600E specifically in thyroid cells of tp53M214K zebrafish to understand whether 
the absence of WT p53 would promote cancer or at least exacerbate the BRAFV600E 
effect on thyroid. Finally, to closely recapitulate the timing of BRAF activation in 
sporadic thyroid carcinomas, I developed a transgenic model that allowed 
temporally restricted expression of BRAFV600E in thyroid cells of zebrafish.  
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The material and methods from the “Frequency of TERT promoter mutations in 
human cancers” work are exclusively described in chapter III.1. The material and 
methods from the studies in zebrafish are described in detail in this chapter and 
briefly in chapter III.2 
 
 
II.1 Plasmid cloning 
II.1.1 p5E-tg promoter plasmid  
The (-2041; -1) region, being -1 the position immediately upstream of the ATG 
sequence of the zebrafish thyroglobulin (tg) gene, was amplified by polymerase 
chain reaction (PCR) from bacterial artificial chromosome (BAC) genomic clone 
DKEY-97I18 BAC, GenBank CR855311.15 (SourceBioScience) using the following 
primers: forward primer 5’-CAGCTGGTACTCTAAATGTGAGAAA-3’ and reverse 
primer 5’-TGTTTAAAAGGGACGATGTAGC-3’. The fragment was initially cloned 
into a pCR™-BluntII-TOPO® plasmid (Thermo Fisher Scientific Inc.). The insert was 
then excised using restriction sites from the backbone plasmid and cloned into the 
KpnI (Thermo Fisher Scientific Inc.) and XhoI (Thermo Fisher Scientific Inc.) 
restriction sites on the multicloning site (MCS) of a p5E-MCS plasmid, containing 
attL4 and attR1 recombination sites and provided by the Tol2Kit (Kwan et al., 2007). 
Ligation product was transformed into One Shot® TOP10 Chemically Competent 
Cells (Thermo Fisher Scientific Inc.). The full-length construct was sequenced for 
accuracy. 
 
II.1.2 pME-mCherry and p3E-polyA plasmids  
pME-mCherry is a middle entry (ME) clone containing attL1 and attL2 
recombination sites. p3E-polyA is a 3’ entry clone containing simian vacuolating 
virus 40 (SV40) late polyA signal and attR2 and attL3 recombination sites. Both 
entry clones were provided by the Tol2Kit (Kwan et al., 2007). pME-mCherry and  
p3E-polyA plasmids were transformed into One Shot® TOP10 Chemically 
Competent Cells (Thermo Fisher Scientific Inc.). The full-length constructs were 
sequenced for accuracy. 
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II.1.3 pME-mCherry-T2A-BRAFWT and pME-mCherry-T2A-BRAFV600E 
plasmids  
Full-length human B-type Raf kinase (BRAF)WT and BRAFV600E coding sequences were 
amplified by PCR from expression vectors previously generated in my lab: pCMV-
BRAFWT and pCMV-BRAFV600E, respectively (Faustino et al., 2012) using the following 
primers: forward primer 5’-CCGGCCCTATGGCGGCGCTGAGC-3’ and reverse 
primer 5’- GTTTCCTGTCCACTGATGATATCG-3’. mCherry coding sequence was 
amplified by PCR from pME-mCherry (Kwan et al., 2007) using the following 
primers: forward primer 5’-GGGCCCCCCCTCGAGGGCCGCCACCATGGTG-3’ and 
reverse primer 5’-GAGAATCCCGGCCCTATGGCGGC-3’. T2A sequence (5’-
GAGGGCAGAGGAAGTCTTCTAACATGCGGTGACGTGGAGGAGAATCCCGGCCCT-3’) 
was synthetized as an oligomer of 54bp and amplified by PCR. All PCR products 
generated were purified individually and assembled in frame into a previously 
linearized pME-MCS (containing attL1 and attL2 recombination sites) using the 
GeneArt® Seamless Assembly Kit (Thermo Fisher Scientific) and according to the 
following order: (1st) mCherry - (2nd) T2A – (3rd) BRAFWT or BRAFV600E. Ligation product 
was transformed into One Shot® TOP10 Chemically Competent Cells (Thermo 
Fisher Scientific Inc.). The full-length constructs were sequenced for accuracy. 
 
II.1.4 pTol2A2-tg:mCherry–pA and pTol2CG2-tg:mCherry–pA plasmids  
p5E-tg promoter, pME-mCherry and p3E-polyA were assembled into a 
pDestTol2pA2, containing attR4 and attR3 recombination sites and provided by the 
Tol2Kit (Kwan et al., 2007), using a Gateway LR Clonase II Enzyme Mix (Thermo 
Fisher Scientific Inc.) and according to the manufacturer’s instructions. Ligation 
product was transformed into One Shot® TOP10 Chemically Competent Cells 
(Thermo Fisher Scientific Inc.). The full-length pTol2A2-tg:mCherry–pA construct 
was sequenced for accuracy. Same protocol was performed to generate the 
pTol2CG2-tg:mCherry–pA, however the three entry clones were assembled into a 
pDestTol2CG2, containing the cmlc2:EGFP cassette and the attR4 and attR3 
recombination sites, provided by the Tol2Kit (Kwan et al., 2007) (Figure 1). The 
full-length pTol2CG2-tg:mCherry–pA construct was sequenced for accuracy. 
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Figure 1. Gateway cloning strategy to generate the pTol2CG2-tg:mCherry-pA plasmid. 
Schematic of the three-part LR recombination reaction used to generate pTol2CG2-
tg:mCherry-pA. Entry clones (p5E-tg, pME-mCh and p3E-pA) containing attL sites and 
pDestTol2CG2 destination plasmid containing attLR sites recombined when LR clonase was 
added to the reaction. 
 
II.1.5 pTol2CG2-tg:mCherry-T2A- BRAFV600E–pA plasmids  
p5E-tg promoter, pME-mCherry-T2A-BRAFV600E and p3E-polyA were assembled into 
a pDestTol2CG2, containing the cardiac myosin light chain (cmlc2): enhanced 
green fluorescent protein (EGFP) cassette and containing attR4 and attR3 
recombination sites, provided by the Tol2Kit (Kwan et al., 2007) using a Gateway 
LR Clonase II Enzyme Mix (Life Technologies) and according to the manufacturer’s 
instructions (Figure 2). Ligation product was transformed into One Shot® TOP10 
Chemically Competent Cells (Thermo Fisher Scientific Inc.). The full-length 
pTol2CG2-tg:mCherry-T2A-BRAFV600E–pA construct was sequenced for accuracy. 
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Figure 2. Gateway cloning strategy to generate the pTol2CG2-tg:mCherry-T2A-
BRAFV600E-pA plasmid. Schematic of the three-part LR recombination reaction used to 
generate pTol2CG2-tg:mCherry-T2A-BRAFV600E –pA. Entry clones (p5E-tg, pME-mCh-T2A-
BRAFV600E and p3E-pA) containing attL sites and pDestTol2CG2 destination plasmid 
containing attLR sites recombined when LR clonase was present in the reaction. 
 
II.1.6 pTol2CG2-tg:loxP-CFP-loxP-mCherry–pA and pTol2CG2-tg:loxP-
CFP-loxP-mCherry-T2A-BRAFV600E–pA plasmids  
pTol2CG2-tg:mCherry-pA was cut with SalI (Thermo Fisher Scientific Inc.), gel 
purified and dephosphorylated with Shrimp Alkaline Phosphatase (SAP) (Thermo 
Fisher Scientific Inc.). loxP-cyan fluorescent protein (CFP)-loxP was amplified from 
a donor plasmid generated in the lab (unpublished plasmid) using the following 
primers: forward primer 5’-
CAAGCTTATCGATACCGCCCGGGATAACTTCGTATAATGTATGCTATACGAAGTTATC
TTG-3’ and reverse primer 5’-CTAGAGAAGCTGAGGACAGGGATCCGGCCGGCC-3’. 
These primers were engineered for recombination deoxyribonucleic acid (DNA) 
assembly and the PCR product was gel purified. Plasmid and insert were ligated 
using the Gibson Assembly Cloning Kit (New England Biolabs) and ligation product 
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was transformed into One Shot® TOP10 Chemically Competent Cells (Thermo 
Fisher Scientific Inc.). The full-length pTol2CG2-tg:loxP-CFP-loxP-mCherry-pA 
construct was sequenced for accuracy. Same protocol was performed to generate 
the pTol2CG2-tg:loxP-CFP-loxP-mCherry-T2A-BRAFV600E–pA however pTol2CG2-
tg:mCherry-T2A-BRAFV600E–pA was used as a backbone. The full-length pTol2CG2-
tg:loxP-CFP-loxP-mCherry-T2A-BRAFV600E–pA construct was sequenced for 
accuracy. 
 
 
 
Figure 3. Cloning strategy to generate conditional constructs. (A) pTol2CG2-tg:loxP-
CFP-loxP-mCherry–pA and (B) pTol2CG2-tg:loxP-CFP-loxP-mCherry-T2A-BRAFV600E–pA 
plasmids. The loxP-CFP-loxP cassette was inserted into previously generated constructs. 
Scissor represent SalI cut. 
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II.1.7 pCS2-CMV:mCherry-pA plasmid  
pTol2-tg:mCherry–pA and pCS2-CMV plasmid were excised with BamI (Thermo 
Fisher Scientific Inc.). mCherry insert was gel purified and linearized pCS2-CMV 
was dephosphorylated with SAP (Thermo Fisher Scientific Inc.). Plasmid and insert 
were ligated using T4 ligase (Thermo Fisher Scientific Inc.) and ligation product was 
transformed into One Shot® TOP10 Chemically Competent Cells (Thermo Fisher 
Scientific Inc.) (Figure 3). The full-length pCS2-CMV:mCherry-pA construct was 
sequenced for accuracy. 
 
II.1.8 pCS2-CMV:mCherry-T2A-BRAFWT-pA and pCS2-CMV:mCherry-
T2A-BRAFV600E-pA plasmids 
pME-mCherry-T2A-BRAFWT and pCS2-CMV plasmid were excised with XbaI 
(Thermo Fisher Scientific Inc.) and XhoI (Thermo Fisher Scientific Inc.). mCherry-
T2A-BRAFWT insert was gel purified and linearized pCS2-CMV was 
dephosphorylated with SAP (Thermo Fisher Scientific Inc.). Plasmid and insert were 
ligated using T4 ligase (Life Technologies) and ligation product was transformed 
into One Shot® TOP10 Chemically Competent Cells (Thermo Fisher Scientific Inc.). 
The full-length pCS2-CMV:mCherry-T2A-BRAFWT-pA construct was sequenced for 
accuracy. Same protocol was performed to generate the pCS2-CMV:mCherry-T2A-
BRAFV600E-pA however pME-mCherry-T2A-BRAFV600E was used to excise the 
mCherry-T2A-BRAFV600E insert (Figure 4). The full-length pCS2-CMV:mCherry-T2A-
BRAFV600E-pA construct was sequenced for accuracy. 
 
II.1.9 Summary of the plasmids generated 
Table 1 summarizes the plasmids generated in this work. 
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Name Insert Size 
5’ entry clones (kanamycin resistant) 
p5E-tg promoter 2.0 kb tg promoter 4843 
Middle entry clones (kanamycin resistant) 
pME-mCherry mCh 3261 
pME-mCherry-T2A-
BRAFWT 
mCh and BRAFWT separated by T2A sequence 5818 
pME-mCherry-T2A-
BRAFV600E 
mCh and BRAFV600E separated by T2A sequence 5818 
3’ entry clone (kanamycin resistant) 
p3E-polyA SV40 late polyA signal 2838 
Destination vector (ampicillin resistant) 
pTol2-tg:mCherry-pA tg promoter and mCh reporter*† 7385 
pTol2CG2-
tg:mCherry-pA 
tg promoter and mCh reporter*† 9298 
pTol2CG2-
tg:mCherry-T2A-
BRAFV600E-pA 
tg promoter, mCh reporter and BRAFV600E 
separated by T2A sequence*† 
 
11855 
pTol2CG2-tg:loxP-
CFP-loxP-mCherry–pA  
tg promoter, CFP flanked by loxP inverted 
sequences and mCh reporter*† 
 
10604 
pTol2CG2-tg:loxP-
CFP-loxP-mCherry-
T2A-BRAFV600E–pA 
tg promoter, CFP flanked by loxP inverted 
sequences and mCh reporter and BRAFV600E 
separated by T2A sequence*† 
 
13161 
Plasmids for in vitro RNA transcription 
pCS2-CMV: mCherry-
pA 
CMV/SP6 cassette with mCh reporter * 4934 
pCS2-CMV: mCherry-
T2A-BRAFWT-pA 
CMV/SP6 cassette with mCh reporter and and 
BRAFWT separated by T2A sequence* 
 
7203 
pCS2-CMV: mCherry-
T2A-BRAFV600E-pA 
CMV/SP6 cassette with mCh reporter and and 
BRAFV600E separated by T2A sequence* 
 
7203 
 
Table 1. List of plasmids generated for transgenesis or in vitro RNA transcription.  
* with SV 40 polyA; † flanked by Tol2 inverted repeats 
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II.2 Cloning-auxiliary techniques 
II.2.1 PCR 
To produce small PCR products, standard PCR protocols using non-proofreading 
enzymes (DreamTaq™ DNA polymerase, Thermo Fisher Scientific Inc. and GoTaq® 
DNA Polymerase, Promega) were performed according to manufacturer’s 
instructions. To produce large PCR products for cloning, PCR protocols using high 
proofreading enzymes (iProof™ High-Fidelity DNA Polymerase, BioRad and Phusion 
High-Fidelity DNA Polymerase, Thermo Fisher Scientific Inc.) were performed 
according to manufacturer’s instructions. PCR reactions were optimized to 
generate none or very few unspecific amplicons and specific PCR products were 
sequenced for accuracy.  
 
II.2.2 DNA sequencing 
PCR products or DNA plasmids to be sequenced were processed using the BigDye® 
Terminator v3.1 Cycle Sequencing Kit (Thermo Fisher Scientific Inc.) and according 
to the manufacturer’s instructions. Cycle sequencing include the following 
conditions: initial denaturation step at 96ºC for 2 minutes followed by 35 cycles at 
96ºC for 10 seconds, 55ºC (or more according to the primer annealing 
temperature) for 30 seconds and 60ºC for 2 minutes and a final extension cycle at 
60ºC for 10 minutes. Samples were centrifuged and purified using Sephadex™ G-
50 (GE Healthcare) columns and denatured with an equal volume of formamide (GE 
Healthcare). Sequencing products were resolved by capillary electrophoresis at the 
Institute of Molecular Pathology and Immunology at the University of Porto 
(IPATIMUP) Sequencing Service Unit and analyzed using the ABI PRISM® BigDye® v3 
Software (Thermo Fisher Scientific Inc.).  
 
II.2.3 DNA quantification 
DNA quantification was determined by spectrophotometry using the Nanodrop 
2000 spectrophotometer (Thermo Fisher Scientific Inc.). The purity of the nucleic 
acid preparation was estimated by the ratio between the readings obtained at 260 
nm and 280 nm (pure preparations of DNA show ratio values of 1.8-2.0). 
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II.2.4 Restriction digestion and ligation 
Restriction digestions of plasmid DNA were performed using commercial 
restriction enzymes and buffers and according to manufacturer’s instructions. For 
most restriction digestions, overnight incubations at 37ºC were performed and the 
volume of enzyme used in each reaction never exceeded 10% of the final reaction 
volume.  
Ligation was performed using a commercial T4 ligase and buffer (Thermo Fisher 
Scientific Inc.) and according to manufacturer’s instructions. All reactions were 
carried out in a final volume of 10μL unless otherwise specified by the 
manufacturer. 
 
II.2.5 Isolation of DNA by agarose gel electrophoresis 
To isolate DNA by agarose gel electrophoresis, agarose gels were prepared with 1x 
Tris base, acetic acid and EDTA solution (TAE) buffer or Tris base, boric acid and 
EDTA solution (TBE) buffer. The final agarose concentration (ranging from 0.8% to 
2.0%) was dependent on the size of the DNA fragments to be isolated. Samples 
were stained with a GelRed working solution prior to loading into the gel. DNA 
fragments were manually excised from the gel and purified using the Wizard® SV 
Gel and PCR Clean-Up System (Promega) and following the manufacturer’s 
instructions. 
 
II.2.6 Plasmid transformation in competent E. Coli 
All plasmids described in this chapter except the pDest plasmids had either 
ampicillin or kanamycin resistance genes and they were transformed and grown in 
ampicillin or kanamycin, respectively, using One Shot® TOP10 Chemically 
Competent Cells (Thermo Fisher Scientific Inc.). pDest-plasmids had ampicillin and 
chloramphenicol resistance genes and they were transformed and grown in 
ampicillin/chloramphenicol using One Shot® ccdB Survival™ 2 T1R Chemically 
Competent Cells (Thermo Fisher Scientific Inc.). For plasmid transformation, frozen 
aliquots of competent cells were thawed on ice. Plasmid DNA (10-50ng/uL) was 
added directly into 50-100μL of cells followed by incubation on ice for 30 minutes. 
The cells/DNA mix was heatshocked for 42 seconds at 42 ºC and then incubated 
on ice for 2 minutes. 150μL of pre-warmed Super Optimal Broth (0.5% Yeast 
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Extract, 2% Tryptone, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4 and 
20 mM Glucose) was added to the mix and incubated at 37 ºC for 60 minutes at 
225rpm. This last step was always performed for kanamycin and 
ampicillin/chloramphenicol resistant plasmids and for larger ampicillin resistant 
plasmids.  
 
II.2.7 Plasmid growth in solid and liquid cultures 
Competent E.coli used for plasmid transformation was spread on plates containing 
a solid medium of lysogeny broth (LB) and agar (10g Bacto-tryptone, 5g yeast 
extract, 10g NaCl and 15g agar, pH 7.5). Liquid cultures containing LB medium 
were prepared by picking single colonies from LB-agar plates. Solid and liquid 
media were supplemented with the appropriate antibiotic: ampicillin (50-
100μg/mL), kanamycin (50μg/mL) and chloramphenicol (30μg/mL). Cultures were 
grown overnight (12-16 hours) at 37ºC (shaking was only required for liquid 
cultures). 
 
II.2.8 Plasmid purification 
For small scale extraction and purification of plasmid DNA, 5mL-liquid culture 
(previously screened by colony PCR) was prepared from single colonies. The culture 
was pelleted for 5 minutes at 5000g and the supernatant was discarded. The 
purification was performed using the NZYMiniprep (Nzytech) according to the 
manufacturer’s instructions. For large scale extraction and purification of plasmid 
DNA, 100mL-liquid culture was prepared from pre-innoculated 5mL-liquid 
cultures. The culture was pelleted for 30 minutes at 3000g at 4ºC and the 
supernatant was discarded. The purification was performed using the NZYMidiprep 
(Nzytech) according to the manufacturer’s instructions. 
 
II.3 Capped messenger ribonucleic acid (mRNA) synthesis  
II.3.1 Capped transposase mRNA synthesis  
pCS2FA-transposase plasmid was provided by the Tol2Kit (Kwan et al., 2007). The 
plasmid was linearized using NotI (Thermo Fisher Scientific Inc.) and gel-purified. 
In vitro capped transcription was performed using Ambion mMessage mMachine 
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SP6 Kit (Thermo Fisher Scientific Inc.) and according to the manufacturer’s 
instructions. In vitro transcribed transposase mRNA was purified using Illustra 
Microspin G-50 (GE Healthcare) columns and run on an agarose gel to confirm its 
integrity. 
 
II.3.2 Capped mCherry mRNA, mCherry-T2A-BRAFWT mRNA and 
mCherry-T2A-BRAFV600E mRNA synthesis  
pCS2-CMV:mCherry was linearized using HpaI (Thermo Fisher Scientific Inc.) and 
gel-purified. In vitro capped transcription was performed using Ambion mMessage 
mMachine SP6 Kit (Thermo Fisher Scientific Inc.) and according to the 
manufacturer’s instructions. In vitro transcribed mCherry mRNA was purified using 
Illustra Microspin G-50 columns (GE Healthcare) and run on an agarose gel to 
confirm its integrity. Same protocol was used to synthesize capped mCherry-T2A-
BRAFWT and mCherry-T2A-BRAFV600E mRNAs using the pCS2-CMV:mCherry-T2A-
BRAFWT and pCS2-CMV:mCherry-T2A-BRAFV600E plasmids, respectively. 
 
II.4 Microinjections  
Microinjections were performed to establish transgenic lines and in mRNA 
experiments. 
 
II.4.1 DNA plasmid microinjections  
pTol2-tg:mCh-pA, pTol2CG2-tg:mCh–pA, pTol2CG2-tg:mCh-T2A-BRAFV600E–pA, 
pTol2CG2-tg:loxP-CFP-loxP-mCh–pA and pTol2CG2-tg:loxP-CFP-loxP-mCh-
T2A-BRAFV600E–pA plasmids were used to generate the transgenic lines described in 
this thesis. Plasmid DNA was co-injected with capped transposase mRNA into one-
cell stage wild-type (WT) or tg(hsp70l:mCherry-T2A-CreERT2) embryos at a final 
concentration of 30ng/μL and 25ng/μL, respectively. Diethylpyrocarbonate 
(DEPC)-water was used to bring the injection mix to a final volume of 10μL. 
Microinjections were performed using the following apparatus: SZX10 Stereo 
Microscope (Olympus), PV820 Pneumatic PicoPump (World Precision Instruments, 
Inc.), MN-153 Micromanipulator (Narishige) and MPH6S Microelectrode holder 
(World Precision Instruments, Inc.). The following injection settings were used: hold 
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pressure set for 3PSI (vent port), eject pressure set for 20PSI (vent port), range set 
for 100ms, duration set for gated, period dial set for 7.0. The needle was calibrated 
to a final drop volume of 1.4nL. 
 
II.4.2 Capped mRNA microinjections  
Capped mCherry, mCherry-T2A-BRAFWT mRNA or mCherry-T2A-BRAFV600E mRNAs 
were microinjected into the yolk of one-cell stage WT or tp53M214K embryos at a final 
concentration of 35ng/μL. DEPC-water was used to bring the injection mix to a 
final volume of 10μL. Microinjections were performed using the following 
apparatus: SZX10 Stereo Microscope (Olympus), PV820 Pneumatic PicoPump (World 
Precision Instruments, Inc.), MN-153 Micromanipulator (Narishige) and MPH6S 
Microelectrode holder (World Precision Instruments, Inc.). The following injection 
settings were used: hold pressure set for 3PSI (vent port), eject pressure set for 
20PSI (vent port), range set for 100ms, duration set for gated, period dial set for 
7.0. The needle was calibrated to a final drop volume of 1nL. 
 
II.5 Transgenesis 
To generate transgenic lines, the following general protocol was used: (1) co-
microinjection of plasmid DNA and capped transposase mRNA as describe in II.4.1; 
(2) screening of injected embryos/larvae for the reporters expressed by the 
transgene; (3) raising injected larva to adulthood; (4) screening mosaic fish and 
select founders (germline transmission of the transgene) by PCR screening of 
sperm/eggs and/or progeny screening; (5) outcrossing with WT and/or tp53M214K 
fish and; (6) screening the transgenic progeny and raise to adulthood (Figure 4).  
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Figure 4. Transgenesis. General transgenesis strategy to generate the transgenic lines 
used in this work: from plasmid injections to F1 generations. 
 
II.5.1 WT lines 
tg(tg:mCh) Embryos from AB strain were injected with pTol2-tg:mCherry-pA 
plasmid to generate mosaic tg(tg:mCh) fish. Founder fish were crossed with WT 
fish to generate the tg(tg:mCh) line. These lines were selected for mCh reporter. 
 
tg(tg:mCh;cmlc2:EGFP) lines Embryos from AB strain were injected pTol2CG2-
tg:mCherry-pA plasmid to generate mosaic tg(tg:mCh;cmlc2:EGFP) fish. Founder 
fish were crossed with WT fish to generate the tg(tg:mCh;cmlc2:EGFP) line. These 
lines were selected for mCh and EGFP reporters, respectively. 
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tg(tg:mCh-T2A-BRAFV600E;cmlc2:EGFP) line Embryos from AB strain were injected 
with pTol2CG2-tg:mCherry-T2A-BRAFV600E-pA plasmid to generate mosaic 
tg(tg:mCh-T2A-BRAFV600E;cmlc2:EGFP) fish. Founder fish were crossed with WT fish 
to generate the tg(tg:mCh-T2A-BRAFV600E;cmlc2:EGFP) line. This line was selected 
for mCh and EGFP reporters. 
 
tg(tg:mCh; tg:mCh-T2A-BRAFV600E;cmlc2:EGFP) line tg:mCh fish were crossed 
with tg(tg:mCh-T2A-BRAFV600E;cmlc2:EGFP) fish to produce the tg(tg:mCh; tg:mCh-
T2A-BRAFV600E;cmlc2:EGFP) line. This line was selected for mCh and EGFP reporters.  
 
tg(hsp70l:mCh-T2A-CreERT2; tg:loxP-CFP-loxP-mCh; cmlc2:EGFP) line 
tg(hsp70l:mCh-T2A-CreERT2) fish were used to provide embryos to inject the 
pTol2CG2-tg:loxP-CFP-loxP-mCherry–pA plasmid and generate mosaic 
tg(hsp70l:mCh-T2A-CreERT2; tg:loxP-CFP-loxP-mCh; cmlc2:EGFP) fish. Founder 
fish were crossed with WT fish if they carried the hsp70l:mCh-T2A-CreERT2 allele 
or tg(hsp70i:mCh-T2A-CreERT2) fish if they did not. This line was selected for CFP 
and EGFP reporters and the hsp70l:mCh-T2A-CreERT2 allele. 
 
tg(hsp70l:mCh-T2A-CreERT2; tg:loxP-CFP-loxP-mCh T2A-BRAFV600E; 
cmlc2:EGFP) line tg(hsp70l:mCh-T2A-CreERT2) fish were used to provide embryos 
to inject the pTol2CG2-tg:loxP-CFP-loxP-mCherry-T2A-BRAFV600E–pA plasmid and 
generate mosaic tg(hsp70l:mCh-T2A-CreERT2; tg:loxP-CFP-loxP-mCh T2A-
BRAFV600E; cmlc2:EGFP) fish. Founder fish were crossed with WT fish if they carried 
hsp70l:mCh-T2A-CreERT2 allele or tg(hsp70i:mCh-T2A-CreERT2) fish if they did not. 
This line was selected for CFP and EGFP reporters and the hsp70l:mCh-T2A-CreERT2 
allele. 
 
II.5.2 tp53M214K lines 
tp53M214K tg(tg:mCh) line tp53M214K fish were crossed with tg(tg:mCh) fish to 
produce heterozygous tp53M214K tg(tg:mCh). This line was crossed again with 
tp53M214K fish to produce homozygous tp53M214K tg(tg:mCh) fish. All lines were 
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selected for mCh reporter. tp53M214K mutation was confirmed by genotyping the fin 
of selected fish. 
 
tp53M214K tg(tg:mCh;cmlc2:EGFP) line tp53M214K fish were crossed with 
tg(tg:mCh;cmlc2:EGFP) fish to produce heterozygous tp53M214K 
tg(tg:mCh;cmlc2:EGFP). This line was crossed again with tp53M214K fish to produce 
homozygous tp53M214K tg(tg:mCh;cmlc2:EGFP) fish. All lines were selected for mCh 
and EGFP reporters. tp53M214K mutation was confirmed by genotyping the fin of 
selected fish. 
 
tp53M214K tg(tg:mCh-T2A-BRAFV600E;cmlc2:EGFP) line tp53M214K fish were crossed 
with tg(tg:mCh-T2A-BRAFV600E;cmlc2:EGFP) fish to produce a heterozygous tp53M214K 
tg(tg:mCh-T2A-BRAFV600E;cmlc2:EGFP) line. This line was crossed again with 
tp53M214K fish to produce a homozygous tp53M214K tg(tg:mCh-T2A-
BRAFV600E;cmlc2:EGFP) line. All lines were selected for mCh and EGFP reporters. 
tp53M214K mutation was confirmed by genotyping the fin of selected fish. 
 
tp53M214K tg(tg:mCh; tg:mCh-T2A-BRAFV600E;cmlc2:EGFP) line tp53M214K 
tg(tg:mCh) fish were crossed with tp53M214K tg(tg:mCh-T2A-BRAFV600E;cmlc2:EGFP) 
fish to produce the tp53M214K tg(tg:mCh; tg:mCh-T2A-BRAFV600E;cmlc2:EGFP) line. 
This line was selected for mCh and EGFP reporters. tp53M214K mutation was 
confirmed by genotyping the fin of selected fish. 
 
II.6 Fish strains and husbandry 
AB wild-type fish was the zebrafish strain used throughout the work. Embryos and 
larvae <7dpf/dpi were collected from pair mating or outcrosses and kept in embryo 
medium (5.0mM NaCl, 0.17mM KCl, 0.33mM CaCl,  0.33mM MgSO4, 0.05% 
methylene blue, pH 7.4) at 28ºC on a 14 hour light/10 hour dark cycle. Zebrafish 
≥7dpf/7dpi were kept in a recirculating system at 28ºC on a 14 hour light/10 hour 
dark cycle according to Westerfield et al., 2000. Fish were kept in standard 
densities (10-12 fish/liter of water). 
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II.7 Screening and Imaging 
The transgenic lines generated expressed mCherry, EGFP and/or CFP reporters. 
Screening of embryos, larvae and adult fish was performed on a Zeiss Stereo LUMAR 
stereoscope. Images were acquired on the Zeiss Stereo Lumar.V12 stereoscope 
equipped with a Hamamatsy Orca-ER CCD Camera, controlled with the 
MicroManager v1.14 software. Bright field (BF) images were acquired using the 
Lumar filter LP420 and fluorescence images were acquired with Lumar filters for 
Texas Red®, EGFP and CFP. 
 
II.8 Fin clip and gDNA extraction 
Fish were fasten, prior to anesthesia, in tricaine methane sulfonate 
(MS222) (168ug/L, Sigma). The fin was clipped with a sharp scalpel at a point not 
greater than halfway between the tip of the fin and the point where the scales end. 
Fish were then immediately transferred to a container with fresh system water and 
monitored until they recovered and regained swimming ability. Fin tissue was 
placed in an eppendorf tube containing 100μL of 50mM NaOH. The sample was 
heated at 95ºC for 15 minutes or until the tissue was noticeably friable. The sample 
was cooled to 4ºC and 1/10th volume of 1M Tris-HCl, pH 8.0 was added to 
neutralize the basic solution. A centrifugation to pellet the debris was performed 
at maximum speed for 10 minutes at room temperature. The supernatant 
containing the genomic DNA was collected to a new tube and stored at 4ºC or 
longer at -20ºC.  
 
II.9 Genotyping 
tp53M214K mutation was genotyped using primers to amplify the loss-of-function 
(LOF) point mutation on exon 7 of the  zebrafish tp53 gene (homozygous fish were 
selected if T>A was in both alleles; heterozygous fish were selected if T>A was in 
one allele) as described by Berghmans et al., 2005. The following primers were 
used: forward primer 5’-CACAAGTGTCCTGTTATCGAT-3’ and reverse primer 5’-
CATGGCAAGGCAACTGAACTGT-3’. 
Conditional lines were also genotyped for the hsp70l:mCh-T2A-CreERT2 allele using 
primers to amplify the Cre recombinase (Cre) coding sequence. The 
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tg(hsp70l:mCherry-T2A-CreERT2) line (Hans et al., 2011) does not have a 
transgenesis marker and progeny from this line can result in WT or transgenic fish. 
It was only possible to genotype adults. The following primers were used: forward 
primer 5’-GCATTTCTGGGGATTGCTTA-3’ and reverse primer 5’-
CCCGGCAAAACAGGTAGTTA-3’. 
 
II.10 Histopathology 
7dpf larvae were euthanized by submersion in ice water (5 parts of ice/1 part of 
water, 0-4ºC) for at least twenty minutes to ensure death by hypoxia. Larvae ≥8dpf 
were euthanized by an overdose of MS222 (200mg/L, Sigma) by prolonged 
immersion. Larvae 7-14dpf were fixed in formaldehyde (Sigma-Aldrich) for one 
day and larvae ≥15dpf were fixed in formaldehyde (Sigma-Aldrich) for two days 
and then decalcified in 0.5M ethylenediaminetetraacetic acid (EDTA) for one or two 
more days before paraffin embedding and sectioning. 3μm longitudinal sections 
representative of the whole larvae or representative of the adult head were 
performed. Hematoxylin-Eosin (HE) staining were performed according to standard 
techniques by the HistopathUnit at Instituto Gulbenkian de Ciência (IGC).  
Images were acquired on a Leica DM LB2 upright microscope equipped with an IDS 
color CCD camera using the following objectives: 10x 0.25NA and 40x 0.75NA and 
using the uEye Cockpit software (Imaging Development Systems GmbH, Germany).  
 
II.11 Measurement of standard length in larvae 
Parichy et al., 2009 proposed standard length (SL), defined by the distance from 
the snout to the caudal peduncle, as a readout of developmental stage (Parichy et 
al., 2009). SL was measured at 7dpf in larvae anesthetized in tricaine methane 
sulfonate (MS222 168ug/L, Sigma). Images were acquired on the Zeiss Stereo 
LUMAR stereoscope equipped with a Hamamatsy Orca-ER CCD Camera and EGFP 
and Texas Red® filtersets, controlled with the MicroManager v1.14 software. 
Measurements were performed using the LAS AF Lite software (Leica 
Microsystems). 
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II.12 Measurement of body mass index (BMI) 
Body weight (kg) and body length (m) of adult fish were measured at 3 months post 
fertilization (mpf) and 12mpf. Fish were fasten prior to anesthesia in 
MS222 (168ug/L, Sigma). Body length was measured from the head to the end of 
the caudal fin. Body weight and body length were used to calculate the BMI 
according to the formula: BMI = (body weight kg)/(body length m2).  
 
II.13 Measurement of thyroid volume in adult fish 
Paraffin blocks were exhaustively sectioned into 3-μm-thick sections covering the 
whole thyroid of the adult fish as previously described. Thyroid middle sections 
were determined according to the distance between the first and the last sections 
displaying thyroid tissue and the ventral aorta position. 5 longitudinal sections of 
each fish were chosen (middle section, 1/3 and 2/3 of total thyroid sections 
starting from the middle section) (Figure 5). Images were acquired on a Leica DM 
LB2 upright microscope equipped with an IDS color CCD camera using the following 
objectives: 10x 0.25NA and 20x 0.5NA and using the uEye Cockpit software 
(Imaging Development Systems GmbH, Germany). To measure the follicle area, 
measurements were performed on ImageJ2 (National Institutes of Health, USA) and 
for each fish total follicle area was calculated by the sum of all individual areas. To 
calculate a representative total thyroid volume, total follicle area and thickness 
were multiplied.  
 
Figure 5. Measurement of thyroid volume in adult fish using five 3-μm-thick sections 
that would be representative of the volume. Pink circles outlined by purple dashes 
represent thyroid follicles and grey boxes represent 3μm-tissue sections.  
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II.14 Preparation of embryo lysates 
Embryos from mRNA experiments were manually dechorionated and deyolked at 
4hpf/4hpi (n=50) as described by Link et al., 2006. Embryo lysates were prepared 
by adding 100μL of radioimmunoprecipitation assay buffer (RIPA) Buffer (10 mM 
Tris-Cl pH 8.0, 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1% sodium 
deoxycholate, 0.1% SDS, 140 mM NaCl and 1 mM PhenylMethylSulfonyl Fluoride-
PMSF) supplemented with 1x phosphatase and 1x protease inhibitors 
(ThermoFisher Scientific). Embryos were mashed with a cell pestle for 30 seconds 
on ice. Protein extracts were incubated for 30 minutes on ice and centrifuged at 
13.000rpm for 10 minutes at 4ºC. The supernatant was collected to a new 
eppendorf tube and stored at -80ºC prior to use.  
 
II.15 Dissection of thyroid tissue in adult zebrafish 
Adult zebrafish was euthanized by an overdose of MS222 (200mg/L, Sigma, MI, 
USA) by prolonged immersion, rinse in water and then dried on a paper towel. 
Thyroid tissue was dissected with the help of a Zeiss Stereo LUMAR stereoscope 
and immediately transferred to an eppendorf placed on dry ice until preparation of 
tissue lysates.   
 
II.16 Preparation of tissue lysates 
Tissue lysates were prepared by adding 100μL of RIPA Buffer (10 mM Tris-Cl pH 
8.0, 1 mM EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% 
SDS, 140 mM NaCl and 1 mM PMSF) supplemented with 1x phosphatase and 1x 
protease inhibitors (ThermoFisher Scientific). Dissected tissue was mashed with a 
cell pestle for 45 seconds on ice. Protein extracts were incubated on ice for 30 
minutes and centrifuged at 13000rpm for 10 minutes at 4ºC. The supernatant was 
collected to a new eppendorf tube and stored at -80ºC prior to use.  
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II.17 Immunoblotting 
Total protein extracts from tissue or embryo lysates were thawed and prepared by 
adding an equal volume of 2x Laemmli sample buffer (100 mM Tris-Cl pH 6.8, 2% 
SDS and 20% glycerol supplemented with 1/10 volume of B-mercaptoethanol). 
Samples were heated at 95ºC for 5 minutes and immediately run in 10% sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE) gels. After proper 
resolution, samples were transferred to HyBond-P PVDF membranes (GE 
Healthcare) previously activated with methanol. Following the transfer, the 
membranes were stained with Ponceau Red to confirm protein loading. Membranes 
were blocked with 5% non-fat milk in 1x tris-buffered saline (TBS)-t20 for 60 
minutes in slow shaking. Then, membranes were probed overnight at 4ºC with 
primary antibodies. The following primary antibodies and dilutions were used: 
Living Colors® DsRed Polyclonal Antibody (dilution 1:1000 in 5% non-fat milk in 1x 
TBS-t20, Clontech Lab), Raf-B Antibody - C19 sc:166, (dilution 1:500 in 5% non-
fat milk in 1x TBS-t20, Santa Cruz Biotechnology), phospho p44/42 MAPK (ERK1/2) 
(Thr202/Tyr 204) Antibody (dilution 1:1000 in 5% non-fat milk in 1x TBS-t20, Cell 
Signaling), PCNA Antibody FL-261 (dilution 1:1000 in 5% non-fat milk in 1x TBS-
t20, Santa Cruz Biotechnology), CDKN2a/p16 (F12) Antibody (dilution 1:1000 in 5% 
non-fat milk in 1x TBS-t20, Santa Cruz Biotechnology), p53 Antibody (dilution 
1:500 in 5% non-fat milk in 1x TBS-t20, Anaspec), Anti-active caspase 3 Antibody 
(dilution 1:500 in 5% non-fat milk in 1x TBS-t20, Abcam), Anti-pan-Akt (Phospho 
T308) Antibody (dilution 1:1000 in 5% non-fat milk in 1x TBS-t20, Abcam), 
Phospho-Akt (Ser 473) (D9E) XP® Antibody (dilution 1:1000 in 5% non-fat milk in 
1x TBS-t20, Cell Signaling) and Phospho-p38 MAPKinase (Thr180/Tyr182) 
Antibody (dilution 1:1000 in 5% non-fat milk in 1x TBS-t20, Cell Signaling). 
Overnight probing was followed by washes in 1x TBS-t20 and by incubation for 1-
3 hours at room temperature with species-specific horseradish peroxidase (HRP)-
conjugated antibodies. The following secondary antibodies and dilutions were 
used: goat anti-mouse IgG-HRP Antibody (dilution 1:1000 or 1:2000 in 5% non-
fat milk in 1x TBS-t20, Santa Cruz Biotechnology) and goat anti-rabbit IgG-HRP 
Antibody (dilution 1:1000/1:2000 in 5% non-fat milk in 1x TBS-t20, Santa Cruz 
Biotechnology, USA). Membranes were washed in 1x TBS-t20 and developed 
manually using the Pierce™ ECL Plus Western Blotting Substrate detection system 
(ThermoFisher Scientific). Protein expression levels from western blot band 
densities were quantified on ImageJ2 and normalized for tubulin. 
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II.18 Heatshock and drug treatment 
2 ½ mpf fish were heat-shocked in a 37ºC water bath for 30 minutes and 
immediately a drug treatment was carried out. 4-hydroxyl-tamoxifen (4-OHT) 
(H7904, Sigma) was dissolved at 10mM in 100% ethanol and stored at -20ºC 
(protected from light). Subsequent dilutions to prepare working solutions were 
made immediately before use, in embryo medium, to 2.5μM. Controls were treated 
with an equivalent amount of 100% ethanol diluted in embryo medium. Fish 
received treatment at 28ºC for 5 hours in the dark followed by a recovery period in 
fresh water for 12 hours. 
 
II.19 Statistical analysis 
Statistical analysis was performed using GraphPad Prism version 6.0 (GraphPad 
Software Inc, San Diego, CA) using T-Student test and Mann-Whitney U test. Results 
were considered statistically significant when p<0.05 (*p<0.05; **p<0.01; 
***p<0.001 and ****p<0.0001) and not statistically significant when p≥0.05. 
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III.1 Frequency of TERT promoter mutations in human cancers 
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Reactivation of telomerase has been implicated in human tumorigenesis, but the underlying
mechanisms remain poorly understood. Here we report the presence of recurrent somatic
mutations in the TERT promoter in cancers of the central nervous system (43%), bladder
(59%), thyroid (follicular cell-derived, 10%) and skin (melanoma, 29%). In thyroid cancers,
the presence of TERT promoter mutations (when occurring together with BRAF mutations) is
signiﬁcantly associated with higher TERT mRNA expression, and in glioblastoma we ﬁnd a
trend for increased telomerase expression in cases harbouring TERT promoter mutations.
Both in thyroid cancers and glioblastoma, TERT promoter mutations are signiﬁcantly
associated with older age of the patients. Our results show that TERTpromoter mutations are
relatively frequent in speciﬁc types of human cancers, where they lead to enhanced
expression of telomerase.
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R
eactivation or re-expression of telomerase is referred to be a
widespread feature in human cancers, although the genetic
basis remains poorly understood in many cancer types.
Somatic mutations in the coding region of TERT (human
telomerase reverse transcriptase) are infrequent in human
tumours, but germline and somatic mutations in TERT promoter
were recently found in a high percentage of human melanomas
and human cancer cell lines1,2. Such mutations occurred in two
hotspot positions, located  124 and  146 bp upstream from
the ATG start site ( 124 G4A and  146 G4A, C4T on
opposite strand) and conferred enhanced TERT promoter
activity1,2, by putatively generating a consensus binding site
(GGAA) for ETS transcription factors within the TERT promoter
region1,2.
Our aim was to investigate whether the aforementioned TERT
promoter mutations were present in cancer types other than
melanoma, having for that matter screened 741 primary tumours
from the thyroid, kidney, bladder, gastrointestinal stromal
tumour (GIST), adrenal medulla (phaeochromocytomas) and
central nervous system (CNS). Besides skin melanoma, we have
also included ocular melanoma (not studied in the previous
reports), benign lesions of the thyroid and skin and 58 human
cancer-derived cell lines. Our results highlight TERT promoter
mutations as frequent events in speciﬁc types of human cancers.
Results
TERT mutations in tumours and cell lines. Overall, TERT
promoter mutations were found in 142 (19%) human tumour
samples (Table 1; Fig. 1a) and 14 (24%) human cell lines (Fig. 1b;
Supplementary Tables S1 and S2). The  124-bp mutation was
the most frequent, being present in 99 cases, whereas the  146-
bp mutation was present in 43 cases. The  124 G4A and  146
G4A mutations were found in a mutually exclusive fashion. Two
tandem GG4AA mutations at positions  124/ 125 and
 138/ 139 bp were observed in one cell line each
(Supplementary Fig. S1 and Supplementary Table S1). TERT
promoter mutations were not detected in normal thyroid tissue
nor in benign lesions (nevi, thyroiditis, goitres and adenomas).
No mutations were detected in 26 kidney cancers, 17 phaeo-
chromocytomas and 36 GISTs.
TERT mutations in melanoma. We have analysed both skin and
ocular melanomas, a type of melanoma that was not previously
studied1,2. TERT mutations were present in 16 out of 56 (29%)
skin melanomas, but absent in the 25 ocular melanomas
(Table 1). All the four skin melanoma-derived cell lines but
none of the six ocular melanoma-derived cell lines harboured
TERT mutations (Fig. 1b and Supplementary Table S1). Ten out
of 16 (63%) skin melanomas with TERT mutation also harboured
the BRAFV600E mutation, whereas the BRAF mutation was
present in 9 out of 38 (24%) melanomas without TERT mutation
(P¼ 0.01, Fisher’s exact test, two-sided) (Supplementary Fig. S2
and Supplementary Table S3).
TERT mutations in CNS tumours. In CNS tumours, TERT
promoter mutations were found in 43% (51/118) of all cases
with an equal prevalence of both mutations (Table 1 and
Supplementary Table S4). The frequency of TERT mutations was
different according to the tumour histology and grade (Fig. 1c):
although pilocytic astrocytomas (World Health Organization
(WHO) grade 1) and diffuse astrocytoma (WHO grade 2) showed
a lower frequency of mutations (8% and 15%, respectively),
the most aggressive form, glioblastoma multiforme (GBM;
WHO grade 4), present the highest frequency of TERT mutations
(62%). Oligodendrogliomas (WHO grade 2) and anaplastic
oligodendrogliomas (WHO grade 3) also harboured a high fre-
quency of TERT mutations (45% and 54%, respectively).
The presence of TERT mutations was signiﬁcantly associated
with a higher mean age at diagnosis (Supplementary Table S5) in
CNS patients as a whole (Po0.0001; Mann–Whitney test, two-
tailed) and also in GBM patients only (P¼ 0.0247; Mann–
Whitney test, two-tailed); in oligodendroglioma patients, we
found the same trend, although not statistically signiﬁcant
(P¼ 0.0709; Mann–Whitney test, two-tailed). In addition, we
observed that, in a subset of 14 GBM (8 TERT wild-type tumours
and 6 TERT-mutated tumours), the tumours with TERT
mutations showed a trend to increased immunohistochemistry
(IHC) expression of telomerase, although this difference was
not statistically signiﬁcant (P¼ 0.4250; Mann–Whitney test,
two-tailed) (Fig. 2).
TERT mutations in thyroid cancer. We analysed a large series of
follicular cell-derived thyroid samples including normal thyroid
(n¼ 27), benign (n¼ 81) and malignant lesions (n¼ 263)
(Table 1 and Supplementary Table S6). TERT mutations were
only detected in malignant tumours (10%) (Fig. 1d), namely in
Table 1 | Prevalence of TERT promoter recurrent mutations
in human cancers.
Organ/tissue Number TERTmutation, N (%)
Melanocytes
Nevi 9 0
Skin melanoma 56 16 (29%)
Ocular melanoma 25 0
CNS
Pilocytic astrocytoma 13 1 (8%)
Diffuse astrocytoma 20 3 (15%)
Oligodendroglioma 22 10 (45%)
Anaplastic oligodendroglioma 24 13 (54%)
Glioblastoma 39 24 (62%)
Thyroid
Benign 81 0
PTC 169 13 (8%)
FTC 64 9 (14%)
PDTC 14 3 (21%)
ATC 16 2 (13%)
MTC 28 0
Bladder
Low grade 21 14 (67%)
High grade 61 34 (56%)
Kidney
CCRCC 12 0
CromRCC 4 0
PRCC 10 0
Adrenal
Phaeochromocytoma 17 0
GI
GIST 36 0
Total 741 142 (19%)
ATC, anaplastic thyroid carcinoma; CCRCC, clear cell renal cell carcinoma; CNS, central nervous
system; CromRCC, chromophobe renal cell carcinoma; FTC, follicular thyroid carcinoma;
GI, gastrointestinal; GIST, gastrointestinal stromal tumour; MTC, medullary thyroid carcinoma;
PDTC, poorly differentiated thyroid carcinoma; PRCC, papillary renal cell carcinoma; PTC,
papillary thyroid carcinoma.
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11% of papillary thyroid carcinomas (PTCs), 14% of follicular
thyroid carcinomas, 21% of poorly differentiated thyroid carci-
nomas and 13% of the anaplastic thyroid carcinomas. Within the
group of PTC, TERT mutations were detected to be associated to
the so-called conventional PTC (cPTC) (11%).The majority of
TERT-mutated thyroid cancers harboured the  124 G4A
mutation (22 out of 27 cases) (Fig. 1d and Supplementary
Table S7). In thyroid cancer patients, TERT mutations were sig-
niﬁcantly associated with guarded prognosis features such as
larger tumours (P¼ 0.008; Mann–Whitney test, two-tailed),
older patients (Po0.0001; Mann–Whitney test, two-tailed)
and male gender (P¼ 0.0312; Fisher’s exact test, two-sided)
(Supplementary Table S5). After histotype stratiﬁcation, such
correlations were only kept in the group of cPTC where we
also found signiﬁcant associations with lymph node metastasis
(P¼ 0.0318; Fisher’s exact test, two-sided) and BRAFV600E
mutation (P¼ 0.001; Fisher’s exact test, two-sided)
(Supplementary Fig. S2 and Supplementary Table S8). Accord-
ingly, we veriﬁed by quantitative RT-PCR (qPCR) that TERT
mRNA is expressed at variable amounts in thyroid tumours, and
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Figure 1 | Frequency and schematic illustration of TERT promoter mutations in human cancers. Graphics depict the overall frequency of TERTmutations
in the four tumour types where TERTmutations were detected (a) and a bar plot showing the number of cell lines of different origin that harbour
TERTmutations (b). The frequency and type of TERTmutations in different histological subtypes of CNS (c), thyroid (d) and bladder (e) tumours is also
shown. A, diffuse astrocytoma; AO, anaplastic oligodendroglioma; ATC, anaplastic thyroid carcinoma; GB-glioblastoma; FTC, follicular thyroid carcinoma;
O, oligodendroglioma; PA, pilocytic astrocytoma; PDTC, poorly differentiated thyroid carcinoma.
a b c P= 0.42510
8
6
4
2
0
TERT wt
(n=8)
TERT mutation
(n=6)
TE
RT
 
ex
pr
es
sio
n
le
ve
l (A
U)
Figure 2 | IHC for TERT in two glioblastomas. (a)A tumour without TERTexpression and without TERTmutation. (b) A tumour with positive staining both
in nucleus and cytoplasm that also harboured a TERTmutation. The graph (c) displays quantiﬁcation of TERT nuclear expression level (IHC) in
glioblastomas with and without TERTmutation. We have measured the extent (o25%, 25–50%, 50–75% and 475%) and the intensity (absent, faint,
moderate or strong) of TERT nuclear staining in 14 glioblastomas (eight TERT wild type and six TERTmutant). The scoring was performed by two
independent observers and is the product of extent and intensity of the staining (Methods). Scale bar, 200mm. There is a trend to higher TERTexpression
in TERT-mutated gliomas, although the difference was not statistically signiﬁcant (P¼0.4250; Mann–Whitney test, two-tailed). Bars represent s.e.m.
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the ones with coexistent TERT and BRAF mutations showed the
highest levels of TERT mRNA expression (P¼ 0.0001, unpaired
t-test; Fig. 3).
TERT mutations in bladder cancer. In bladder cancer, TERT
mutations were frequently detected (48/82; 59%) both in low-
grade tumours (14/21; 67%) and high-grade tumours (34/61;
56%) (Table 1 and Fig. 1e; Supplementary Table S9). The  124
G4A mutation was present in 30 cases, whereas the  146 G4A
was found in 18 cases. No association was found between the
presence of the mutation and the age of the patients.
No mutations were detected in 26 kidney cancers, 17
phaeochromocytoma and 36 GISTs (Supplementary Tables S10,
S11 and S12, respectively).
Discussion
Recent ﬁndings have described that TERT promoter mutations
arise as a novel mechanism of telomerase reactivation/expression
in human cancers1,2. In this work, we report for the ﬁrst time the
presence of these mutations in different histotypes of thyroid
cancer, and our results validate the ﬁndings reported by others in
melanoma, bladder and gliomas1–3. Furthermore, we present for
the ﬁrst time evidence showing that TERT promoter mutations
are signiﬁcantly associated with increased TERT mRNA
expression in thyroid cancers. We also found a trend for
increased telomerase expression in cases of GBM harbouring
TERT promoter mutations. In thyroid cancers, TERT mRNA was
particularly high in cases harbouring both TERT and BRAF
mutations.
The location of these mutations in the TERT promoter, rather
than the coding region of the gene, creating additional binding
sites for transcription factors, represents also a novel mechanism
of genetic activation in cancer.
The frequency of TERT mutations we detected in skin
melanomas is similar to that reported by Horn et al.1 in
primary melanomas (33%), but lower than the frequency found
by the same authors in metastatic melanomas (85%) and by
Huang et al.2 in a series of 70 melanomas and short-term
cultures1,2. In our series, we have analysed few metastatic
melanomas that did not show a signiﬁcantly higher percentage
of TERT mutations. As our series is too small to allow a
conclusion, it remains to be veriﬁed if there is an increased
frequency of TERT mutations in metastatic melanomas, as
suggested by previous reports1,2.
We have conﬁrmed, in skin melanomas, the signiﬁcant
association between TERT and BRAF mutations, as previously
advanced by Horn et al.1, which we now also demonstrate in
thyroid cancers. Interestingly, in benign nevi, which frequently
harbour BRAF mutations, we did not detect TERT mutations.
This ﬁnding, together with the high frequency of TERT mutations
in metastatic melanomas1, suggests that, although BRAF
mutations are thought to be an early event in melanoma
genesis, TERT mutations may occur at a later stage.
No TERT promoter mutations were found in ocular melano-
mas, which, at variance with skin melanomas, harbour GNAQ
mutations instead of BRAF mutations4,5. Our results further
support the assumption that ocular melanomas result from
different etiopathogenic mechanism than skin melanomas5,6.
Our data on CNS tumours indicate that TERT promoter
mutations are frequent events in gliomas, particularly in GBM
where the highest mutation frequency was found. It has been
shown that TERT mutations conferred enhanced TERT promoter
activity in vitro1,2; our ﬁndings ﬁt with this assumption because
we observed that GBM with TERT promoter mutations appear to
display increased telomerase expression, despite the limited
sensitivity of IHC and the low number of cases analysed. Our
results are also in concordance with those of Lotsch et al.7 who
reported that 60% of GBMs were positive for TERT mRNA and
telomerase activity7. It will be interesting to assess whether the
GBM positive for telomerase activity described by Lotsch et al.7
also harbour TERT promoter mutations. Our ﬁndings also
indicate that TERT mutations are associated with older patients,
in accordance with a recent report3. The high frequency of TERT
mutations in CNS tumours, particularly in intermediate and
high-grade tumours, opens a window for new approaches in the
therapy of CNS tumours.
In thyroid cancer, TERT mutations were only found in
follicular cell-derived cancers (PTC, follicular thyroid carcinoma,
poorly differentiated thyroid carcinoma and anaplastic thyroid
carcinoma). No mutations were detected in medullary thyroid
carcinomas, as described by Killela et al.3, nor in normal thyroid
and benign lesions, such as goitre, adenomas or thyroiditis; this
ﬁnding ﬁts with previous studies that reported telomerase
expression in malignant lesions and not in normal tissue or
hyperplastic lesions8,9. TERT mutations were associated with
clinicopathological features (older age, increased tumour size and
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Figure 3 | Quantiﬁcation of TERT mRNA expression level in thyroid tumours. We have performed qPCR in normal thyroid tissue (N), a pool of
mRNA of nine normal thyroids (pool N) and thyroid tumours with different genetic backgrounds: without known genetic alterations (wt), with BRAF
mutation (B), with RET rearrangement (RET), with RAS mutation (R), with TERTmutation (T), with TERT and BRAF mutations (BT) or with RAS and TERT
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s.e.m. The difference is statistically signiﬁcant (Po0.0001, unpaired t-test).
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male gender), but, after histotype stratiﬁcation, these associations
were only maintained in cPTC. Studies in larger series will be
necessary to clarify these associations. In cPTC, TERT mutations
were associated with BRAF mutation, highlighting the coexistence
of activation of BRAF and TERT, previously reported in
melanoma1 (Supplementary Fig. S2). Our results reinforce the
hypothesis of a link between BRAF activation and telomerase
expression, which can be mediated by transcription factors
binding to the newly created consensus binding sites, as
previously advanced by Horn et al.1. Both in thyroid carcinoma
and melanoma, it seems that a ‘background’ status of activated
BRAF enhances the effects of TERT promoter mutation. Our
results in TERT mRNA expression strengthen this assumption,
showing, for the ﬁrst time, an increased TERT expression in
tumours harbouring BRAF and TERT mutation (Fig. 3). Further
observational and mechanistic studies are needed to clarify these
points.
TERT alterations seem to constitute an early and frequent
event in bladder cancer. These ﬁndings ﬁt with the high
prevalence of telomerase activity previously described in bladder
tumours10. The recurrent hotspot mutations in TERT were
advanced to be, in melanomas, induced by ultraviolet radiation2.
Bladder is a target for several chemical carcinogens; it remains to
be found whether TERT mutations can also result from the action
of such agents. The identiﬁcation of TERT mutations in urine
may provide a biomarker for early diagnosis and monitoring of
bladder cancer.
No TERT mutations were detected in kidney cancers, nor in 17
phaeochromocytoma and 36 GISTs. The underlying reasons for
the tissue speciﬁcity of TERT mutations remain to be clariﬁed.
We can hypothesize that TERT mutations can be present in two
settings. As described by Killela et al.3, TERT mutations can be
relevant in tissues with relative low rates of self-renewal, which
ﬁts with our ﬁndings in follicular cell-derived thyroid cancer and
gliomas where they are associated with the older age of the
patients. On the other hand, these mutations can also result from
environmental factors such as ultraviolet radiation and chemical
carcinogens as suggested by their high frequency in melanoma,
bladder and tongue1–3. In summary, our data identify TERT
mutations as common events in human cancers and support the
assumption that TERT promoter mutations may be one of the
mechanisms that underlies telomerase reactivation in several
types of human tumours.
Methods
Human cancer samples. All the procedures described in this study were in
accordance with national and institutional ethical standards and previously
approved by Local Ethical Review Committees. According to Portuguese law,
informed consent is not required for retrospective studies.
Formalin-ﬁxed, parafﬁn-embedded tissues from nine cases of sporadic nevi, 56
cases of sporadic skin melanomas and 25 cases of ocular melanoma were retrieved
from the ﬁles of the Hospital S. Joa˜o (HSJ)/Medical Faculty of Porto (FMUP),
Porto, Portugal, the Department of Pathology of HSJ and the Department of
Pathology of Hospital S. Marcos (HSM), Braga, Portugal. Clinicopathological and
follow-up data were retrieved from the ﬁles of the Department of Pathology,
Department of Dermatology and Oncology Registry of HSJ and Department of
Pathology of HSM, and from RORENO (Oncology Registry of North Region). All
skin melanoma cases were re-evaluated and staged according to the seventh edition
of the American Joint Committee on Cancer11. The overall female:male ratio was
1.2:1. The mean age of the patients was 58 years for females (s.d.±17.6), with a
range from 9 to 94 years, and 62 years for males (s.d.±13.1), with a range from 33
to 79 years.
Follow-up data were available for 53 patients, including the diagnosis of
metastases, through the evaluation of the patients or direct interview with their
relatives and by review of in-hospital patient ﬁles/RORENO. The mean follow-up
time of patients was 41 months (range 1–170). During follow-up, 5 (9%) patients
developed (lymph node, liver or brain) metastases and 8 (15%) patients died due to
malignant melanoma. The remaining patients were alive and without evidence of
melanoma recurrence at the last follow-up. Additional information regarding the
melanoma subtype, age, gender, thickness and molecular analysis of TERT, BRAF
and NRAS is compiled in Supplementary Table S3.
Formalin-ﬁxed, parafﬁn-embedded tissues from 372 tumours and tumour-like
lesions of the thyroid and 27 normal thyroids were collected from the ﬁles of
IPATIMUP, HSJ/FMUP and the Portuguese Institute of Oncology, Coimbra,
Portugal. The histology of all tumour samples was revised, and the ﬁnal
classiﬁcation was made according to the WHO criteria12. In Supplementary Tables
S6 and S7, we have summarized the information regarding histological
classiﬁcation of the lesions, gender, mean age of the patients, molecular data and
the size of the tumours.
Representative formalin-ﬁxed parafﬁn-embedded samples from 118 gliomas
were retrieved from pathology archives of the Department of Pathology of
HSJ/FMUP and the Department of Pathology of HSM, Braga, Portugal. The
tumours were reviewed and classiﬁed according to the WHO classiﬁcation of CNS
tumours (2007) (ref. 13,14). This cohort includes lesions that were classiﬁed as
pilocytic astrocytoma (n¼ 13), astrocytoma grade 2 (n¼ 20), oligodendroglioma
(n¼ 22), anaplastic oligodendroglioma (n¼ 24) and glioblastoma (n¼ 39). Further
information regarding the CNS cases is available in Supplementary Table S4.
Formalin-ﬁxed, parafﬁn-embedded tissues were collected from 82 patients with
non-muscle invasive bladder cancer who underwent transurethral resection of the
bladder malignant tumours in the Portuguese Institute of Oncology, Porto.
Haematoxylin–eosin-stained sections were reviewed according to the standard
histopathological examination by two independent pathologists. Staging and
grading were conducted according to the American Joint Committee on Cancer11,
and the 2004 WHO classiﬁcation system15. Supplementary Table S9 summarizes
the clinicopathological parameters.
Formalin-ﬁxed, parafﬁn-embedded tissues from 26 kidney cancers were
collected from the HSJ/FMUP. Cases were classiﬁed as clear cell renal cell
carcinoma (n¼ 12), chromophobe renal cell carcinoma (n¼ 4) and papillary renal
cell carcinoma (n¼ 10). Information addressing the diagnosis, age, gender, nuclear
grade and staging is obtainable in Supplementary Table S10.
Formalin-ﬁxed, parafﬁn-embedded tissues from 17 pheochromocytomas were
collected from the HSJ/FMUP and IPATIMUP, Porto, Portugal. Supplementary
Table S11 summarizes the clinicopathological parameters.
Formalin-ﬁxed, parafﬁn-embedded tissues from 36 GIST were collected from
the HSJ/FMUP and IPATIMUP, Porto, Portugal. Tumours were classiﬁed
according to the WHO pathological classiﬁcation16, and the parameters analysed in
each case included: age, gender and tumour size. These data and the molecular
characterization of these tumours can be observed in Supplementary Table S12.
Cell lines. DNA from 58 cell lines deposited in IPATIMUP cell line bank was
retrieved. All the cell lines were authenticated using DNA proﬁle analysis, obtained
with the PowerPlex 16 system (Promega, Madison, USA), according to the DNA
proﬁles available in American Type Culture Collection and Health Science
Research Resource Bank.
DNA extraction. DNA from formalin-ﬁxed, parafﬁn-embedded tissues was
retrieved from 10-mm cuts after careful microdissection. DNA extraction was
performed using the Ultraprep Tissue DNA Kit (AHN Biotechnologie, Nordhau-
sen, Germany) following the manufacturer’s instructions.
RNA extraction. Total RNA was extracted from frozen thyroid tumours (n¼ 24)
and normal tissue specimens (n¼ 3) using a Trizol commercial kit (Life Tech-
nologies, GIBCO BRL, Carlsbad, CA) according to the manufacturer’s protocol.
RNA was quantiﬁed spectrophotometrically, and its quality was checked by ana-
lysis of 260/280Zm and 260/230Zm ratios.
PCR and Sanger sequencing. Coding regions of BRAF, GNAQ HRAS, NRAS,
cKIT and PDGFR were screened for mutations in DNA extracted from parafﬁn
blocks using PCR and Sanger sequencing. The genetic characterization of part of
the tumours had already been previously reported. For information on primers and
PCR conditions, see refs 5,17,18. To screen for TERT promoter mutations, we
analysed the hotspots previously identiﬁed by PCR followed by Sanger sequencing.
TERT promoter mutation analysis was performed with the pair of primers
FwTERT: 50-CAGCGCTGCCTGAAACTC-30 and RwTERT: 50-GTCCTGCCCC
TTCACCTT-30 . Ampliﬁcation of genomic DNA (25–100 ng) was performed by
PCR using the Qiagen Multiplex PCR kit (Qiagen, Hilden, Germany) according to
the manufacturer’s instructions. Sequencing reaction was performed with the ABI
Prism BigDye Terminator Kit (Perkin-Elmer, Foster City, CA), and the fragments
were run in an ABI prism 3100 Genetic Analyser (Perkin-Elmer). The sequencing
reaction was performed in a forward direction, and an independent PCR
ampliﬁcation/sequencing, both in a forward and reverse direction, was performed
in positive samples or samples that were inconclusive.
Quantitative RT-PCR. qPCR for human TERT was performed in 28 thyroid
samples, 24 tumours and 3 normal tissue specimens. We also included a normal
reference that was produced by pooling RNAs from nine samples of normal
thyroid tissue19.
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For cDNA preparation, 1 mg of total RNA was reverse transcribed using the
RevertAid ﬁrst strand cDNA synthesis kit (Fermentas, Burlington, ON, Canada).
Reverse transcription products were ampliﬁed for the TERT by qPCR (IDT; no.
HS.PT.56a.40988589) using TaqMan PCR Master Mix (Applied Biosystems, Foster
City, CA, USA) with TBP gene (TATA-binding protein) as endogenous control
(Applied Biosystems; no. 4326322E-0705006). The ABI PRISM 7500 Fast Sequence
Detection System (Applied Biosystems) was used to detect the ampliﬁcation level
and was programmed to an initial step of 2min at 50 C, 10min at 95 C, followed
by 45 cycles of 95 C for 15 s and 60 C for 1min. TBP and TERT ampliﬁcations
were done in triplicate using 1 ml of cDNA (B50 ng) for each sample. The relative
quantiﬁcation of target genes was determined using the DDCT method, which was
previously validated by Livak’s Linear Regression Method (slope¼ 0.0696)
(Sequence Detector User Bulletin 2; Applied Biosystems).
Immunohistochemistry. IHC for telomerase was performed in representative
tumour tissue sections of 14 glioblastomas. Brieﬂy, deparafﬁnized and rehydrated
sections were subjected to microwave treatment in 10mM sodium citrate buffer,
pH 6.0, for antigen retrieval. The sections were incubated overnight at 4 C in a
humidiﬁed chamber with the primary antibody telomerase (polyclonal, rabbit,
1:500) from Rockland Immunochemicals Inc., Gilbertsville, PA. The detection was
performed with a labelled streptavidin–biotin immunoperoxidase detection system
(Thermo Scientiﬁc/Lab Vision, Fremont, USA), and the immunohistochemical
staining was developed with 3,30-diaminobenzidine substrate. Omission of the
primary antibody incubation was used as negative control. Previously tested liver
cancer case was used as positive control. IHC evaluation was performed inde-
pendently by two observers (V.M. and J.L.). An IHC score was established, which
corresponded to the product of the intensity of expression (absent¼ 0, faint¼ 1,
moderate¼ 2 and strong¼ 3) with the tumour extent of protein expression
(0–25%¼ 0, 26–50%¼ 1, 51–75%¼ 2 and 475%¼ 3) (ref. 6).
Statistical analysis. Statistical analysis was conducted with StatView for Win-
dows, version 5.0 (SAS Institute, Cary, NC). The results are expressed as a per-
centage or mean±s.d. Statistical analysis was performed both on the whole series
and considering the different groups of lesions. For the analysis of the relationship
between patients’ age, tumour size and TERT status of the tumours, we used the
unpaired t-test, Mann–Whitney test and analysis of variance. Fisher’s exact test was
used in the statistical analysis of the other parameters. Graphs and ﬁgures were
done in GraphPad v6.0. Results were considered statistically signiﬁcant if Po0.05.
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SUPPLEMENTARY INFORMATION FOR JVINAGRE - NCOMMS-13-03296-A  
 
 
Supplementary Figure S1 - The panel illustrates the three mutations identified in this 
study and their location in chromosome 5 in relation to the TERT ATG translation start 
site.  
 
 
 
Supplementary Figure S2 - Bar plot indicating the number of cases with TERT 
mutations in BRAF-mutated and BRAF-wild-type conventional papillary thyroid 
carcinomas (cPTC) and melanomas. For both tumour types, the presence of TERT 
mutations is significantly associated with the presence of BRAF mutations (asterisks, 
Fisher’s exact test two-sided). 
Supplementary Table S1 - Genetic alterations in thyroid and melanoma cell lines  
 
Origin Cell line BRAF RAS 
RET 
GNAQ TERT 
Thyroid       
 XTC-1 WT WT ND - WT 
 HTH74 V600E WT ND - -124G>A 
 K1 V600E WT ND - -124G>A 
 BCPAP V600E WT ND - -124/-125GG>AA 
 C643 WT HRASG13E ND - -124G>A 
 8505C V600E WT ND - -146G>A 
 TPC-1 WT WT RET/PTC1 - -124G>A 
 T238     WT 
 TT   C634W  WT 
 MZ-CRC-1   M918T  WT 
       
Skin 
melanoma 
      
 A375 V600E WT  WT -146G>A 
 BLM WT WT  WT -146G>A 
 G361 V600E WT  WT -138/-139GG>AA 
 Mewo WT WT  WT -146G>A 
Uveal 
melanoma 
      
 92.1 WT WT  Q209L WT 
 OMM1 WT WT  WT WT 
 OMM2.3 WT WT  Q209L WT 
 Mel 202 WT WT  Q209L WT 
 Mel 270 WT WT  Q209P WT 
 Mel 285 WT WT  WT WT 
*All the cell lines are deposited in the cell line bank from the IPATIMUP and were authenticated 
using DNA profile analysis, obtained with the PowerPlex 16 system (Promega, Madison, USA), 
according to ATCC and HSRRB available DNA profiles. 
 
 
 
 
 
 
 
 
 
 
Supplementary Table S2 - Genetic alterations in cell lines  
 
Origin Derivation Cell line TERT 
Colorectal Colon adenocarcinoma COLO-205 WT 
Colon adenocarcinoma Caco-2 WT 
Colon adenocarcinoma SW 480 WT 
Colon adenocarcinoma HT29 WT 
Colon adenocarcinoma HCT-15 WT 
Colon adenocarcinoma HCT-116 WT 
Colon adenocarcinoma SW48 WT 
Colon adenocarcinoma Co-115 WT 
    
Gastric Gastric adenocarcinoma AGS WT 
Gastric adenocarcinoma MKN28 WT 
Well-differentiated gastric carcinoma NCI-N87 WT 
Poorly-differentiated gastric carcinoma SNU-638 WT 
Poorly-differentiated gastric carcinoma MKN-45 WT 
Poorly-differentiated gastric carcinoma 
Metastasis 
KATO III WT 
Diffuse Gastric Carcinoma IPA220A WT 
Diffuse Gastric Carcinoma GP202 WT 
    
Breast 
 
Breast adenocarcinoma MDA-MB-231 -124G>A 
Breast adenocarcinoma MCF-7AZ WT 
Breast adenocarcinoma SKBR3 WT 
Breast adenocarcinoma MCF-7/6 WT 
Breast adenocarcinoma BT-549 -146G>A 
Breast adenocarcinoma BT-20 WT 
Breast adenocarcinoma MDA-MB-468 WT 
Breast adenocarcinoma SUM149 WT 
Kidney    
 CCRCC Caki-2   -124G>A 
 CCRCC 786-O -124G>A 
    
Leukemia Acute promyelocytic leukemia NB-4  WT 
Acute promyelocytic leukemia HL-60 WT 
    
Peripheral B 
Lymphocytes 
Lymphoblastoid cell lines GM20770 WT 
Lymphoblastoid cell lines GM20890 WT 
Lymphoblastoid cell lines GM11840 WT 
Lymphoblastoid cell lines GM19782 B WT 
Lymphoblastoid cell lines GM20515 WT 
Lymphoblastoid cell lines GM19777 WT 
Lymphoblastoid cell lines GM20797 WT 
Lymphoblastoid cell lines GM10847 B WT 
   
Lung 
 
Lung Adenocarcinoma A549 WT 
   
CNS Glioblastoma SF-767 WT 
   
*All the cell lines are deposited in the cell line bank from the IPATIMUP and were 
authenticated using DNA profile analysis, obtained with the PowerPlex 16 system 
(Promega, Madison, USA), according to ATCC and HSRRB available DNA profiles. 
Supplementary Table S3 – Summary of clinico-pathological and genetic data in 56 
skin melanoma   
Case Code Melanoma subtype Age Gender Thickness (mm) BRAF NRAS TERT 
MEL1 Superficial spreading 74 M 1.20 
 
Pos 
 
MEL2 Superficial spreading 36 F 0.95 
   
MEL3 Superficial spreading NA F 0.50 V600E 
  
MEL4 Superficial spreading NA M 1.40 
  
-146 G>A 
MEL5 Superficial spreading 46 F 3.10 
   
MEL6 Nodular 52 F 0.90 
   
MEL7 Nodular 59 M 3.20 V600E 
  
MEL8 Lentigo maligna 67 F 0.50 V600E 
  
MEL9 Nodular 54 F 16.00 
   
MEL10 Nodular 33 M 19.50 V600E 
  
MEL11 Superficial spreading 57 F 3.65 
  
-146 G>A 
MEL12 Lentigo maligna 79 F 0 V600E 
 
-146 G>A 
MEL13 Acral lentiginous 94 F 2.10 
   
MEL14 Acral lentiginous 50 F 1.00 
   
MEL15 Superficial spreading 49 M 10.00 
 
Pos -124 G>A 
MEL16 Superficial spreading 55 M 2.30 
   
MEL17 Nodular 82 F 3.50 V600E 
  
MEL18 Nodular 35 F 2.50 V600E 
 
-124 G>A 
MEL19 Superficial spreading 58 M 7.70 
   
MEL20 Nodular 42 F 1.70 V600E 
 
-124 G>A 
MEL21 Nodular 61 F 4.40 
  
-124 G>A 
MEL22 Acral lentiginous 69 M 4.00 
   
MEL23 Superficial spreading 41 M 0 V600E 
  
MEL24 Acral lentiginous 72 F 0.70 
   
MEL25 Superficial spreading . M 0.50 
   
MEL26 Nodular 76 M 6.00 
   
MEL27 Superficial spreading 66 M 0 
  
-124 G>A 
MEL28 Superficial spreading 55 F 1.78 
   
MEL29 Acral lentiginous 67 F 4.00 
   
MEL30 Nodular 63 M 5.00 
   
MEL31 Acral lentiginous 60 M 5.40 V600E Pos -124 G>A 
MEL32 Superficial spreading NA M 0.50 V600E 
 
-146 G>A 
MEL33 Acral lentiginous 71 M 5.20 
   
MEL34 Superficial spreading 75 F 70.00 V600E 
 
-124 G>A 
MEL35 Nodular 69 F 7.00 V600E 
 
-146 G>A 
MEL36 Acral lentiginous 9 F 3.25 
   
MEL37 Superficial spreading 39 F 2.30 
   
MEL38 Acral lentiginous 68 M 4.50 
   
MEL39 Acral lentiginous NA M 2.70 
   
MEL40 Superficial spreading NA F 1.20 V600E 
 
-146 G>A 
MEL41 Superficial spreading 59 F 3.30 V600E 
  
MEL42 Acral lentiginous NA F 4.00 
   
MEL43 Lentigo maligna NA M 5.90 
 
Pos 
 
 Supplementary Table S4 -  Summary of clinico-pathological and genetic data in 118 
gliomas 
 
Case Code Age Gender Diagnosis (Grade) TERT 
GLI1 4 F Pilocytic Astrocytoma (I)   
GLI2 27 M Pilocytic Astrocytoma (I)   
GLI3 22 M Pilocytic Astrocytoma (I)   
GLI4 31 F Pilocytic Astrocytoma (I)   
GLI5 27 M Pilocytic Astrocytoma (I) -124 G>A 
GLI6 18 M Pilocytic Astrocytoma (I)   
GLI7 30 F Pilocytic Astrocytoma (I)   
GLI8 12 F Pilocytic Astrocytoma (I)   
GLI9 NA NA Pilocytic Astrocytoma (I)   
GLI10 NA NA Pilocytic Astrocytoma (I)   
GLI11 NA NA Pilocytic Astrocytoma (I)   
GLI12 NA NA Pilocytic Astrocytoma (I)   
GLI13 NA NA Pilocytic Astrocytoma (I)   
GLI14 18 F Diffuse Astrocytoma (II)   
GLI15 NA NA Diffuse Astrocytoma (II) -124 G>A 
GLI16 38 M Diffuse Astrocytoma (II)   
GLI17 22 M Diffuse Astrocytoma (II)   
GLI18 50 M Diffuse Astrocytoma (II)   
GLI19 31 F Diffuse Astrocytoma (II)   
GLI20 30 M Diffuse Astrocytoma (II)   
GLI21 59 M Diffuse Astrocytoma (II)   
GLI22 NA NA Diffuse Astrocytoma (II)   
GLI23 53 F Diffuse Astrocytoma (II)   
GLI24 20 M Diffuse Astrocytoma (II)   
GLI25 69 M Diffuse Astrocytoma (II) -146 G>A 
GLI26 42 F Diffuse Astrocytoma (II)   
MEL44 Lentigo maligna NA F 0.50 
   
MEL45 Acral lentiginous 68 F 2.20 V600E 
  
MEL46 Nodular 71 F 7.80 
   
MEL47 Superficial spreading 59 M 1.20 
   
MEL48 Superficial spreading NA M 0.35 
   
MEL49 Melanoma nodular 42 M 20.00 V600E 
 
-124 G>A 
MEL50 Superficial spreading 61 F 4.30 V600E 
  
MEL51 Nodular 79 M 22.00 
 
Pos -146 G>A 
MEL52 Lentigo maligna 61 F 3.40 
   
MEL53 Acral lentiginous 75 M 6.10 
   
MEL54 Superficial spreading 49 F 2.90 V600E 
 
-146 G>A 
MEL55 Acral lentiginous NA M 4.40 
   
MEL56 Lentigo maligna 75 M 0.30 
   
GLI27 27 F Diffuse Astrocytoma (II)   
GLI28 60 F Diffuse Astrocytoma (II) -124 G>A 
GLI29 NA NA Diffuse Astrocytoma (II)   
GLI30 NA NA Diffuse Astrocytoma (II)   
GLI31 NA NA Diffuse Astrocytoma (II)   
GLI32 NA NA Diffuse Astrocytoma (II)   
GLI33 NA NA Diffuse Astrocytoma (II)   
GLI34 72 F Oligodendroglioma (II) -124 G>A 
GLI35 9 M Oligodendroglioma (II)   
GLI36 33 M Oligodendroglioma (II)   
GLI37 42 F Oligodendroglioma (II) -124 G>A 
GLI38 46 F Oligodendroglioma (II)   
GLI39 45 F Oligodendroglioma (II) -124 G>A 
GLI40 43 M Oligodendroglioma (II)   
GLI41 53 M Oligodendroglioma (II) -146 G>A 
GLI42 53 F Oligodendroglioma (II) -124 G>A 
GLI43 54 F Oligodendroglioma (II) -124 G>A 
GLI44 43 F Oligodendroglioma (II) -124 G>A 
GLI45 34 M Oligodendroglioma (II) -146 G>A 
GLI46 40 M Oligodendroglioma (II)   
GLI47 45 F Oligodendroglioma (II) -124 G>A 
GLI48 NA NA Oligodendroglioma (II)   
GLI49 NA NA Oligodendroglioma (II)   
GLI50 NA NA Oligodendroglioma (II)   
GLI51 NA NA Oligodendroglioma (II)   
GLI52 NA NA Oligodendroglioma (II)   
GLI53 NA NA Oligodendroglioma (II)   
GLI54 NA NA Oligodendroglioma (II)   
GLI55 NA NA Oligodendroglioma (II) -124 G>A 
GLI56 65 M Anaplastic Oligodendroglioma (III) -124 G>A 
GLI57 47 F Anaplastic Oligodendroglioma (III) -124 G>A 
GLI58 65 F Anaplastic Oligodendroglioma (III)   
GLI59 50 M Anaplastic Oligodendroglioma (III) -146 G>A 
GLI60 36 F Anaplastic Oligodendroglioma (III) -124 G>A 
GLI61 53 M Anaplastic Oligodendroglioma (III) -146 G>A 
GLI62 65 M Anaplastic Oligodendroglioma (III) -146 G>A 
GLI63 47 M Anaplastic Oligodendroglioma (III) -124 G>A 
GLI64 50 M Anaplastic Oligodendroglioma (III)   
GLI65 70 F Anaplastic Oligodendroglioma (III)   
GLI66 40 M Anaplastic Oligodendroglioma (III) -124 G>A 
GLI67 67 F Anaplastic Oligodendroglioma (III) -124 G>A 
GLI68 64 F Anaplastic Oligodendroglioma (III) -146 G>A 
GLI69 44 M Anaplastic Oligodendroglioma (III)   
GLI70 42 F Anaplastic Oligodendroglioma (III) -124 G>A 
GLI71 68 F Anaplastic Oligodendroglioma (III) -124 G>A 
GLI72 NA NA Anaplastic Oligodendroglioma (III)   
GLI73 NA NA Anaplastic Oligodendroglioma (III)   
GLI74 NA NA Anaplastic Oligodendroglioma (III)   
GLI75 NA NA Anaplastic Oligodendroglioma (III) -124 G>A 
GLI76 NA NA Anaplastic Oligodendroglioma (III)   
GLI77 NA NA Anaplastic Oligodendroglioma (III)   
GLI78 NA NA Anaplastic Oligodendroglioma (III)   
GLI79 NA NA Anaplastic Oligodendroglioma (III)   
GLI80 56 M Glioblastoma (IV) -146 G>A 
GLI81 27 F Glioblastoma (IV)   
GLI82 54 F Glioblastoma (IV) -124 G>A 
GLI83 46 F Glioblastoma (IV)   
GLI84 77 M Glioblastoma (IV) -124 G>A 
GLI85 67 F Glioblastoma (IV) -146 G>A 
GLI86 50 F Glioblastoma (IV) -146 G>A 
GLI87 73 M Glioblastoma (IV) -146 G>A 
GLI88 57 M Glioblastoma (IV) -124 G>A 
GLI89 28 M Glioblastoma (IV)   
GLI90 51 F Glioblastoma (IV) -124 G>A 
GLI91 69 M Glioblastoma (IV) -146 G>A 
GLI92 53 M Glioblastoma (IV)   
GLI93 56 F Glioblastoma (IV) -124 G>A 
GLI94 66 M Glioblastoma (IV) -124 G>A 
GLI95 68 F Glioblastoma (IV)   
GLI96 58 F Glioblastoma (IV)   
GLI97 73 M Glioblastoma (IV) -124 G>A 
GLI98 61 F Glioblastoma (IV)   
GLI99 66 F Glioblastoma (IV) -124 G>A 
GLI100 60 F Glioblastoma (IV) -124 G>A 
GLI101 54 M Glioblastoma (IV) -124 G>A 
GLI102 66 F Glioblastoma (IV) -124 G>A 
GLI103 79 M Glioblastoma (IV) -124 G>A 
GLI104 31 M Glioblastoma (IV)   
GLI105 NA NA Glioblastoma (IV) -124 G>A 
GLI106 NA NA Glioblastoma (IV)   
GLI107 NA NA Glioblastoma (IV) -124 G>A 
GLI108 NA NA Glioblastoma (IV) -124 G>A 
GLI109 NA NA Glioblastoma (IV) -124 G>A 
GLI110 NA NA Glioblastoma (IV) -124 G>A 
GLI111 NA NA Glioblastoma (IV)   
GLI112 NA NA Glioblastoma (IV)   
GLI113 NA NA Glioblastoma (IV) -124 G>A 
GLI114 NA NA Glioblastoma (IV)   
GLI115 NA NA Glioblastoma (IV) -146 G>A 
GLI116 NA NA Glioblastoma (IV)   
GLI117 NA NA Glioblastoma (IV)   
GLI118 NA NA Glioblastoma (IV)   
 Supplementary Table S5 – Comparison of the clinico-pathological features of tumours 
with and without TERT mutations 
 
 
  
Tumour 
type 
Clinical features All 
patients 
 
TERT wild 
type 
 
TERT 
mutated 
 
p 
value 
Thyroid* 
(n=263) 
Mean age at 
diagnosis, yr (±SD) 
 
Gender  
Male 
Female 
 
Mean tumour size, 
cm 
 
48±17 
 
 
  
61 (24%) 
189 (76%) 
 
3.5±3.4 
 
46±16 
 
 
 
50 (22%) 
174 (78%) 
 
3.4±3.4 
62±13 
 
 
 
11(42%) 
15 (58%) 
 
4.6±2.7 
<0,0001 
 
 
 
0,03 
 
 
0,008 
CNS 
(n=118) 
Mean age at 
diagnosis, yr (±SD) 
 
Gender  
Male 
Female 
47±18 
 
 
 
42 (49%) 
43 (51%) 
 
38±17 
 
 
 
21 (51%) 
20 (49%) 
57±12 
 
 
 
20 (47%) 
23 (53%) 
 
<0,0001 
 
 
 
NS 
 
 
Skin 
melanoma 
(n=56) 
Mean age at 
diagnosis, yr (±SD) 
 
Gender  
Male 
Female 
 
60±16 
 
 
 
26 (46%) 
30 (54%) 
 
60±14 
 
 
 
19 (48%) 
21 (52%) 
 
63±12 
 
 
 
7 (44%) 
9 (56%) 
NS 
 
 
 
NS 
 
 
Bladder 
(n=82) 
 
 
 
Mean age at 
diagnosis, yr (±SD) 
 
Gender  
Male 
Female 
 
63±10 
 
 
 
66 (80%) 
16 (20%) 
 
65±12 
 
 
 
24 (70%) 
10 (30%) 
 
63±12 
 
 
 
42 (88%) 
     6 (12%) 
 
NS 
 
 
 
NS 
The numbers in parentheses indicate percentages. In some cases information regarding age, 
gender or  tumour size was missing. 
*Only follicular cell-derived thyroid carcinomas: FTC, PTC, PDTC and ATC. 
Supplementary Table S6 – Clinico-pathological characteristics and TERT promoter mutation in the 399 thyroid samples analysed 
 
Histotypes No. Of cases Gender ratio (♀:♂) Mean age (years±SE) Tumour size (cm±SE) BRAFV600E mutation TERT n (%) 
Normal Thyroid 27 3,5:1 47,0 ± 14,8 NA 0 0 (0,0) 
Lymphocytic 
Thyroiditis 
9 9:0 44,6 ± 15,7 NA 0 0 (0,0) 
Nodular Goiter 12 1,75:1 56,2 ± 13,4 NA 0 0 (0,0) 
Follicular Thyroid Adenoma 
Conventional 52 7:1 43,8 ± 12,1 3,5 ± 1,6 0 0 (0,0) 
Oncocytic Variant 8 7:0 
 
47,0 ± 14,0 2,7 ± 1,2 0 0 (0,0) 
Follicular Thyroid Carcinoma 
Conventional 36 2,5:1 53,7 ± 14,7 4,5 ± 2,8 0 9 (25,0) 
Oncocytic Variant 28 5,5:1 51,4 ± 20,2 4,6 ± 3,6 0 0 (0,0) 
Papillary thyroid carcinoma 
Conventional 110 3,1:1 43,1 ± 16,2 2,6 ± 1,6 61 12 (10,9) 
Follicular Variant 39 3,9:1 45,8 ±14,7 2,6 ± 1,2 2 0 (0,0) 
Microcarcinoma 5 5:0 46,0 ±14,4 0,4 ± 0,4 1 0 (0,0) 
Mucoepidermoid 
Carcinoma 
4 2:0 43,5 ± 33,2 NA 0 1 (25,0) 
Oncocytic Variant of PTC 
Conventional 
Pattern 
4 4:0 45,3 ±11,1 2,8 ± 1,8 4 0 (0,0) 
Follicular Pattern 3 2:1 45,3 ±22,5 5,2 ± 3,9 1 0 (0,0) 
Warthin-like PTC 4 4:0 
 
55,5 ±11,2 2,0 ± 0,8 4 0 (0,0) 
       
PDTC 14 1:1 57,0 ± 17,4 6,7 ± 2,8 1 2 (14,2) 
Anaplastic 16 1,3:1 62,1 ± 12,8 6,9 ± 3,1 5 2 (12,5) 
MTC 28 2,3:1 46,4 ± 16,7 3,0 ± 0,9 0 0 (0,0) 
 Supplementary Table S7 - Summary of clinico-pathological and genetic data in 351 
tumour and tumour like thyroid lesions   
 
 
Case Code Age Gender Diagnosis RAS BRAF TERT 
THY1 50 F FTA       
THY2 50 F FTA       
THY3 59 M FTA       
THY4 28 F FTA       
THY5 45 F FTA       
THY6 51 F FTA       
THY7 37 F FTA       
THY8 53 F FTA       
THY9 57 F FTA       
THY10 66 F FTA       
THY11 63 F FTA       
THY12 40 F FTA       
THY13 34 F FTA       
THY14 65 F FTA       
THY15 35 F FTA       
THY16 34 F FTA       
THY17 18 F FTA       
THY18 37 F FTA       
THY19 43 F FTA       
THY20 53 F FTA       
THY21 45 F FTA       
THY22 33 F FTA       
THY23 34 F FTA       
THY24 46 M FTA       
THY25 53 F FTA       
THY26 65 F FTA       
THY27 29 F FTA       
THY28 34 F FTA       
THY29 34 F FTA       
THY30 NA NA FTA       
THY31 NA NA FTA       
THY32 56 F FTA       
THY33 33 F FTA       
THY34 47 M FTA       
THY35 30 F FTA       
THY36 55 M FTA       
THY37 NA F FTA       
THY38 41 F FTA       
THY39 45 F FTA       
THY40 44 F FTA       
THY41 NA NA FTA       
THY42 64 F FTA       
THY43 NA NA FTA       
THY44 61 F FTA       
THY45 45 F FTA       
THY46 46 F FTA       
THY47 29 M FTA       
THY48 40 F FTA       
THY49 35 M FTA       
THY50 42 F FTA       
THY51 35 F FTA       
THY52 21 F FTA       
THY53 36 F FHCA       
THY54 NA NA FHCA       
THY55 25 F FHCA       
THY56 62 F FHCA       
THY57 38 F FHCA       
THY58 57 F FHCA       
THY59 52 F FHCA       
THY60 59 F FHCA       
THY61 54 F cPTC       
THY62 39 F cPTC   V600E   
THY63 48 M cPTC Pos     
THY64 28 F cPTC   V600E   
THY65 49 F cPTC   V600E   
THY66 38 F cPTC       
THY67 24 F cPTC   V600E   
THY68 76 F cPTC   V600E   
THY69 55 F cPTC       
THY70 28 F cPTC       
THY71 36 F cPTC   V600E   
THY72 69 F cPTC   V600E   
THY73 68 F cPTC       
THY74 55 F cPTC   V600E   
THY75 30 F cPTC Pos     
THY76 47 F cPTC   V600E   
THY77 32 F cPTC Pos     
THY78 25 F cPTC   V600E   
THY79 55 F cPTC       
THY80 31 F cPTC   V600E   
THY81 64 F cPTC   V600E   
THY82 30 F cPTC       
THY83 55 F cPTC       
THY84 56 F cPTC       
THY85 25 F cPTC       
THY86 28 F cPTC   V600E   
THY87 18 F cPTC       
THY88 56 F cPTC       
THY89 14 M cPTC       
THY90 57 F cPTC   V600E   
THY91 40 F cPTC       
THY92 53 M cPTC   V600E -124 G>A 
THY93 61 F cPTC       
THY94 44 M cPTC   V600E   
THY95 82 M cPTC   V600E -124 G>A 
THY96 42 M cPTC   V600E -124 G>A 
THY97 46 F cPTC       
THY98 46 M cPTC   V600E   
THY99 39 M cPTC   V600E   
THY100 79 F cPTC   V600E -124 G>A 
THY101 32 F cPTC       
THY102 37 F cPTC   V600E   
THY103 72 F cPTC   V600E -124 G>A 
THY104 77 M cPTC   V600E -124 G>A 
THY105 60 M cPTC   V600E   
THY106 15 M cPTC       
THY107 38 F cPTC   V600E   
THY108 38 M cPTC   V600E   
THY109 38 M cPTC   V600E   
THY110 27 F cPTC       
THY111 40 F cPTC   V600E   
THY112 66 M cPTC   V600E -124 G>A 
THY113 57 F cPTC   V600E   
THY114 50 F cPTC   V600E   
THY115 13 F cPTC       
THY116 37 F cPTC   V600E   
THY117 26 F cPTC   V600E   
THY118 30 F cPTC       
THY119 52 F cPTC   V600E   
THY120 42 F cPTC   V600E   
THY121 NA NA cPTC       
THY122 73 F cPTC       
THY123 54 F cPTC       
THY124 16 M cPTC       
THY125 47 F cPTC   V600E   
THY126 55 F cPTC   V600E   
THY127 31 F cPTC Pos     
THY128 52 F cPTC       
THY129 25 F cPTC       
THY130 39 F cPTC   V600E   
THY131 41 M cPTC   V600E   
THY132 36 F cPTC   V600E   
THY133 35 F cPTC       
THY134 63 F cPTC   V600E   
THY135 NA NA cPTC       
THY136 26 F cPTC       
THY137 31 F cPTC       
THY138 30 M cPTC       
THY139 58 F cPTC   V600E -124 G>A 
THY140 40 F cPTC       
THY141 45 M cPTC   V600E   
THY142 43 M cPTC   V600E -124 G>A 
THY143 67 M cPTC   V600E   
THY144 30 F cPTC       
THY145 31 F cPTC       
THY146 33 F cPTC   V600E   
THY147 44 F cPTC   V600E   
THY148 NA NA cPTC       
THY149 61 F cPTC   V600E -124 G>A 
THY150 54 F cPTC   V600E   
THY151 72 M cPTC   V600E -124 G>A 
THY152 52 F cPTC   V600E   
THY153 20 M cPTC       
THY154 NA NA cPTC       
THY155 47 M cPTC   V600E -146 G>A 
THY156 36 F cPTC       
THY157 59 M cPTC       
THY158 33 F cPTC       
THY159 30 F cPTC   V600E   
THY160 29 M cPTC       
THY161 40 F cPTC   V600E   
THY162 27 F cPTC   V600E   
THY163 64 F cPTC   V600E   
THY164 43 F cPTC       
THY165 25 F cPTC       
THY166 42 F cPTC   V600E   
THY167 53 F cPTC   V600E   
THY168 22 F cPTC   V600E -150 G>A 
THY169 41 F cPTC   V600E   
THY170 7 M cPTC       
THY171 39 F fvPTC Pos     
THY172 46 F fvPTC       
THY173 36 M fvPTC Pos     
THY174 68 F fvPTC       
THY175 56 F fvPTC Pos     
THY176 44 F fvPTC       
THY177 21 M fvPTC       
THY178 30 F fvPTC Pos     
THY179 61 M fvPTC       
THY180 41 M fvPTC Pos     
THY181 38 F fvPTC Pos     
THY182 52 F fvPTC       
THY183 33 F fvPTC       
THY184 57 M fvPTC       
THY185 40 F fvPTC   V600E   
THY186 75 F fvPTC       
THY187 47 F fvPTC       
THY188 57 F fvPTC       
THY189 57 F fvPTC       
THY190 22 F fvPTC   V600E   
THY191 67 F fvPTC       
THY192 41 F fvPTC       
THY193 25 F fvPTC       
THY194 61 F fvPTC Pos     
THY195 42 F fvPTC       
THY196 44 F fvPTC       
THY197 40 F fvPTC       
THY198 72 F fvPTC       
THY199 60 M fvPTC       
THY200 34 M fvPTC   K601E   
THY201 38 F fvPTC       
THY202 76 F fvPTC       
THY203 36 F fvPTC       
THY204 48 F fvPTC       
THY205 30 F fvPTC       
THY206 53 F fvPTC       
THY207 38 F fvPTC       
THY208 21 F fvPTC       
THY209 42 M fvPTC       
THY210 30 F mPTC       
THY211 64 F mPTC   V600E   
THY212 35 F mPTC       
THY213 44 F mPTC       
THY214 57 F mPTC       
THY215 20 F MEC       
THY216 67 F MEC     -124 G>A 
THY217 NA NA MEC       
THY218 NA NA MEC       
THY219 45 F hcPTC   V600E   
THY220 43 F hcPTC   V600E   
THY221 33 F hcPTC   V600E   
THY222 60 F hcPTC   V600E   
THY223 45 F hcfvPTC       
THY224 68 F hcfvPTC   V600E   
THY225 23 M hcfvPTC       
THY226 68 F wPTC   V600E   
THY227 55 F wPTC   V600E   
THY228 41 F wPTC   V600E   
THY229 58 F wPTC   V600E   
THY230 55 M FTC Pos     
THY231 53 F FTC       
THY232 82 F FTC     -124 G>A 
THY233 56 F FTC       
THY234 54 F FTC Pos     
THY235 42 F FTC       
THY236 85 M FTC       
THY237 78 M FTC Pos   -124 G>A 
THY238 66 M FTC Pos     
THY239 59 F FTC Pos   -124 G>A 
THY240 41 F FTC       
THY241 72 M FTC       
THY242 45 M FTC       
THY243 51 F FTC       
THY244 24 M FTC       
THY245 33 F FTC       
THY246 42 F FTC       
THY247 60 F FTC     -124 G>A 
THY248 76 F FTC     -146 G>A 
THY249 27 F FTC Pos     
THY250 38 M FTC       
THY251 49 F FTC Pos   -124 G>A 
THY252 34 F FTC       
THY253 53 F FTC       
THY254 60 F FTC       
THY255 56 F FTC       
THY256 56 F FTC       
THY257 45 F FTC     -146 G>A 
THY258 36 F FTC       
THY259 NA NA FTC       
THY260 64 M FTC Pos     
THY261 67 M FTC       
THY262 58 F FTC Pos   -124 G>A 
THY263 58 F FTC Pos   -124 G>A 
THY264 52 F FTC       
THY265 54 F FTC Pos     
THY266 57 F FHCC       
THY267 55 F FHCC       
THY268 56 F FHCC       
THY269 70 F FHCC       
THY270 NA NA FHCC       
THY271 19 F FHCC Pos     
THY272 24 F FHCC       
THY273 59 F FHCC       
THY274 78 F FHCC       
THY275 43 F FHCC       
THY276 63 F FHCC       
THY277 26 F FHCC       
THY278 26 F FHCC       
THY279 NA NA FHCC       
THY280 86 F FHCC       
THY281 53 F FHCC       
THY282 41 M FHCC       
THY283 29 M FHCC       
THY284 68 F FHCC       
THY285 77 F FHCC       
THY286 69 F FHCC       
THY287 41 M FHCC       
THY288 35 F FHCC       
THY289 59 F FHCC       
THY290 57 F FHCC       
THY291 23 F FHCC Pos     
THY292 36 M FHCC Pos     
THY293 86 F FHCC       
THY294 63 F PDTC       
THY295 NA NA PDTC       
THY296 58 M PDTC   V600E   
THY297 68 F PDTC       
THY298 NA NA PDTC     -124 G>A 
THY299 71 F PDTC       
THY300 52 F PDTC       
THY301 70 M PDTC     -124 G>A 
THY302 64 M PDTC       
THY303 38 M PDTC       
THY304 80 M PDTC       
THY305 11 M PDTC       
THY306 52 F PDTC       
THY307 54 F PDTC Pos   -146 G>A 
THY308 60 M Anaplastic   V600E -124 G>A 
THY309 72 M Anaplastic       
THY310 NA NA Anaplastic   V600E   
THY311 74 F Anaplastic   V600E   
THY312 52 F Anaplastic       
THY313 55 M Anaplastic       
THY314 NA NA Anaplastic       
THY315 NA F Anaplastic       
THY316 56 F Anaplastic       
THY317 59 F Anaplastic       
THY318 75 F Anaplastic   V600E   
THY319 82 F Anaplastic       
THY320 69 M Anaplastic   V600E   
THY321 39 M Anaplastic       
THY322 70 M Anaplastic       
THY323 44 F Anaplastic     -146 G>A 
THY324 63 M MTC       
THY325 NA NA MTC       
THY326 NA NA MTC       
THY327 32 F MTC       
THY328 NA NA MTC       
THY329 NA NA MTC       
THY330 NA NA MTC       
THY331 NA NA MTC       
THY332 NA NA MTC       
THY333 NA NA MTC       
THY334 68 F MTC       
THY335 NA NA MTC       
THY336 37 F MTC       
THY337 NA NA MTC       
THY338 71 F MTC       
THY339 40 M MTC       
THY340 NA NA MTC       
THY341 56 F MTC       
THY342 NA NA MTC       
THY343 38 F MTC       
THY344 NA NA MTC       
THY345 NA NA MTC       
THY346 23 M MTC       
THY347 NA NA MTC       
THY348 36 F MTC       
THY349 NA NA MTC       
THY350 NA NA MTC       
THY351 NA NA MTC       
 
Supplementary Table S8 – Comparison of the clinico-pathological features of 
conventional PTC with and without TERT mutations 
 
 
 
Tumour 
type 
Clinical features All 
patients 
 
TERT wild 
type 
 
TERT 
mutated 
 
p 
value 
Conventional 
Papillary 
Thyroid 
Carcinoma 
(n=110) 
Mean age at 
diagnosis, yr (±SD) 
 
Gender  
Male 
Female 
 
Mean tumour size, 
cm 
 
LN metastasis 
(positive/total) 
 
BRAF mutation 
(positive/total) 
 
NRAS mutation 
(positive/total) 
 
43±16 
 
 
 
26 (25%) 
80 (75%) 
 
2,6±1,6 
 
 
67 (73%) 
 
 
61 (57%) 
 
 
4(7%) 
41±15 
 
 
 
18 (19%) 
76 (81%) 
 
2,4±1,4 
 
 
56 (68%) 
 
 
49 (50%) 
 
 
4 (10%) 
63±14 
 
 
 
8 (67%) 
4 (33%) 
 
4,3±2,2 
 
 
11 (100%) 
 
 
12 (100%) 
 
 
0 (0%) 
<0,0001 
 
 
 
0,0012 
 
 
0,0004 
 
 
0,03 
 
 
0,001 
 
 
NS 
 
Supplementary Table S9 - Summary of clinico-pathological and genetic data in 82 
bladder cancers 
   
Case Code Age Gender Stage Grade TERT 
BC1 66 M Ta Low Grade -146 G>A 
BC2 NA M T1 Low Grade 
 
BC3 80 M Ta Low Grade -146 G>A 
BC4 70 M Ta Low Grade 
 
BC5 67 M Ta Low Grade -124 G>A 
BC6 80 M Ta Low Grade -124 G>A 
BC7 65 M Ta Low Grade -124 G>A 
BC8 40 M Ta Low Grade -124 G>A 
BC9 36 M T1 Low Grade -124 G>A 
BC10 64 M Ta Low Grade 
 
BC11 65 M Ta Low Grade -124 G>A 
BC12 47 F Ta Low Grade 
 
BC13 54 M Ta Low Grade -124 G>A 
BC14 41 M T1 Low Grade 
 
BC15 50 M T1 Low Grade -124 G>A 
BC16 67 M Ta Low Grade -124 G>A 
BC17 97 M Ta Low Grade -146 G>A 
BC18 40 F Ta Low Grade -124 G>A 
BC19 60 M Ta Low Grade 
 
BC20 70 M T1 Low Grade -146 G>A 
BC21 46 F Ta Low Grade 
 
BC22 61 F Ta High Grade -146 G>A 
BC23 NA M T1 High Grade -124 G>A 
BC24 59 M T1 High Grade -124 G>A 
BC25 77 M T1 High Grade -146 G>A 
BC26 65 M T1 High Grade -124 G>A 
BC27 83 F T1 High Grade -124 G>A 
BC28 64 M T1 High Grade 
 
BC29 NA M NA High Grade -124 G>A 
BC30 NA M NA High Grade -146 G>A 
BC31 67 M T1 High Grade -124 G>A 
BC32 NA M Ta High Grade 
 
BC33 NA M T1 High Grade 
 
BC34 NA M T1 High Grade 
 
BC35 NA M T1 High Grade -146 G>A 
BC36 74 M T1 High Grade -124 G>A 
BC37 75 M Ta High Grade 
 
BC38 76 F T1 High Grade 
 
BC39 45 M Ta High Grade 
 
BC40 NA M T1 High Grade 
 
BC41 76 F T1 High Grade 
 
BC42 NA M T1 High Grade -124 G>A 
BC43 72 F Ta High Grade 
 
BC44 NA F T1 High Grade 
 
BC45 67 M T1 High Grade -124 G>A 
BC46 NA M T1 High Grade -146 G>A 
BC47 NA M T1 High Grade -146 G>A 
BC48 51 M T1 High Grade -146 G>A 
BC49 50 M Ta High Grade -124 G>A 
BC50 74 M T1 High Grade -124 G>A 
BC51 70 F T1 High Grade -124 G>A 
BC52 50 M T1 High Grade -146 G>A 
BC53 68 M T1 High Grade -124 G>A 
BC54 56 M T1 High Grade 
 
BC55 53 M T1 High Grade 
 
BC56 60 F T1 High Grade 
 
BC57 74 M T1 High Grade 
 
BC58 73 M T1 High Grade 
 
BC59 60 F T1 High Grade 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
BC60 64 F T1 High Grade 
 
BC61 74 M T1 High Grade 
 
BC62 51 M T1 High Grade 
 
BC63 63 M T1 High Grade -124 G>A 
BC64 57 M Ta High Grade -146 G>A 
BC65 67 F Ta High Grade -146 G>A 
BC66 58 M Ta High Grade -124 G>A 
BC67 66 M T1 High Grade -124 G>A 
BC68 64 M T1 High Grade 
 
BC69 70 M T1 High Grade -146 G>A 
BC70 68 M Ta High Grade -146 G>A 
BC71 64 M T1 High Grade 
 
BC72 59 F T1 High Grade -124 G>A 
BC73 63 M T1 High Grade -124 G>A 
BC74 66 M Ta High Grade 
 
BC75 76 M T1 High Grade -124 G>A 
BC76 71 M T1 High Grade 
 
BC77 61 M T1 High Grade -124 G>A 
BC78 76 M T1 High Grade -124 G>A 
BC79 61 M T1 High Grade 
 
BC80 68 F T1 High Grade 
 
BC81 72 M T1 High Grade 
 
BC82 71 M T1 High Grade -146 G>A 
Supplementary Table S10 - Summary of clinico-pathological and genetic data in 26 
kidney cancers   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CCRC – Clear cell renal carcinoma; CromRCC – chromophobe renal cell cancer; PRCC – Papillary 
renal cell carcinoma;  
 
  
Case code Diagnosis Age Gender Nuclear grade Staging TERT 
RCC1 CCRCC 68 M 
   
RCC2 CCRCC 44 M 
   
RCC3 CCRCC 49 M 
   
RCC4 CCRCC 49 M 3 pT1a Nx Mx 
 
RCC5 CCRCC 57 M 2 pT1a Nx Mx 
 
RCC6 CCRCC 48 F 2 pT1a Nx Mx 
 
RCC7 CCRCC 48 F 2 pT1a Nx Mx 
 
RCC8 CCRCC 68 M 2 pT3a Nx Mx 
 
RCC9 CCRCC 50 M 4 pT3b Nx M0 
 
RCC10 CCRCC 50 M 4 pT3b Nx M1 
 
RCC11 CCRCC 62 M 3 pT2 Nx Mx 
 
RCC12 CCRCC 62 M 3 pT2 Nx Mx 
 
RCC13 CromRCC 59 M 
   
RCC14 CromRCC 77 F 2 pT2 Nx Mx 
 
RCC15 CromRCC 77 F 2 pT2 Nx Mx 
 
RCC16 CromRCC 72 M 4 pT2 Nx Mx 
 
RCC17 PRCC NA M 
   
RCC18 PRCC 61 M 
   
RCC19 PRCC 26 F 2 pT2 N2 MX 
 
RCC20 PRCC 78 M 2 pT1b Nx Mx 
 
RCC21 PRCC 34 M 1 pT1a Nx Mx 
 
RCC22 PRCC 60 M 
 
pT1b Nx Mx 
 
RCC23 PRCC 60 M 
 
pT1b Nx Mx 
 
RCC24 PRCC 71 M 
   
RCC25 PRCC 71 M 
   
RCC26 PRCC 75 M 3 pT1a Nx Mx 
 
Supplementary Table S11 - Summary of clinico-pathological and genetic data in 17 
phaeochromocytoma   
  
 
 
 
 
 
 
 
 
 
 
 
 
  
Case code Age Gender Tumor size (cm) MEN/NF/VHL TERT 
PHEO1 51 M 4,5 NA   
PHEO2 56 M 7 NA   
PHEO3 54 F 4 NA   
PHEO4 46 F 7 NA   
PHEO5 53 F 2,5 NA   
PHEO6 42 M 8,5 NA   
PHEO7 20 F 1,5 MEN2   
PHEO8 55 F 3,5 NA   
PHEO9 19 F 7 NA   
PHEO10 56 M 4,5 NA   
PHEO11 62 M 6 NA   
PHEO12 45 M 7 NA   
PHEO13 73 F 5 NA   
PHEO14 57 M 3,5 NA   
PHEO15 61 M 1,7 NA   
PHEO16 20 F 6 MEN2   
PHEO17 46 F 10 NF1   
Supplementary Table S12 - Summary of clinico-pathological and genetic data in 36 
gastrointestinal stromal tumour   
  
 
Case code Age Sex Tumor Size (cm) KIT PDGFRA TERT 
GIST1 80 F   exon 11 N567K, L576V, 568del575     
GIST2 59 M 1,2 exon 11 V560D     
GIST3 52 M 9,5 exon 11 69997:T>A    
GIST4 67 M 17 exon 11 W557F delK558     
GIST5 58 F 3,5 exon 11 556del557     
GIST6 54 M 19 exon 11 V559D     
GIST7 79 F 7 exon 11 del557-558     
GIST8 46 M 5,5 exon 11 del 550-557, ins550-551    
GIST9 54 M 3,1 exon 11 552del557, K550Q, P551R     
GIST10 76 F 6,7 
 
exon 18 D842V    
GIST11 55 F 6,5 exon 11 del560V     
GIST12 43 M 14,5 exon 11 564del578     
GIST13 73 F 0,8 exon 11 delV559     
GIST14 62 M 2,5 exon 11 del_K558     
GIST15 38 M 3,5 exon 11 V560E     
GIST16 88 F 23 exon 11 L576P     
GIST17 81 F   exon 11 L576P     
GIST18 78 F   
 
exon 12 583del586    
GIST19 40 F 4 exon 9 502-503dup     
GIST20 63 F 9 exon 9 502-503dup     
GIST21 75 M 8 exon 11 Q575H, P577T, delL576     
GIST22 59 F   exon 11 552del570     
GIST23 78 F 24 exon 11 551del553     
GIST24 58 M 13,5 exon 11 557del558     
GIST25 76 M 14 exon 9 502-503dup     
GIST26 20 F 2     
GIST27 77 F 6     
GIST28 74 M 3     
GIST29 58 F 3,5     
GIST30 72 F 8     
GIST31 62 M 6,5     
GIST32 73 M 6     
GIST33 66 F 14     
GIST34 63 F 6,5     
GIST35 55 M 4     
GIST36 82 F 7     
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III.2 Targeted expression of BRAFV600E in thyroid cells of 
transgenic zebrafish induces hyperplasia reverted by loss of 
WT p53 
 
Abstract 
The BRAFV600E mutation is the most common genetic alteration in papillary thyroid 
carcinomas (PTCs) and are found in 29%-83% of all cases. PTCs harboring B-type 
Raf kinase (BRAF)V600E are often invasive and this mutation is also present in more 
advanced stages of the disease such as in poorly differentiated and anaplastic 
carcinomas arising from PTCs. BRAFV600E kinase activate the mitogen-activated 
protein kinases (MAPK) pathway, promoting cellular processes such as 
proliferation, survival, motility and invasion.  
To explore the role of BRAFV600E in thyroid cancer pathogenesis, I targeted its 
expression to thyroid cells of transgenic zebrafish under a thyroid-specific 
promoter. Fish showed impairment of normal thyroid morphogenesis at early 
stages of development and they seemed to compensate for BRAFV600E-induced 
thyroid dysfunction by developing hyperplasia and goiter but not neoplasia. Also, 
activation of BRAFV600E expression in thyroid cells of transgenic zebrafish during 
adulthood resulted in a hyperplasic phenotype similar to when BRAFV600E was 
expressed shortly after birth. In BRAFV600E-expressing animals, upregulation of p53 
was observed suggesting a protective mechanism to prevent cancer. Thus, I 
targeted BRAFV600E expression to thyroid cells of tp53M214K zebrafish in order to 
overcome p53 blockage and progression to cancer. Suprisingly, BRAFV600E-
expressing tp53M214K fish developed a normal thyroid until adulthood.  
In summary, thyroid-specific expression of BRAFV600E induced goiter but not 
neoplasia which was prevented by loss of WT p53 protein.  
 
Introduction 
To create functional follicles, thyroid cells must aggregate, polarize and establish 
selective permeability barriers between the lumen and the outer compartments. 
Cellular adhesion, intracellular trafficking, specialized cell-cell junction assembly 
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and precise regulated morphogenetic cell movements must all be coordinated (Yap 
et al., 1997).  
Disturbances in these cellular processes can be mediated by external factors such 
as goitrogens or internal factors such as hormonal imbalance or genetic alterations. 
Ultimately, these factors have important implications in thyroid diseases, mostly 
characterized by disturbed follicular architecture. 
PTCs are characterized by nonoverlapping genetic alterations in more than 70% of 
the cases. These alterations include rearrangements in the tyrosine kinase (TK) 
receptors Rearranged-during-transfection (RET), Neurotrophic Tyrosine Kinase, 
Receptor, Type 1 (NTRK1), Anaplastic Lymphoma Receptor Tyrosine Kinase (ALK) 
and A Kinase (PRKA) Anchor Protein 9/B-type Raf kinase (AKAP9/BRAF) and also 
point mutations in Rat Sarcoma Viral Oncogene Homolog (RAS) and BRAF genes. 
Ultimately, most cases will lead to an aberrant activation of the RAS-RAF-MEK-ERK 
kinase pathway (DeLellis et al., 2004; Kumar et al., 2005; Nikiforov, 2012). Up to 
90% of the BRAF gene mutations consist in the BRAFV600E (Garnett et al., 2004; Frasca 
et al., 2008). 
The initial evidence that BRAFV600E is required for the cell proliferation, 
transformation and tumorigenicity of follicular thyroid cells was demonstrated in a 
xenograft mice model (Liu et al., 2007) even though many studies have supported 
the role of BRAF mutation in tumor initiation.  
Targeted expression of the BRAFV600E in thyroid cells was induced in transgenic 
FVB/N mice using a bovine thyroglobulin promoter. This study showed that BRAF 
induced thyroid dysfunction which was compensated by increased levels of 
thyroid-stimulating hormone (TSH) and goiter development. Also, multifocal 
tumors involving both lobes of the thyroid gland with mixed papillary and follicular 
growth pattern were observed in 12 and 22-week-old mice. PTCs presented the 
classical architecture, tall-cell features and a high potential for invasiveness. 
Tumors from one of the transgenic lines progressed into poorly differentiated 
carcinomas (Knauf et al., 2005). PTCs were also observed in a thyrocyte-specific 
knock-in of BRAFV600E in mice but with a very short latency and complete penetrance 
by 3 weeks. When this model was crossed with a thyroid stimulating hormone 
receptor (TshR) knockout mice to genetically ablate TSH signaling, thyroid growth 
was reduced and low-grade PTCs were observed but only at 9 weeks of age (Franco 
et al., 2011). More evidence of BRAFV600E involvement in mice thyroid tumorigenesis 
was perceived when BRAFV600E expression was induced in follicular thyroid cells in a 
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doxycycline-inducible manner. As early as one week after doxycycline treatment, 
development of highly penetrant and high-grade papillary thyroid carcinomas with 
poorly differentiated features and a reversible activation of the MAPK pathway were 
observed. Upon doxycycline withdrawal, thyroid architecture was reestablished but 
a second induction not only resulted in hypothyroidism but also reduced thyroid-
specific genes expression (Chakravarty et al., 2011).  
TP53 mutations are not frequent in thyroid cancer (only 10%) and most have been 
documented in anaplastic carcinomas. Indeed, well-differentiated thyroid cancers 
rarely present mutations in TP53 suggesting a role on cancer progression to poorly 
differentiated and aggressive phenotypes. Of note, studies on thyroid tumor 
samples revealed an accumulation of p53 in poorly differentiated and anaplastic 
forms but also in a few well-differentiated tumors in the absence of any p53 
mutation suggesting that p53 inactivation may result from loss of interaction with 
MDM2 (Soares et al.,  1994). 
Modeling thyroid cancer in mice have shown that acquired mutations drive tumor 
progression. In general, BRAFV600E is sufficient to initiate PTCs and TP53 mutations 
constrained progression from papillary to anaplastic thyroid carcinoma (McFadden 
et al., 2014). By generating a thyroid-specific cre recombinase-estrogen receptor 
(CreER) transgenic mouse and using a Cre-regulated BRAFV600E and a conditional 
Trp53, it was found that p53 loss does enable progression to aggressive anaplastic 
thyroid cancer but additional events may be required for full anaplastic conversion 
(McFadden et al., 2014). 
Here, I describe the generation of a novel transgenic zebrafish line, tg(tg:mCh-
T2A-BRAFV600E), that expresses BRAFV600E specifically in the thyroid cells allowing 
imaging of the thyroid development and monitoring of the effect of the oncogene 
in live animals. By crossing this transgenic line with tp53M214K, I generated a second 
novel zebrafish line providing new insights of the dynamics of BRAFV600E and p53 in 
zebrafish thyroid. Finally, I used those lines to generate a conditional BRAFV600E 
expressing line that can be used for future studies and disclose in detail the thyroid 
phenotypes occurring due to BRAFV600E either in the presence of absence of a WT 
p53 at different stages of life.  
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Material and Methods 
Zebrafish husbandry and embryo culture 
Zebrafish embryos were obtained from natural spawning of adult fish and were 
raised at 28.5ºC according to Westerfield et al., 2000 and staged in hours post-
fertilization (hpf) as described by Kimmel et al., 1995. 
 
Fish strains 
The following zebrafish lines were used in this study: tg(tg:mCh), tg(tg:mCh-T2A-
BRAFV600E), tg(tg:mCh;tg:mCh-T2A-BRAFV600E), tp53M214K tg(tg:mCh), tp53M214K 
tg(tg:mCh-T2A-BRAFV600E), tp53M214K tg(tg:mCh;tg:mCh-T2A-BRAFV600E), 
tg(hsp70l:mCh-T2A-CreERT2;tg:loxP-CFP-loxP-mCh) and tg(hsp70l:mCh-T2A-
CreERT2;tg:loxP-CFP-loxP-mCh-T2A-BRAFV600E), all containing the cmlc2:EGFP 
transgenesis marker. Details on the strategy to generate these lines are briefly 
described below and in Chapter II. 
 
Generation of plasmids for transgenic lines 
A bacterial artificial chromosome (BAC) genomic clone DKEY-97I18 BAC (GenBank 
CR855311.15) containing the first exon of the zebrafish thyroglobulin (tg) gene 
was obtained from SourceBioScience (Nottingham, UK). An insert corresponding to 
the region from -2041bp until -1bp relative to the tg ATG was amplified and cloned 
into a p5E-MCS plasmid provided by the Tol2Kit (Kwan et al., 2007). mCherry-T2A-
BRAFV600E was amplified and cloned into a pME-entry clone. To build the final 
constructs, [p5E-tg promoter, pME-mCherry and p3E-polyA] or [p5E-tg promoter, 
pME-mCherry-T2A-BRAFV600E and p3E-polyA] were assembled into a pDestTol2pA 
or a pDestTol2CG2 with cmlc2:EGFP cassette. The final constructs used for 
injection were verified by sequencing and named Tol2tg:mCh and Tol2tg:mCh-
T2A-BRAFV600E. To generate conditional constructs, the loxP-CFP-loxP cassette was 
cloned downstream of the tg promoter using the above-mentioned constructs as 
backbones. 
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Transgenesis 
For generation of transgenic fish, WT and tg(hsp70l:mCherry-T2A-CreERT2) 
embryos were injected with 30ng/μL of plasmid and 25 ng/μL of capped 
transposase messenger ribonucleic acid (mRNA) at one-cell stage. Microinjections 
were performed using a SZX10 Stereo Microscope (Olympus) and PV820 Pneumatic 
PicoPump (World Precision Instruments, Inc.).  
mRNA injections 
For mRNA experiments, mCherry, mCherry-T2A-BRAFWT and mCherry-T2A-
BRAFV600E were cloned into a pCS2-CMV plasmid. Capped mRNA was generated by 
in vitro transcription using the mMessage mMachine SP6 kit (Ambion) linearized 
with HpaI. Capped mRNA was injected into the yolk of one-cell stage WT or tp53M214K 
embryos at a final concentration of 35ng/μL. Microinjections were performed using 
a SZX10 Stereo Microscope (Olympus) and PV820 Pneumatic PicoPump (World 
Precision Instruments, Inc.).  
Histology 
Zebrafish was fixed in 10% neutral-buffered formalin, decalcified in 
(ethylenedinitrilo)tetraacetic acid (EDTA) and embedded in paraffin. Details for each 
stage are described in Chapter II. Three-micrometer-thick sections were prepared 
and stained with hematoxylin-eosin (HE). 
Western blot 
Thyroid tissue or embryos were placed in RIPA Buffer (Sigma) supplemented with 
protease and phosphatase inhibitor cocktail (Sigma) and homogenized with a 
pestle. Protein lysates were centrifuged and supernatant collected. Lysates were 
subjected to SDS PAGE, transferred to HyBond-P PVDF membranes (GE Healthcare) 
and probed with antibodies to BRAF, phospho-ERK1/2, pAKT S473, pAKT T308, 
PCNA, p16, p53, activated caspase 3, p38 and mCherry (Clontech Lab, Santa Cruz 
Biotechnology, Cell Signaling, Anaspec and Abcam). Membranes were hybridized 
with species-specific HRP-conjugated antibodies (Santa Cruz Biotechnology) and 
bands visualized with Pierce™ ECL Plus Western Blotting Substrate detection system 
(Thermo Fisher Scientific Inc.). Antibody dilutions are described in Chapter II. 
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Drug treatment 
Fish were heat-shocked in a 37ºC water bath for 30 minutes and immediately a 
drug treatment was carried out with 2.5μM of 4-hydroxyl-tamoxifen (4-OHT) 
(H7904, Sigma). Controls were treated with an equivalent amount of 100% ethanol 
diluted in embryo medium. Fish received treatment at 28ºC for 5 hours in the dark 
followed by a recovery period in fresh water for 12 hours. 
 
Results 
Generation and validation of a thyroid-specific reporter line 
A thyroid-specific reporter line allow experimental approaches to study the role of 
BRAFV600E in zebrafish thyroid. I generated a control reporter construct in which the 
zebrafish tg promoter was used to drive expression of a monomeric red 
fluorophore mCherry protein. I also generated a reporter construct in which the 
zebrafish tg promoter was used to drive expression of mCherry and BRAFV600E 
proteins. 
The tg promoter was chosen because (1) tg mRNA expression in zebrafish is 
detected shortly after thyroid specification at 34hpf; (2) it is exclusive to thyroid 
cells and not to calcitonin-producing cells, which can be found as distinct glands 
elsewhere in the fish body (Alt et al., 2006) and; (3) tg mRNA is kept at high levels 
throughout zebrafish thyroid development (Alt et al., 2006; Opitz et al., 2011). The 
region from -2041bp until -1 relative to the tg ATG was cloned because it was 
expected that the putative regulatory region of the zebrafish tg coding sequence 
would lay between the tg ATG and the gene that was immediately upstream of the 
tg (Figure 1). By the same time and for the purpose of generating a thyroid-specific 
reporter line, Opitz et al., 2012 cloned the region from -3591bp until -518bp 
relative to the tg ATG and reported that this region drove robust reporter 
expression specifically in thyroid cells of transgenic zebrafish. The -3591bp until 
-2041bp region was not included in this work because it belonged to the phf20l1 
gene and it was unlikely to harbor a promoter.  
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Figure 1. Putative tg promoter. Schematic representation of the putative tg promoter 
flanked upstream by the PHD finger protein 20-like 1 (phf20l1) gene (encoded in the 
reverse strand) and downstream by the tg gene. The region from -2041bp until -1 relative 
to the tg ATG was chosen to be the tg promoter region. 
 
The fluorophore mCherry was chosen as a reporter because a cmlc2:EGFP 
transgenesis marker was to be included in the plasmid backbone. The cmlc2:EGFP 
cassette comprises a ~900-bp enhancer-promoter from the cardiac myosin light 
chain (cmlc2) gene which drives cytoplasmic EGFP expression specifically in the 
developing heart (Huang et al., 2003; Auman et al., 2007). This cassette is 
particularly useful to screen embryos and fish.  
mCherry reporter was not fused to BRAF coding sequence, so a self-cleaving 2A 
peptide (Thoseaasigna virus 2A- T2A) that was described to have the highest 
cleavage efficiency (close to 100%) (Donnelly et al., 2001) was chosen. This allow 
the cleavage between the upstream gene (mCherry) and the downstream gene 
(BRAF) of the 2A sequence.  
A simian vacuolating virus 40 (SV40) late polyadenylation (polyA) signal sequence 
derived from the p3E-polyA plasmid was also included because in many systems, 
including zebrafish, SV40 signal proved to be much more effective in the 
stabilization of mRNA transcripts and in the promotion of translation (Carswellet 
al., 1989). 
Finally, a Tol2-based destination plasmid was chosen not only because it greatly 
simplified the generation of expression constructs using the Gateway technology 
but also because, Tol2 constructs were reported to have a very high transgenesis 
efficiency (Kawakami et al., 2004). Also, a Tol2Kit containing many entry clones 
was available for the community (Kwan et al., 2007).  
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For generation of the two transgenic reporter constructs, a 2.0kb fragment of the 
putative tg promoter was assembled with [mCherry and poly(A)] fragments (Figure 
2A) or [mCherry-T2A-BRAFV600E and poly(A)] fragments (Figure 2B) into a 
pDestTol2pA with a cmlc2:EGFP cassette.  
 
 
Figure 2. Tol2CG2 constructs. Schematic representation of the (A) Tol2CG2tg:mCh-pA (A) 
and (B) Tol2CG2tg:mCh-T2A-BRAFV600E-pA constructs containing Tol2 elements and the 
cmlc2:EGFP-pA cassette. Not shown here is the Tol2tg:mCh-pA, also generated in this 
work. 
 
Tol2tg:mCh, Tol2CG2tg:mCh or Tol2CG2tg:mCh-T2A-BRAFV600E was injected with 
capped transposase mRNA into one-cell-stage WT zebrafish embryos. By 
fluorescence microscopy, mosaic mCherry expression was observed in thyroid cells 
of F0 animals injected with Tol2tg:mCh or Tol2CG2tg:mCh confirming that the 
selected 2.0kb tg promoter contained regulatory sequences sufficient to drive 
expression specifically to the thyroid cells. In F0 animals injected with 
Tol2CG2tg:mCh-T2A-BRAFV600E, mosaic mCherry expression was never observed 
and embryos were always selected for the transgenesis marker. 
Embryos presenting mosaic mCherry or EGFP expression in the thyroid or heart, 
respectively and according to the line, were grown to adulthood and F0 founders 
were identified by a strong and specific-reporter signal exclusively in those tissues 
in their progeny. Stable transgenic lines were established using F0 founders. A 
robust mCherry expression was confirmed to be observed in the thyroid cells of 
tg(tg:mCh) line (Figure 3) but not in the tg(tg:mCh-T2A- BRAFV600E).  
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Figure 3. tg(tg:mCh) line. (A) 14dpf tg(tg:mCh) larvae revealed (B) mCherry protein 
expression specifically in thyroid cells. Larvae is oriented with anterior to the left. Scale bar: 
250μM.  
 
At this point, EGFP reporter expression in the heart was used to select animals from 
the BRAFV600E-expressing line. By crossing the tg(tg:mCh) with the tg(tg:mCh-T2A- 
BRAFV600E) line, a tg(tg:mCh;tg:mCh-T2A- BRAFV600E) line was generated in order to 
have a thyroid-specific reporter in the BRAFV600E-expressing line. Embryos showing 
mCherry expression in the thyroid given by the Tol2tg:mCh transgene and EGFP 
expression in the heart given by the Tol2CG2tg:mCh-T2A-BRAFV600E transgene were 
grown to adulthood.  
Because the tg(tg:mCh-T2A- BRAFV600E) line was not expressing mCherry, an 
experiment to determine the protein translation efficiency from mCh-T2A-BRAFV600E 
was performed in order to exclude possible problems with the 2A cleavage.  
A pCS2+ expression plasmid was chosen because it contains a strong 
enhancer/promoter (simian CMV) followed by a polylinker and a SV40 late 
polyadenylation site. Also, a SP6 promoter is present in the 5’ untranslated region 
of the mRNA from the sCMV promoter which allows in vitro RNA synthesis of 
sequences cloned into the polylinker. mCherry coding sequence was used as a 
control and mCh-T2A-BRAFWT was used as a control of T2A efficiency and BRAF 
toxicity, because BRAFwt proteins do not have an effect on the development of 
zebrafish embryos (Anastasaki et al., 2012). Capped mRNA was in vitro transcribed 
from the constructs generated: pCS2-CMV:mCh, pCS2- CMV:mCh-T2A-BRAFWT and 
pCS2-CMV:mCh-T2A-BRAFV600E (Figure 4A). 
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After injecting capped mCh-T2A-BRAFV600E mRNA in WT embryos, a severe 
developmental arrest was found at around 4hpi preventing embryos to further 
develop beyond the blastula stage (Figure 4B). Malformations were found in the 
majority of injected embryos (90.43%) (Figure 4C) and survival at 24 hours post 
injection (hpi) was very low (34.8%) (Figure 4D). By fluorescence microscopy, a 
polka-dot pattern was observed confirming mCherry expression in the cell (Figure 
4B). The phenotype produced was believed to be due to expression of mCherry and 
BRAFV600E because no phenotypes were observed in non-injected WT embryos 
(Figure 4B). WT embryos injected with capped mCh or mCh-T2A- BRAFWT mRNAs 
showed no developmental arrest (Figure 4B), a very low frequency of malformations 
(0.76% and 0.64%, respectively) (Figure 4C) and survival at 24hpi (85.8% and 75.5%, 
respectively) not significantly different from non-injected WT embryos (Figure 4D). 
By fluorescence microscopy, it was observed an ubiquitous expression of mCherry 
in WT embryos injected with capped mCh or mCh-T2A-BRAFWT mRNAs (Figure 4B) 
which was consistent with the observations reported by Anastasaki et al., 2012. In 
order to confirm if BRAFV600E was indeed inducing a phenotype, a western blot of 
embryo lysates was performed by probing with antibodies to mCherry and human 
BRAF. Blots confirmed the presence of both mCherry and BRAF proteins in embryos 
injected with mCh-T2A-BRAFV600E mRNA and BRAF probing was similar to those 
injected with the WT form of BRAF (Figure 4E; E’ and E’’).  
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Figure 4. mRNA experiment in WT embryos. (A) Schematic representation of the pCS2-
CMV:mCh, pCS2-CMV:mCh-T2A-BRAFWT and pCS2-CMV:mCh-T2A-BRAFV600E constructs 
(top to bottom) containing the SP6 promoter to drive in vitro RNA synthesis. (B) 
Representative images of 24hpf non-injected and 24hpi injected WT embryos with one of 
the three mRNAs: mCh, mCh-T2A-BRAFWT or mCh-T2A- BRAFV600E. On the left are shown BF 
images; on the right images acquired with a Texas Red® filter. Scale bar: 300μm. (C) 
Percentage of developmental defects at 24hpf or 24hpi (statistical analysis only shown for 
relevant comparisons; p<0.001). (D) Survival at 24hpf or 24hpi (statistical analysis only 
shown for relevant comparisons; p<0.001). (E) Western blot analysis of lysates from 
embryos at 4hpf or 4hpi. 50 embryos were pooled for each condition. Membranes were 
blotted with mCh and BRAF antibodies. Ponceau S stain showed equal amount of protein in 
all lanes. (E’) mCherry and (E’’) BRAF protein levels were quantified and normalized to the 
amount of protein. Values are shown in bar graphs and represent three independent 
experiments (statistical analysis only shown for relevant comparisons; p<0.001). 
 
To rule out a possible activation of p53-mediated apoptosis due to off-targeting 
effect of the mRNA injected (Robu et al., 2007), an mRNA experiment was 
conducted in tp53M214K embryos. tp53M214K embryos lack apoptosis and cell-cycle 
arrest responses to deoxyribonucleic acid (DNA) damage because the tp53-
mediated cell-cycle control is absent (Berghmans et al., 2005).  
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After injecting capped mCh-T2A-BRAFV600E mRNA in tp53M214K embryos, a lower 
developmental arrest was found in embryos at around 4hpi (Figure 5A) when 
compared to tp53M214K embryos. Malformations were found in injected embryos 
(39.40%) (Figure 5B) and survival was low (33.00%) (Figure 5C). By fluorescence 
microscopy, ubiquitous expression of mCherry was observed (Figure 5A). In 
contrast, tp53M214K embryos injected with capped mCh or mCh-T2A- BRAFWT mRNAs 
showed no developmental arrest (Figure 5A), very low frequency of malformations 
(1.00% and 0.28%, respectively) (Figure 5B) and survival at 24hpi (92.60% and 
85.50%, respectively) (Figure 5C) similar to non-injected tp53M214K embryos (0.00% 
and 98% for malformation frequency and survival, respectively) (Figure 5B and 5C). 
Because a less severe phenotype was observed in BRAFV600E-expressing tp53M214K 
embryos, a western blot of embryo lysates was conducted to determine whether 
the phenotype would be due to a decrease of BRAF expression. Blots confirmed the 
presence of both mCherry and BRAF proteins in tp53M214K embryos injected with 
mCh-T2A-BRAFV600E mRNA but BRAF protein levels were significantly lower than 
those found for BRAFWT-expressing tp53M214K embryos (Figure 5D; D’ and D’’) 
(p<0.001) or even BRAFV600E-expressing WT embryos (Figure 4E’’).  
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Figure 5. mRNA experiment in tp53M214K embryos. (A) Representative images of 24hpf 
non-injected and 24hpi tp53M214K embryos injected with one of the three mRNAs: mCh, 
mCh-T2A-BRAFWT or mCh-T2A-BRAFV600E. On the left are shown BF images; on the right 
99 
 
images acquired with a Texas Red® filter. Scale bar: 300μm. (B) Percentage of 
developmental defects at 24hpf or 24hpi (statistical analysis only shown for relevant 
comparisons; p<0.001). (C) Survival at 24hpf or 24hpi (statistical analysis only shown for 
relevant comparisons; p<0.001). (D) Western blot analysis of lysates from embryos at 4hpf 
or 4hpi. 50 embryos were pooled for each condition. Membranes were blotted with mCh 
and BRAF antibodies. Ponceau S stain showed equal amount of protein in all lanes. (D’) 
mCherry and (D’’) BRAF protein levels were quantified and normalized to the amount of 
protein. Values are shown in bar graphs and represent three independent experiments 
(statistical analysis only shown for relevant comparisons; p<0.001). 
 
Taken together, mRNA experiments showed that BRAFV600E-induced phenotype in 
zebrafish embryos was conditioned by p53 and the presence of a WT p53 protein 
triggered protective mechanisms (possibly apoptosis and/or cell cycle arrest) 
against the oncogene.  
The mRNA experiments also confirmed an efficient translation of two independent 
proteins from mCh-T2A-BRAFV600E mRNA. This suggested that, independently of the 
absence of mCherry expression in the tg(tg:mCh-T2A-BRAFV600E) fish, the mutant 
form of BRAF was able to be translated. To confirm BRAF expression in the stable 
tg(tg:mCh-T2A-BRAFV600E) line, western blots of protein extracts from thyroid 
tissues of three month-old fish (Figure 6A) using a BRAF antibody raised against a 
peptide of human origin were performed. It was confirmed an increase in the levels 
of BRAF when compared to tg(tg:mCh) (Figure 6B). Also, a robust increase in the 
levels of phospho- Extracellular Regulated Kinase (pERK), a downstream of BRAF, 
confirmed activation of the MAPK pathway by BRAFV600E (Figure 6B). This suggested 
that the BRAF protein was indeed functional in thyroid cells of the transgenic line. 
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Figure 6. BRAF and pERK expression in tg(tg:mCh-T2A-BRAFV600E) fish. (A) Schematic 
representation of the thyroid tissue dissected from mCh-expressing transgenic zebrafish 
to produce tissue lysates. All follicles were dissected and separated from non-mCh 
expressing tissues. (B) Western blot analysis of lysates from thyroid tissues of tg(tg:mCh) 
(first lane) and tg(tg:mCh-T2A-BRAFV600E) (second lane) fish at 3 months of age. Three fish 
were pooled for each line. Membranes were blotted with BRAF and pERKs antibodies. 
Ponceau S showed equal amount of protein in both lanes.  
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Monitoring BRAFV600E-induced phenotype in transgenic fish 
When analyzing live tg(tg:mCh;tg:mCh-T2A-BRAFV600E) embryos, a robust thyroid-
specific reporter signal became detectable at around 34hpf and it was maintained 
throughout thyroid morphogenesis, similar to tg(tg:mCh) embryos.  
To study whether BRAFV600E produced an initial phenotype during thyroid growth, 
mCherry expression was monitored at 60-72hpf, which was the timepoint when 
conventional fluorescence microscopy was sufficiently sensitive to identify groups 
of thyroid cells that evaginated from pharyngeal epithelium, and up to 7dpf in 
tg(tg:mCh;tg:mCh-T2A-BRAFV600E). It was observed the formation of a unique follicle 
in the pharyngeal region harboring a main mass of thyroid cells that did not detach 
to form more follicles as observed in the tg(tg:mCh) larvae (Figure 7A). This 
phenotype was consistent with an impairment of thyroid morphogenesis.  
Throughout the screening it seemed that many BRAFV600E-expressing transgenic fish 
showed abnormal thyroid morphogenesis. When assessing the percentage of larvae 
displaying such abnormality, 95% (58/61) of tg(tg:mCh;tg:mCh-T2A-BRAFV600E) but 
none (0/37) of age-matched controls displayed abnormal morphogenesis (Figure 
7B). Therefore, the number of follicles were quantified to further highlight the 
impaired development in thyroid. In tg(tg:mCh;tg:mCh-T2A-BRAFV600E) larvae, the 
number of follicles (1-2 follicles) was much lower than the number observed in 
tg(tg:mCh) larvae (3-7 follicles) (p<0.0001) (Figure 7C).  
Besides the lower number of follicles, no obvious developmental defects were 
observed in tg(tg:mCh;tg:mCh-T2A-BRAFV600E) larvae. Nevertheless, a reduced 
number of follicles suggested hypoplasia. Larval growth was monitored and 
standard length (SL) was used as a proxy for developmental stage as described by 
Parichy et al., 2009. By 7 days post fertilization (dpf), tg(tg:mCh-T2A-BRAFV600E) 
larvae grew marginally faster (2.8% increase in SL) than the controls (p<0.01) 
(Figure 7D). 
Since conventional fluorescence microscopy was only able to give an idea of thyroid 
organization, histological examination of the lower jaw from 7-, 14-, 21- and 28-
days-old larvae was performed. tg(tg:mCh) revealed thyroid follicles located 
predominantly in the connective tissue in the lower jaw. Individual follicles were 
already organized by 7dpf and their number increased with age (Figure 7E). Each 
follicle was round or oval and was lined by a single-layered epithelium; the center 
of the follicle was filled with homogenous colloid (Figure 7E). tg(tg:mCh-T2A-
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BRAFV600E) revealed an unique follicle at very young age that only became organized 
into a follicular-like structure by 28dpf in the connective tissue in the lower jaw 
(Figure 7E). This structure remained attached (Figure 7E). Each thyroid follicle was 
round or oval and was lined by overlapping layers of epithelium consisting of 
cuboidal cells predominantly basophilic (Figure 7E). Many follicles showed clear 
vesicles at the periphery and/or lack colloid (Figure 7E).  
The abnormal thyroid morphogenesis observed in tg(tg:mCh-T2A-BRAFV600E) larvae 
suggested that it could underly a compromised thyroid function. Disturbance of 
thyroid hormone (TH) synthesis is known to have fatal consequences as TH action 
serves important regulatory functions throughout all phases of life (Brix et al., 
2011). It did not appear to be the case in tg(tg:mCh-T2A-BRAFV600E) larvae as 
survival registered up to 28dpf was similar to that observed for tg(tg:mCh) controls 
(Figure 7F).  
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Figure 7. Characterization of tg(tg:mCh-T2A-BRAFV600E) larvae. (A) Representative 
phenotypes of (A1) tg(tg:mCh) and (A2) tg(tg:mCh-T2A-BRAFV600E) at 7dpf and mCherry 
expression found in thyroid cells (A1’ and A2’, respectively). Scale bar: 0.5mm (left) and 
75μm (right). (B) Frequency of normal and abnormal thyroid morphogenesis at 7dpf 
assessed in tg(tg:mCh) (n=37) and tg(tg:mCh;tg:mCh-T2A-BRAFV600E) (n=61) (p<0.0001). 
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(C) Average number of follicles at 7dpf quantified in tg(tg:mCh) (n=37) and 
tg(tg:mCh;tg:mCh-T2A-BRAFV600E)  (n=61) (p<0.0001). (D) SL measured at 7dpf in 
tg(tg:mCh) (n=31) and tg(tg:mCh;tg:mCh-T2A-BRAFV600E)  (n=31) (p<0.01). (E) HE stain of 
longitudinal sections representative of the lower jaw at 7-, 14-, 21- and 28dpf. Insets show 
detail of the epithelium. Scale bar: 120μm. (F) Survival curves for tg(tg:mCh) (n=25) and 
tg(tg:mCh-T2A-BRAFV600E) (n=25) (p>0.05). Values are percentages of fish alive for a certain 
timepoint. 
 
tg(tg:mCh-T2A-BRAFV600E) fish were monitored as they reach the juvenile stage and 
past sexual maturity in order to understand how thyroid organization and function 
would be compromised later in life. tg(tg:mCh-T2A-BRAFV600E) were found to grow 
slower than the controls and this was evident by 3 months of age (Figure 8A). Body 
mass index (BMI) was calculated and a dramatic 25% decrease in body mass was 
observed in tg(tg:mCh-T2A-BRAFV600E) fish when compared to controls (Figure 8B). 
This suggested that the stunted growth observed could have been due to thyroid 
dysfunction in the BRAFV600E-expressing line. 
At this stage, it was difficult to interpret an increase in mCherry expression 
observed in living animals from the BRAFV600E-expressing line so histological 
examination was performed at 2- and 3-months of age. tg(tg:mCh) fish displayed 
thyroid follicles distributed predominantly in the connective tissue along the 
ventral aorta in the lower jaw (Figure 8C: C1 and C1’). Each follicle was round to 
oval and was lined by a single-layered epithelium; the center of the follicle was 
filled with homogenous colloid (Figure 8C: C1’’). tg(tg:mCh-T2A-BRAFV600E) fish 
showed signs indicating follicular hyperplasia in the lower jaw (Figure 8C: C2, C2’, 
C3 and C3’). Two major patterns were observed: one of the patterns had relatively 
large follicles but less numerous than the other pattern and this was evident at 2 
months post fertilization (mpf) (Figure 8: C2 versus C3) and at 3mpf (Figure 8: C2’ 
versus C3’). The follicles were of different shapes and sizes and were lined by 
variably basophilic cuboidal to columnar epithelial cells (Figure 8C: C2’’). Some 
follicles containing excessive colloid were lined by a flattened layer of epithelial 
cells, similar epithelium observed in controls. There was formation of focal 
papillary structures growing into the lumen that lacked fibrovascular cores and 
showed no complex branching; these papillae were lined by basophilic cuboidal to 
columnar epithelial cells (Figure 8C: C3’). Taken together, none of the tg(tg:mCh) 
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(0/10) but all tg(tg:mCh-T2A-BRAFV600E)  fish (10/10) displayed signs of thyroid 
hyperplasia (hyperplasia incidence at 3mpf: p<0.0001) (Figure 8D).  
To have a better understanding of the volume occupied by hyperplasic follicles, 3-
μm-thick sections covering the whole thyroid of the adult fish were selected to 
measure a representative thyroid volume. Most tg(tg:mCh-T2A-BRAFV600E) fish 
showed an increase in thyroid volume which must represent enlarged follicles 
(Figure 8E). Few tg(tg:mCh-T2A-BRAFV600E) fish showed similar thyroid volume to 
that seen in controls which must represent small but numerous hyperplasic follicles 
(total thyroid volume, p<0.05) (Figure 8E). 
To understand the molecular mechanisms underlying the hyperplasia observed in 
tg(tg:mCh-T2A-BRAFV600E) fish, thyroid tissue was dissected from both those fish 
and controls. tg(tg:mCh-T2A-BRAFV600E) fish displayed hyperplasia indicating that 
thyroid cells were proliferating in response to the presence of BRAFV600E. Western 
blots of protein extracts from thyroid tissues of tg(tg:mCh-T2A-BRAFV600E) fish 
revealed an increase in proliferating cell nuclear antigen (PCNA) levels (p<0.05) 
(Figure 8F and F’), an indicator of proliferation, when compared to tg(tg:mCh) fish.  
High proliferation suggested that the proliferation-induced pathways were 
activated. The MAPK pathway includes signaling molecules such as RAF that 
ultimately lead to the expression of genes that regulate cell proliferation and 
survival. In BRAF mutated thyroid carcinomas, the MAPK pathway was found to be 
constitutively activated. MAPK pathway activation was assessed by the protein 
levels of pERKs, a downstream effector of that pathway. There was a robust increase 
in pERK protein levels in tg(tg:mCh-T2A-BRAFV600E) fish when compared to controls 
(p<0.0001) (Figure 8F and F’). This suggested an activation of the MAPK pathway 
through BRAFV600E, permissive to cell proliferation and growth. 
The phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)-V-Akt murine 
thymoma viral oncogene homolog (AKT) pathway, responsible for signals that 
reduce apoptosis and allow proliferation was also found to be overactivated in BRAF 
mutated thyroid carcinomas compared to normal thyroid (Faustino et al., 2012). 
PI3K-AKT pathway activation was assessed by the protein levels of pAKT S473 and 
pAKT T308, two important phosphorylation sites that activate the kinase. A 
consistent increase in the levels of pAKT S473 (p<0.01) and pAKT T308 (p<0.0001) 
was found in tg(tg:mCh-T2A-BRAFV600E) fish (Figure 8F and F’) suggesting that PI3K-
AKT activation played a role in the development of hyperplasia. 
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Paradoxically, BRAFV600E was also found to induce senescence and apoptosis by 
blocking proliferation (Wajapeyee et al., 2008). In BRAFV600E-expressing transgenic 
animals it was be expected the opposite observation as proliferation was being 
induced. 
p16, an important mediator in blocking cell progression from G1 to S phase, was 
evaluated to exclude BRAFV600E-induced senescence as a restraining factor to 
malignancy. p16 protein levels were downregulated in tg(tg:mCh-T2A-BRAFV600E) 
fish (p>0.05) (Figure 8F and F’) suggesting that BRAFV600E did not induce senescence. 
Activated caspase 3, an important protein in the execution-phase of cell apoptosis, 
was also evaluated to exclude BRAFV600E-induced apoptosis as a mechanism to clear 
genetically unstable cells. Suprisingly, activated caspase 3 protein levels were 
increased in tg(tg:mCh-T2A-BRAFV600E) fish (p<0.0001) (Figure 8F and F’). 
To confirm if caspase activation was induced by p53 as a response to oncogenic 
stress, p53 protein levels were assessed. Increased levels of p53 protein were 
found in tg(tg:mCh-T2A-BRAFV600E) fish (p<0.0001) (Figure 8F and F’) confirming 
that apoptosis was triggered in BRAFV600E-expressing thyroid cells. 
To determine whether p53 activation was mediated indirectly by BRAFV600E through 
BRAFV600E-mediated p38 activation, levels of p38 were assessed. p38 protein levels 
in tg(tg:mCh-T2A-BRAFV600E) fish were not different from the controls (p>0.05) 
(Figure 8F and F’).  
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Figure 8. Characterization of tg(tg:mCh-T2A-BRAFV600E) juveniles. (A) Representative 
phenotypes of tg(tg:mCh) and tg(tg:mCh-T2A-BRAFV600E) at 3 months of age. Scale bar: 
5mm. (B) BMI measured from tg(tg:mCh) (n=39) and tg(tg:mCh-T2A-BRAFV600E) (n=39) 
(p<0.0001). (C) HE stain of longitudinal sections representative of the lower jaw at 2- and 
3mpf. Scale bar: 250μm. C1’’ and C2’’ are higher magnifications of the follicles. Scale bar: 
62μm. (D) Incidence of hyperplasia at 3mpf. Values correspond to the percentage of fish 
with hyperplasia confirmed by histology (ten fish were studied from each line) (p<0.0001). 
(E) Representative thyroid volume assessed in tissue sections. Values correspond to the 
volume of each fish studied; ten in total for each line (p<0.05). (F) Western blot analysis of 
lysates from thyroid tissue at 3mpf. Three fish were pooled for each line. Membranes were 
blotted with relevant antibodies. Ponceau S is shown in Figure 6. (F’) Protein levels were 
quantified and normalized to the amount of protein. Values are shown in bar graphs and 
represent three independent experiments (statistical analysis only shown for relevant 
comparisons; p<0.05, p<0.01 and p<0.0001). 
 
tg(tg:mCh-T2A-BRAFV600E) fish were monitored until they reach 12 months of age. 
At this stage, the differences in body weight and body length proved not to be 
transient (Figure 9A) as reflected by a 11% decrease in body mass when compared 
to tg(tg:mCh) fish (p<0.001) (Figure 9B).  
At this stage, it was observed a pattern of mCherry expression that suggested 
enlarged follicles so histological examination was performed to confirm such 
hypothesis. tg(tg:mCh) fish displayed thyroid follicles scattered predominantly in 
the connective tissue near the ventral aorta (Figure 9C: C1 and C1’). Each follicle 
was round or oval and was lined by a single-layered epithelium; the center of the 
follicle was filled with homogenous colloid (Figure 9C: C1 and C1’). tg(tg:mCh-
T2A-BRAFV600E)  fish displayed signs indicating colloid goiter which involved the 
lower jaw. Follicles were predominantly large or very large close to each other with 
varying shapes (Figure 9C: C2 and C2’). Small follicles were also observed. Follicles 
were lined by basophilic and cuboidal epithelial cells and follicles with excessive 
colloid lined by a flattened layer of epithelial cells (Figure 9C: C2 and C2’). These 
follicles were well-differentiated and in some cases due to their size, follicles even 
constricted the ventral aorta. Taken together, none of the tg(tg:mCh) (0/20) but 
most of the tg(tg:mCh-T2A-BRAFV600E) fish (18/20) displayed colloid goiter as 
confirmed by histology (goiter incidence at 12mpf: p<0.0001) (Figure 9D).  
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When examining tissue sections of tg(tg:mCh-T2A-BRAFV600E) fish, many exhibited 
follicles that were markedly larger (Figure 9C: C2 and C2’). In order to determine 
the extension of the goiterous thyroid, 3-μm-thick sections covering the whole 
thyroid of the adult fish were selected to determine thyroid volume. On average, 
tg(tg:mCh-T2A-BRAFV600E) fish displayed a 6-fold increase in thyroid volume when 
compared to controls (p<0.001) (Figure 9E).  
Although colloid goiter has a good prognosis and survival in humans, thyroid 
dysfunction without a proper follow-up can result in complications. In tg(tg:mCh-
T2A-BRAFV600E) fish there was never an experimental interference in the endocrine 
homeostasis besides the expression of BRAF oncogene by thyroid cells and fish 
were subjected to the same husbandry conditions as age-matched controls. To 
verify whether a goiterous state could have influenced the lifespan, all fish from 
this work that were not used for histological examination were included to 
determine survival rates.  Survival up to 12mpf was similar to that observed for the 
tg(tg:mCh) fish (p>0.05) (Figure 9F).  
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Figure 9. Characterization of tg(tg:mCh-T2A-BRAFV600E) adults. (A) Representative 
phenotypes of tg(tg:mCh) and tg(tg:mCh-T2A-BRAFV600E) at 12 months of age. Scale bar: 
7.5mm. (B) BMI measured from tg(tg:mCh) (n=25) and tg(tg:mCh-T2A-BRAFV600E) (n=28) 
(p<0.001). (C) HE stain of longitudinal sections representative of the lower jaw at 12mpf. 
Scale bar: 250μm. C1’ and C2’ are higher magnifications of the follicles. Scale bar: 62μm. 
(D) Incidence of goiter at 12mpf. Values correspond to the percentage of fish with goiter 
confirmed by histology (twenty fish were studied from each line) (p<0.0001). (E) 
Representative thyroid volume assessed in tissue sections. Values correspond to the volume 
of each fish studied; twenty in total for each line (p<0.001). (F) Survival curves for tg(tg:mCh) 
(n=25) and tg(tg:mCh-T2A-BRAFV600E) (n=25) up to 12mpf (p>0.05). Values are percentages 
of fish alive for a certain timepoint. 
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Mutating tp53 prevents BRAFV600E-induced thyroid dysfunction in transgenic fish 
tg(tg:mCh-T2A-BRAFV600E)  fish displayed an increase in the protein levels of WT p53 
by 3 months of age concomitant with thyroid hyperplasia suggesting that p53 was 
restraining tumor progression. In order to facilitate cancer development, a tp53M214K 
zebrafish line was used. 
tp53M214K-homozygous zebrafish are viable and develop tumors by 16 months of 
age that histologically resemble malignant peripheral neural shealth tumors not 
seen in humans and mice with germline mutations of TP53 (Berghmans et al., 2005; 
Storer et al., 2010). Of note, zebrafish p53 is highly similar to mammalian p53 in 
both structure and function sharing 48% homology in amino acid sequence to 
human p53 (Cheng et al., 1997). p53 is ubiquitously expressed early in zebrafish 
development (1hpf), at the pharyngula stage (24-48hpf) is predominantly 
expressed in the head and by 48hpf the protein levels are barely detectable (Cheng 
et al., 1997; Lee et al., 2008). 
tp53M214K missense mutation affects the tp53 protein at an aminoacid position that 
is orthologous to TP53 mutations found in human cancer cells. The orthologous 
human codon for the tp53M214K mutation is in exon 7, methionine-246, which was 
found to be mutated in 124 different human tumors, 8 of which exhibit the same 
amino acid change (Olivier et al., 2002; Berghmans et al., 2005). This codon is also 
positioned between other known mutation hot spots in the DNA-binding domain 
(DBD) of the human TP53 gene at codons 245, 248, and 249 of exon 7 (Olivier et 
al., 2002; Berghmans et al., 2005). 
tp53M214K mutated protein is not able to activate transcription through the p21 
response element and behaves in a dominant-negative manner, inhibiting the 
ability of the WT tp53 to activate downstream effectors (Berghmans et al., 2005). 
Homozygous tp53M214K fish were identified from an incross of heterozygous fish. 
The formed were crossed with tg(tg:mCh) fish to produce heterozygous tp53M214K 
tg(tg:mCh) or with tg(tg:mCh-T2A-BRAFV600E)  to produce heterozygous tp53M214K 
tg(tg:mCh-T2A-BRAFV600E) fish. Heterozygous fish were incrossed and the 
homozygous progeny also harboring the transgene were used for all further 
experiments. These clutches exhibited Mendelian segregation for the tp53M214K 
mutation and embryonic development of the mutant was not affected as described 
by Berghmans et al., 2005. 
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When analyzing live tp53M214K tg(tg:mCh-T2A-BRAFV600E)  embryos, a robust thyroid-
specific reporter signal became detectable at around 34hpf and it was maintained 
throughout thyroid morphogenesis similar to tp53M214K tg(tg:mCh) embryos.  
To study whether BRAFV600E would interfere with thyroid morphogenesis in the 
absence of WT p53 protein in tp53M214K tg(tg:mCh-T2A-BRAFV600E), mCherry 
expression was evaluated from 60-72hpf and up to 7dpf. In that line it was 
observed the organization of follicular-like structures in the pharyngeal region 
consistent with normal thyroid morphogenesis similarly to tp53M214K tg(tg:mCh). 
Throughout the screening it was obvious that homozygous BRAFV600E-expressing 
larvae developed normally and were indistinguishable from homozygous controls 
in terms of viability and fertility (Figure 10A). When assessing the percentage of 
larvae displaying normal thyroid morphogenesis, 84% (137/163) of tp53M214K 
tg(tg:mCh;tg:mCh-T2A-BRAFV600E) and 90% (87/96) of controls showed signs 
indicating no impairment of thyroid morphogenesis (p>0.05) (Figure 10B). The 
number of follicles were quantified in order to confirm that thyroid morphogenesis 
was indeed normal. In tp53M214K tg(tg:mCh;tg:mCh-T2A-BRAFV600E) larvae the 
number of follicles (2-5 follicles) was similar to the number found in tp53M214K 
tg(tg:mCh) (2 to 6 follicles) (p>0.05) (Figure 10C).  
A similar growth between both lines was verified when measuring SL at 7dpf 
(p>0.05) (Figure 10D).  
By conventional fluorescence microscopy, it was verified that thyroid was 
developing normally in tp53M214K tg(tg:mCh;tg:mCh-T2A-BRAFV600E) larvae. However, 
it was important to clarify whether thyroid cells were organized similarly to tp53M214K 
controls so histological examination of the lower jaw was performed from 7-, 14-
, 21- and 28-days-old larvae. tp53M214K tg(tg:mCh) revealed thyroid follicles located 
predominantly in the connective tissue of the lower jaw. The individual follicles 
were round or oval and were lined by a single-layered cuboidal epithelium; the 
center of the follicle was filled with colloid and vesicles were seen (Figure 10E). 
tp53M214K tg(tg:mCh-T2A-BRAFV600E) larvae displayed the same histology features 
described above (Figure 10E).  
The survival in tp53M214K tg(tg:mCh-T2A-BRAFV600E) was similar to the controls which 
was consistent with normal thyroid growth during the larval stage (p>0.05) (Figure 
10F). 
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Figure 10. Characterization of tp53M214K tg(tg:mCh-T2A-BRAFV600E) larvae. (A) 
Representative phenotypes of (A1) tp53M214K tg(tg:mCh) and (A2) tp53M214K tg(tg:mCh-T2A-
BRAFV600E) at 7dpf and mCherry expression found in thyroid cells (A1’ and A2’, respectively). 
Scale bar: 0.5mm (left) and 75μm (right). (B) Frequency of normal and abnormal thyroid 
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morphogenesis at 7dpf assessed in tp53M214K tg(tg:mCh) (n=96) and tp53M214K 
tg(tg:mCh;tg:mCh-T2A-BRAFV600E) (n=163) (p>0.05). (C) Average number of follicles at 7dpf 
quantified in tp53M214K tg(tg:mCh) (n=96) and tp53M214K tg(tg:mCh;tg:mCh-T2A-BRAFV600E) 
(n=163) (p>0.05). (D) SL measured at 7dpf in tp53M214K tg(tg:mCh) (n=30) and tp53M214K 
tg(tg:mCh-T2A-BRAFV600E) (n=29). (p>0.05). (E) HE stain of longitudinal sections 
representative of the lower jaw at 7-, 14-, 21- and 28dpf. Insets show the detail of the 
epithelium. Scale bar: 120μm. (F) Survival curves for tp53M214K tg(tg:mCh) (n=25) and 
tp53M214K tg(tg:mCh-T2A-BRAFV600E) (n=25) (p>0.05). Values are percentages of fish alive for 
a certain timepoint. 
 
tp53M214K tg(tg:mCh-T2A-BRAFV600E) were monitored as they reach the juvenile stage 
and past sexual maturity. They grew indistinguishable from tp53M214K tg(tg:mCh) 
controls (Figure 11A). It was observed a similar BMI between the two lines at 3 
months of age (p>0.05) (Figure 11B). It was also confirmed that tp53M214K fish had 
a similar BMI to that of tp53wt fish (p>0.05) (Supplementary Figure 1A). 
Assuming that a normal thyroid development would not promote tissue 
dysfunction later on, histological examination was performed to confirm this 
hypothesis. tp53M214K tg(tg:mCh-T2A-BRAFV600E) and controls displayed similar 
histology. Thyroid follicles were located in the connective tissue near the ventral 
aorta (Figure 11C: C1, C1’, C2 and C2’); each follicle was round to oval and was 
lined by a single-layered cuboidal epithelium while the center of the follicle was 
filled with homogeneous colloid (Figure 11C: C1’’ and C2’’); sometimes vesicles 
were seen. None of the tp53M214K tg(tg:mCh-T2A-BRAFV600E) displayed signs of 
thyroid hyperplasia nor did the controls.  
Importantly, some tp53M214K tg(tg:mCh) displayed follicles larger than the BRAFV600E-
expressing mutant line. This was confirmed when measuring the thyroid volume 
by selecting 3-μm-thick-sections representative of the whole thyroid of adult fish; 
but it was not significantly different from the volume found for BRAFV600E-expressing 
line (p>0.05) (Figure 11D).  
No hyperplasia or neoplasia was observed by 3 months of age in tp53M214K 
tg(tg:mCh-T2A-BRAFV600E) fish. Protein extracts from thyroid tissues were used to 
understand whether the reversion of the BRAFV600E-induced phenotype would be 
explained by low proliferation. A low increase in PCNA levels was found in tp53M214K 
tg(tg:mCh-T2A-BRAFV600E) (p<0.05) (Figure 11E and E’) suggesting that proliferation 
was not suppressed but it may have not be sufficient to induce hyperplasia. 
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Low protein levels of pERKs (p>0.05) in tp53M214K tg(tg:mCh-T2A-BRAFV600E) fish 
(Figure 11E and E’) confirmed that the MAPK pathway was downregulation even in 
the presence of BRAFV600E. This suggested the presence of an inhibitory factor acting 
downstream of BRAF, restraining MAPK pathway activation. Similar pAKT S473 
protein levels were found in tp53M214K tg(tg:mCh-T2A-BRAFV600E) when compared to 
the controls (p>0.05) (Figure 11E and E’) but the protein levels of pAKT T308 were 
lower in the former line (p<0.05) (Figure 11E and E’). This suggested that 
suppression of AKT phosphorylation at residue T308 was due to inhibition of PDK1. 
Absence of WT p53 was expected to not activate senescence and/or apoptosis. 
Protein levels of p16 (p<0.05) and activated caspase 3 (p<0.0001) were very low 
and concomitant with low levels of p53 (p<0.05). This confirmed the inability of the 
p53M214K protein to induce a programmed cell death (Figure 11E and E’). Strikingly, 
high levels of tp53M214K protein in tp53M214K tg(tg:mCh) controls were found and 
should represent an accumulation of the mutant protein, but not the WT tetramer. 
The protein levels of p38 were assessed to understand if downregulation of ERK 
would suppress p38 activity. Similar protein levels of p38 to that found for the 
controls were observed (p>0.05) (Figure 11E and E’). Furthermore, the protein 
levels of BRAF in in tp53M214K tg(tg:mCh-T2A-BRAFV600E) fish were consistently 
upregulated confirming the expression of this oncogene. 
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Figure 11. Characterization of tp53M214K tg(tg:mCh-T2A-BRAFV600E) juveniles. (A) 
Representative phenotypes of tp53M214K tg(tg:mCh) and tp53M214K tg(tg:mCh-T2A-BRAFV600E)  
at 3 months of age. Scale bar: 5mm. (B) BMI measured from tp53M214K tg(tg:mCh) (n=11) and 
tp53M214K tg(tg:mCh-T2A-BRAFV600E)  (n=30) (p>0.05). (C) HE stain of longitudinal sections 
representative of the lower jaw at 2-and 3mpf. Scale bar: 250μm. C1’’ and C2’’ are higher 
magnifications of the follicles. Scale bar: 62μm. (D) Representative thyroid volume assessed 
in tissue sections. Values correspond to the volume of each fish studied; ten in total for 
each line (p>0.05). (E) Western blot analysis of lysates from thyroid tissue at 3mpf. Three 
fish were pooled for each line. Membranes were blotted with relevant antibodies. Ponceau 
S showed equal amount of protein in both lanes. (E’) Protein levels were quantified and 
normalized to the amount of protein. Values are shown in bar graphs and represent three 
independent experiments (statistical analysis only shown for relevant comparisons; p<0.05 
and p<0.0001). 
 
tp53M214K tg(tg:mCh-T2A-BRAFV600E)  fish were monitored until they reach 12 months 
of age. At this stage, those fish grew indistinguishable from the controls (Figure 
12A). Because a late thyroid dysfunction was yet to be verified, the BMI was 
calculated. Similar BMI was found in BRAFV600E-expressing mutant fish comparing to 
controls (p>0.05) (Figure 12B). It was also confirmed that tp53M214K fish had a similar 
BMI to that of tp53wt fish (p>0.05) (Supplementary Figure 1B). 
To discard a possible late BRAFV600E thyroid dysfunction in the tp53M214K line, 
histological examination was performed. tp53M214K tg(tg:mCh) fish displayed thyroid 
follicles scattered predominantly in the connective tissue near the ventral aorta. 
Each follicle was round or oval and was lined by a single-layered cuboidal 
epithelium; the center of the follicle was filled with homogenous colloid (Figure 
12C: C1 and C1’). These features were also found in tp53M214K tg(tg:mCh-T2A-
BRAFV600E) although a conspicuous enlargement of thyroid follicles was observed 
(Figure 12C: C2 and C2’). In one fish (1/11), the follicles were larger suggesting 
colloid goiter but goiter was never found in any of the controls (0/9) (goiter 
indicence at 12mpf: p>0.05) (Figure 12D).  
Tissue sections of tp53M214K tg(tg:mCh-T2A-BRAFV600E) fish were measured in order 
to understand if the enlargement would be similar to that found for the WT p53 
line, both expressing the BRAF oncogene under the same conditions. On average, 
tp53M214K tg(tg:mCh-T2A-BRAFV600E) fish displayed a 3-fold increase in follicle 
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volume when compared to controls (p<0.001) (Figure 12E), still lower that the 
volume measured in tg(tg:mCh-T2A-BRAFV600E) for the same age. 
To evaluate survival, all fish from this work that were not used for histological 
examination were included.  Survival up to 12mpf was similar to that observed for 
controls (p>0.05) (Figure 12F). 
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Figure 12. Characterization of tp53M214K tg(tg:mCh-T2A-BRAFV600E) adults. (A) 
Representative phenotypes of tp53M214K tg(tg:mCh) and tp53M214K tg(tg:mCh-T2A-BRAFV600E) at 
12 months of age. Scale bar: 7.5mm. (B) BMI measured from tp53M214K tg(tg:mCh) (n=25) 
and tp53M214K tg(tg:mCh-T2A-BRAFV600E) (n=28) (p>0.05). (C) HE stain of longitudinal 
sections representative of the lower jaw at 12mpf. Scale bar: 250μm. C1’ and C2’ are higher 
magnifications of the follicles. Scale bar: 62μm. (D) Incidence of goiter at 12mpf. Values 
are percentages of fish with goiter confirmed by histology (eleven and nine fish were 
studied from BRAFV600E and control line, respectively) (p>0.05). (E) Representative thyroid 
volume assessed by tissue sections. Values correspond to the volume of each fish studied; 
eleven and nine fish were studied from BRAFV600E and control line, respectively (p<0.001). (F) 
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Survival curves for tp53M214K tg(tg:mCh) (n=25) and tp53M214K tg(tg:mCh-T2A-BRAFV600E) 
(n=25) up to 12mpf (p>0.05). Values are percentages of fish alive for a certain timepoint. 
 
Reduced BRAFV600E expression in tp53M214K fish may explain absence of BRAF-induced 
phenotype 
It was observed an abnormal thyroid morphogenesis in tg(tg:mCh-T2A-BRAFV600E) 
larvae by 7dpf and accelerated growth that was not seen in age-matched tp53M214K 
tg(tg:mCh-T2A-BRAFV600E) fish  (p<0.0001) (Figure 13A). tg(tg:mCh-T2A-BRAFV600E) 
fish developed thyroid hyperplasia by 3 months of age and colloid goiter was 
observed at 12 months of age as well as a delay in growth (BMI at 3mpf: p<0.01 
and at 12mpf: p<0.01), concomitant with BRAFV600E expression in thyroid cells 
(Figure 13B). Hyperplasia and reduced growth were not observed in age-matched 
tp53M214K tg(tg:mCh-T2A-BRAFV600E) fish (Figure 13B). This suggested that in the 
absence of WT p53, the BRAFV600E-induced phenotypes in fish were not sustained. 
In one hand, BRAFV600E expression at 3 months of age in tg(tg:mCh-T2A-BRAFV600E) 
fish is consistent with activation of MAPK and PI3K-AKT pathways through pERKs 
and pATKs, respectively (Figure 13D). This suggested a role of these pathways in 
the hyperplasia observed. On the other hand, upregulation of p53 and activated 
caspase 3 (Figure 13D) suggested that p53 put a brake in BRAF-expressing cells. 
When compared to the tp53M214K tg(tg:mCh-T2A-BRAFV600E) fish, BRAFV600E expression 
is reduced concomitant with low levels of pERKs and pATKs (Figure 13D). This 
suggested that even in the absence of the brake that would favor progression to 
malignancy, the downregulation of important pathways have contributed to 
produce no evidences of hyperplasia or cancer until 12 months of age in the 
BRAFV600E-expressing tp53M214K line. 
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Figure 13. Comparison between BRAFV600E-expressing tp53wt and tp53M214K lines. (A) 
SL measured at 7dpf from tp53wt tg(tg:mCh-T2A-BRAFV600E) (n=31) and tp53M214K tg(tg:mCh-
T2A-BRAFV600E) (n=29) (p<0.0001). (B) BMI measured at 3 months of age from tp53wt 
tg(tg:mCh-T2A-BRAFV600E) (n=39) and tp53M214K tg(tg:mCh-T2A-BRAFV600E) (n=30) (p<0.01). 
(C) BMI measured at 12 months of age from tp53wt tg(tg:mCh-T2A-BRAFV600E) (n=27) and 
tp53M214K tg(tg:mCh-T2A-BRAFV600E) (n=18) (p<0.01). (D) Western blot analysis of lysates 
from thyroid tissue at 3mpf. Values are shown in bar graphs and represent three 
independent experiments, each corresponding to a pool of three fish (statistical analysis 
only shown for relevant comparisons; p<0.001 and p<0.0001). 
 
 
Conditional targeted expression of BRAFV600E in thyroid cells of transgenic zebrafish 
(preliminary data) 
 
Expressing BRAFV600E in thyroid cell lines and in the thyroid of mice models have 
shown contradictory data. Mitsutake et al., 2005 showed that in vitro conditional 
BRAFV600E expression failed to transform rat differentiated thyroid PCCL3 cells and 
induce apoptosis in parallel with increased DNA synthesis, dedifferentiation and 
chromosomal instability (Mitsutake et al., 2005). Moreover, Vizioli et al., 2011 
demonstrated that primary cultures of thyroid transfected with BRAFV600E promote 
oncogene-induced senescence but not oncogenic transformation (Vizioli et al., 
2011). In mice, Shimamura et al., 2013 described that conditional BRAFV600E 
expression did not induce tumor formation and engineered postnatal expression 
of BRAFV600E in a small number of thyroid cells did not initiate tumorigenesis in 
thyroid (Shimamura et al., 2013) despite of mice modeled to thyroid-specific 
expression of BRAFV600E developed goiter and invasive PTCs early in life (Knauf et al., 
2005; Mercer et al., 2005; Franco et al., 2011).  
In tg(tg:mCh-T2A-BRAFV600E) fish, a very early impairment of thyroid morphogenesis 
and development of hyperplasia was observed by 2 months of age. In order to 
model sporadic thyroid cancer, a transgenic model was developed in which BRAFV600E  
was expressed late in life and controlled in a very efficient manner under 
physiological serum TSH concentrations. 
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In the past decade, the Cre-loxP technology, when combined with inducible 
systems, has allowed a controlled spatial and/or temporal expression of mutations 
from tumor suppressor genes and oncogenes. 
The tg(hsp70l:mCherry-T2A-CreERT2) transgenic line is a non-leaky conditional line 
that has a bicistronic mRNA coding for mCherry and CreERT2 separated by a viral 
T2A peptide sequence under the control of the zebrafish heat shock cognate 70-
kd protein, like (hsp70l) promoter (Hans et al., 2011). In the absence of tamoxifen 
(TAM), Cre-loxP-site-specific recombination does not occur whereas in the 
presence of TAM and after heat shock full recombination can be achieved. A 
construct, in which BRAFV600E expression would be normally suppressed by the 
presence of a floxed gene but induced when this gene was rearranged by Cre, was 
developed. 
To facilitate cloning, the following previous constructs were used: Tol2CG2tg:mCh 
and Tol2CG2tg:mCh-T2A-BRAFV600E. The loxP-CFP-loxP cassette was cloned 
downstream of the tg promoter and upstream of the mCh or mCh-T2A-BRAFV600E 
(Figure 14A and 14B, respectively). CFP reporter was chosen because it would allow 
to monitor the recombination process in thyroid cells upon heat shock and TAM 
treatment.  
Tol2CG2tg:loxP-CFP-loxP-mCh or Tol2CG2tg:loxP-CFP-loxP-mCh-T2A-BRAFV600E 
was injected with capped transposase mRNA into one-cell-stage 
tg(hsp70l:mCherry-T2A-CreERT2) embryos. By fluorescence microscopy, mosaic 
CFP expression was observed in thyroid tissue of F0 animals injected with 
Tol2CG2tg:loxP-CFP-loxP-mCh or Tol2CG2tg:loxP-CFP-loxP-mCh-T2A-BRAFV600E. 
This was the confirmation that the construct was functional and tg promoter was 
sufficient to drive expression of CFP specifically to the thyroid cells. 
Embryos presenting mosaic CFP or EGFP expression in the thyroid or the heart, 
respectively were grown to adulthood and F0 founders were identified by a 
specific-reporter signal exclusively in those tissue of their progeny. Stable 
transgenic lines were established using F0 founders. A robust CFP expression was 
confirmed in thyroid cells of both F0-hsp70l:mCherry-T2A-CreERT2;tg:loxP-CFP-
loxP-mCh and F0-hsp70l:mCherry-T2A-CreERT2;tg:loxP-CFP-loxP-mCh-T2A-
BRAFV600E lines.  
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When analyzing live embryos from the lines above-mentioned, a robust thyroid 
specific reporter signal became detectable at around 34hpf and it was maintained 
throughout thyroid growth similar to tg(tg:mCh) embryos. 
A preliminary experiment was conducted by inducing Cre-loxP-mediated 
recombination in tg(hsp70l:mCherry-T2A-CreERT2;tg:loxP-CFP-loxP-mCh-T2A-
BRAFV600E) fish at 2 ½ months of age. This age was chosen not only because 
recombination during larval stage would not portrayed the sporadic cancer but also 
because fish would handle better the anesthesia, performed in order to monitor 
the reporter expression. 
The recombination was induced by heat shock followed by exposure to the active 
metabolite of TAM, 4-Hydroxyl-Tamoxifen (4-OHT). Recombination efficiency was 
assessed by a gradual loss of CFP expression and gradual gain of mCherry 
expression, which was ubiquitous in the initial hours after the heat shock and 
specifically to the thyroid cells in the days that followed (Figure 14C).  
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Figure 14. Conditional constructs (A) Schematic representation of the (A) Tol2tg:loxP-
CFP-loxP-mCh and (B) Tol2tg:loxP-CFP-loxP-mCh-T2A-BRAFV600E constructs containing 
Tol2 elements and the cmlc2:EGFP-pA cassette. (C) Schematic representation of the Cre-
mediated recombination of the hsp70l:mCh-T2A-CreERT allele in the blue-to-red reporter 
tg:loxP-CFP-loxP-mCh/mCh-T2A-BRAFV600E line in the presence of heat and 4-OHT 
exposure and final transgenes kept in the genome. 
 
Transgenic embryos carrying the CFP reporter and the tg(hsp70l:mCh-T2A-
CreERT2) allele displayed a strong CFP signal until 2 ½ months of age. Heat shock 
and exposure to 4-OHT led shortly after to a strong ubiquitous mCherry expression 
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indicating successful induction of CreERT2 expression. Fish were monitored and CFP 
expression was completely lost during the first weeks after induction. This 
confirmed the successful recombination event in most or all thyroid cells. mCherry 
expression was never detected; observation that corroborated with the absent 
mCherry expression in tg(tg:mCh-T2A-BRAFV600E) fish.  
Without having an expressing reporter that would help to monitor thyroid 
morphology, fish were grown until they reached 4 months of age and then 
histological examination was performed. tg(hsp70l:mCherry-T2A-CreERT2;tg:loxP-
CFP-loxP-mCh-T2A-BRAFV600E) fish, in which recombination was not induced, 
displayed thyroid follicles scattered predominantly in the connective tissue near 
the ventral aorta (Figure 15 A). Follicles were round to oval and were lined by a 
single-layered epithelium confining a very homogenous colloid (Figure 15 A’). Fish 
in which recombination was induced showed follicular hyperplasia in the lower jaw 
(Figure 15B). The follicles were either big or very small and were very close. The 
epithelium lining the follicles was variably basophilic cuboidal to columnar (Figure 
15B’). There was a marked inflammatory infiltrate likely to be of lymphocytic origin 
surrounding the follicles and inside the blood vessels nearby (Figure 15: B’’ and 
B’’’). Because the hyperplasia described resembled that found in tg(tg:mCh-T2A-
BRAFV600E) fish, it suggested that expression of BRAFV600E was induced successfully. 
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Figure 15. Cre-mediated recombination of the hsp70l:mCh-T2A-CreERT2 allele in the 
blue-to-red reporter tg(tg:loxP-CFP-loxP-mCh-T2A-BRAFV600E) line in the absence 
and presence of heat and 4-OHT exposure. (A) Scheme of the transgene in the absence 
of recombination and HE stain of longitudinal sections representative of the lower jaw. Scale 
bar: 250μm. (B) Higher magnification of the follicles. Scale bar: 62μm. B: Scheme of the 
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transgene upon recombination and HE stain of longitudinal sections representative of the 
lower jaw. Scale bar: 250μm. B’-B’’’: Higher magnification of the follicles. Scale bar: 62μm.  
 
This experiment was not performed on tg(hsp70l:mCherry-T2A-CreERT2;tg:loxP-
CFP-loxP-mCh) fish because no age-matched adults were available at that time. 
Instead, an experiment similar to the one described for the tg(hsp70l:mCherry-
T2A-CreERT2;tg:loxP-CFP-loxP-mCh-T2A-BRAFV600E) was performed on 14dpf 
larvae. Successful recombination event was confirmed by the loss of CFP and gain 
of mCherry expression one week after heat shock and 4-OTH treatment (Figure 
16). This was also the confirmation that the blue-to-red reporter lines were 
working upon heat shock and 4-OTH treatment. Of note, blue-to-red 
recombination was not seen in all larvae suggesting that Cre-mediated 
recombination was not successful in some cases. On the contrary, the experiment 
on adults resulted in blue loss in all fish studied. This suggested the presence of 
WTs in larvae from incrosses; in the absence of the tg(hsp70l:mCh-T2A-CreERT2) 
allele recombination did not occur. All tg(hsp70l:mCherry-T2A-CreERT2;tg:loxP-
CFP-loxP-mCh-T2A-BRAFV600E) adults were screened for the tg(hsp70l:mCh-T2A-
CreERT2) allele and recombination was always efficient.  
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Figure 16. Cre-mediated recombination of the hsp70l:mCh-T2A-CreERT2 allele in the 
blue-to-red reporter tg(hsp70l:mCherry-T2A-CreERT2;tg:loxP-CFP-loxP-mCh) line in 
the absence and presence of heat and 4-OHT exposure. Scheme of the transgene in the 
absence and one week after recombination (top) and live imaging of the follicles losing CFP 
and gaining mCh expression. Larvae is oriented with anterior to the right. Scale bar: 250μm.  
 
Discussion 
The BRAFV600E is by far the most common genetic event associated to an oncogene 
found in PTCs and many believe that it is present at the early stage of these 
carcinomas. Because there is almost no concomitance of BRAF with RET/PTC or RAS 
in PTCs, a single oncogenic hit may be sufficient to activate the MAPK pathway and, 
when combined with other events, results in cell transformation (Soares et al., 
2003; Xing, 2005; Frasca et al., 2008). 
Our results showed that the most common human BRAF mutation is capable of 
inducing a dramatic change in zebrafish thyroid tissue. Thyroid-specific 
expression of BRAFV600E led to an impaired thyroid morphogenesis that was 
permissive to the development of hyperplasia and colloid goiter found in virtually 
all transgenic fish from the tg(tg:mCh-T2A-BRAFV600E) line.  
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We propose a contribution to thyroid cell proliferation by BRAFV600E (Liu et al., 2007) 
in our transgenic model. We found in juvenile thyroids that overexpression of 
BRAFV600E was concomitant with an overexpression of pERKs and pAKTs, 
representing an activation of the MAPK and PI3K-AKT pathways, respectively. This 
observation corroborate with the fact that (1) BRAFV600E can gain up to 500-fold 
increased activation stimulating the MAPK pathways in cells that harbor the BRAF 
mutation, even in the absence of any extracellular stimuli (Cantwell-Doris et al., 
2011) and (2) constitutive activation of effectors along the MAPK and PI3K-AKT 
pathways are essential in thyroid cancer (Mitsutake et al., 2005; Palona et al., 2006; 
Faustino et al., 2012; Xing., 2013). Upregulation of proliferation may have been 
due to phosphorylation and stabilization of genes responsible for cell-cycle entry 
promoted by a sustained ERK signaling (Chambard et al., 2007). This was key to a 
successful development of hyperplasia by 3 months of age. Also, high levels of 
ERKs could have possibly induced cell-cycle arrest by expression of cylin-
dependent kinases (CDK)-inhibitor proteins such as p21 and p27 (Chambard et al., 
2007), however activation of AKT indicated that the arrest was counteracted 
allowing cells to engage in active proliferation. We also found high levels of p53 
and activated caspase 3 which indicated that an apoptotic machinery could have 
been suppressing tumors at this stage. This observation is consistent with 
Mitsutake et al., 2005 that reported that BRAFV600E expression allowed activation of 
apoptosis (Mitsutake et al., 2005). We propose that apoptosis possibly reduced the 
number of cells that were dependent on the RAF signaling and likely to acquire 
genomic instability. This must have restrained tumor development in tg(tg:mCh-
T2A-BRAFV600E) fish by 3 months of age. 
Furthermore, we propose that thyroid-specific expression of BRAFV600E induced 
dysfunction in this tissue possibly due to repression of sodium iodide symporter 
(NIS) expression which is tighly regulated by the thyroid-stimulating hormone 
(TSH)- thyroid stimulating hormone receptor (THSR)-cyclic adenosine 
monophosphate (AMP)-protein kinase A (PKA) signaling pathway. Our hypothesis 
is supported by data showing that BRAFV600E induce transforming growth factor beta 
(TGFβ) secretion leading to NIS repression in a MEK-ERK-independent manner but 
cooperating with the pathway (Riesco-Eizaguirre et al., 2009). Upon NIS repression, 
we propose that the iodide uptake mediated by this symporter was compromised 
and so was the TH synthesis. In turn, homeostatic compensation could have been 
achieved through increased TSH released by the pituitary. TSH levels enabled 
thyroid to reach a steady state through development of goiter. Our hypothesis is 
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consistent with the mice model of thyroid cancer described by Knauf et al., 2005. 
Thyroid-specific expression of BRAFV600E induced thyroid dysfunction which was 
compensated through increased TSH levels and goiter development at 5 weeks of 
age (Knauf et al., 2005). 
Altogether, these observations indicate that BRAFV600E promoted thyroid cell 
transformation in zebrafish but contrarily to human and mice PTCs, differentiated 
or poorly differentiated carcinomas were not observed at least until 12 months of 
age. The difference may simply represent a limitation of this particular zebrafish 
model as previously seen in some mice models of thyroid cancer (Chakravarty et 
al., 2011; Shimamura et al., 2013).  
Lower body weight in the tg(tg:mCh-T2A-BRAFV600E) juveniles and adult zebrafish 
suggested that thyroid of these fish may have failed at some point of development 
to produce enough TH. Insufficient TH could have been due to either an impairment 
in the TH synthesis or transport. TH or TSH levels were not measured but because 
no other phenotype associated with TH deficit was observed during development, 
it is tempting to speculate that TH levels were near normal at all times; TSH levels 
may have been elevated. This hypothesis was supported by the gradual thyroid 
enlargement which by 2 months of age was 2-fold and by 12 months was 6-fold 
greater than controls. This suggested that thyroid enlargement resulted from a 
transient hypothyroid state arising due to BRAFV600E effect in thyroid cells which was 
then compensated by high levels of TSH that eventually promoted in part the 
development of a steady goiterous state.  
As transgene expression was driven by the tg promoter and cell dedifferentiation 
promoted by BRAFV600E is known to reduce the activity of the tg promoter, that may 
have led to a discrete decrease in BRAFV600E expression that conveniently attenuated 
its full-oncogenic effect yet enough to induce proliferation. Although transgene 
copy number was not measure, it can not be excluded as one of the reasons that 
may have conditioned the amount of BRAFV600E expression, independently of the 
mechanisms regulating the tg promoter and subsequently the transgene 
expression. 
Our data indicated that although expression of BRAFV600E can cause the 
transformation of thyroid cells, additional mutations must be required for the 
progression to cancer in our model. Molecularly, loss of p53, in addition to 
activating mutation in the BRAF gene, is a genetic signature of thyroid tumor 
progression (Soares et al., 1994; Bai et al., 2006; Morita et al., 2008). Suprisingly, 
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tp53M214K tg(tg:mCh-T2A-BRAFV600E) fish did not readily develop neoplasia. This 
indicated that this particular oncogenic stimulus proved to be insufficient for 
tumorigenesis initiation in our model. Additional genetic alterations other that p53 
loss must be required for thyroid tumorigenesis in zebrafish. Also, many key 
proteins involved in cancer have unknown or non-canonical functions, and thus 
the multihit nature of some models can result in unpredictable outcomes.  
In summary, thyroid-specific expression of BRAFV600E induced abnormal thyroid 
morphogenesis which transitied to hyperplasia and colloid goiter during 
adulthood. These phenotype supported an important role of BRAFV600E in thyroid 
cells and indicated that the tg(tg:mCh-T2A-BRAFV600E) model should be useful to 
understand further phenotypes promoted by BRAFV600E. Furthermore, WT p53 loss 
in a thyroid-specific expression of BRAFV600E transgenic zebrafish did not cooperate 
with BRAFV600E expression in the genesis of tumors. These two models will be useful 
tools for the study of thyroid cancer pathogenesis namely to disclose which 
promoting and/or suppressing signals are ultimately preventing neoplasia. 
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Supplementary data 
 
 
Supplementary figure 1. BMI in p53wt and tp53M214K fish. (A) BMI measured at 3 months 
of age from tp53wt tg(tg:mCh) (n=39) and tp53M214K tg(tg:mCh) (n=11) (p>0.05). (B) BMI 
measured at 12 months of age from tp53wt tg(tg:mCh) (n=25) and tp53M214K tg(tg:mCh) 
(n=21) (p>0.05). 
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The RAS/BRAF/MEK/ERK pathway is mutated in about 30% of all cancers (Garnett 
et al., 2004) and mutations in the B-type Raf kinase (BRAF) gene are found in 
approximately 7% of cancers (Davies et al., 2002), including thyroid cancer (Soares 
et al., 2003). The predominant mutation in the BRAF gene involves a thymidine to 
adenosine transversion accounting for the majority of the observed mutations in 
BRAF (Davies et al., 2002). Nevertheless, BRAF mutation may be complemented by 
other genetic events (Woodman et al., 2010). A classical example is melanocytic 
nevi that frequently harbor oncogenic BRAF mutations, but only a minority progress 
to melanoma. In human melanocytes, persistent BRAFV600E expression triggers 
oncogene-induced senescence. This implies that bypass of oncogene-induced 
senescence by additional genetic events is necessary for malignant transformation 
of melanocytes (Yu et al., 2009). In zebrafish, transgenic expression of human 
BRAFV600E was sufficient to develop ectopic f-nevi that are only highly melanoma 
prone when combined with a p53 null background (Patton et al., 2005).  
The purpose of this thesis was to identify additional genetic events that contribute 
to thyroid tumorigenesis and have a close relation with BRAFV600E. We focused on 
the recently identified telomerase reverse transcriptase (TERT) promoter mutations 
and disclosed that thyroid BRAFV600E mutation–positive carcinomas harbored those 
mutations (Vinagre et al., 2013). Predicting the necessity of an animal model to 
study additional genetic alterations that in cooperation with BRAFV600E promote 
tumor development in thyroid, we developed a novel model in zebrafish. We 
generated a transgenic zebrafish expressing BRAFV600E in thyroid cells and disclosed 
its relation with p53 mutation which is frequently found in undifferenciated thyroid 
carcinomas. These zebrafish models will be useful tools for the study of genetic 
alterations in thyroid in a biological context. 
 
IV.1 Frequency of TERT promoter mutations in human cancers 
Regulation of promoters is known to be one of the many mechanisms playing an 
important role in human tumorigenesis but until very recently there were only few 
studies addressing the presence of mutations in promoter regions of human 
tumors. For example, a polymorphism in the human SURVIVIN gene promoter 
located at cell cycle-dependent element/cell cycle genes homology region 
(CDE/CHR) repressor binding motifs was found at high frequency in cancer cell 
lines (Xu et al., 2004).  
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Mutations in regulatory parts of the genome, in addition to those in protein-coding 
sequences gained relevance when it was identified two somatic mutations in the 
TERT promoter (Horn et al., 2013; Huang et al., 2013). Until then, the failure to 
discover recurrent mutations or gene rearrangements that would activate TERT 
expression was inconsistent with TERT role in cancer.  
In my lab, we subsequently described the presence of TERT promoter mutations in 
other human cancers and validated the findings reported by others (Horn et al., 
2013; Huang et al., 2013). 
In skin melanomas, we found TERT promoter mutations in a similar frequency to 
that reported (Horn et al., 2013) in primary melanomas (33%), but lower than the 
frequency found by others in metastatic melanomas (85%) (Horn et al., 2013; Huang 
et al., 2013). We have analysed very few metastatic melanomas that did not show 
a significantly higher frequency of TERT promoter mutations. We have also 
confirmed a significant association between TERT and BRAFV600E mutations in 
melanomas, as previously reported (Horn et al., 2013). Interestingly, in benign nevi, 
which also frequently harbour BRAFV600E mutations, no TERT promoter mutations 
were found.  
In the central nervous system (CNS) tumours, we found that TERT promoter 
mutations were frequent events in gliomas, particularly in glioblastomas (GBM) 
(62%). Our results were in accordance with studies reporting that TERT promoter 
mutations were detected in 55% (Nonoguchi et al., 2013) or in 51% (Kilella et al., 
2013) of the glioblastomas analysed. Another study described that 60% of GBMs 
were positive for TERT mRNA and telomerase activity but TERT promoter mutations 
were not assessed (Lotsch et al., 2013). Our findings also indicated that TERT 
mutations were associated with older patients, in accordance with another report 
(Killela et al., 2013).  
In bladder cancer, we find a very high frequency of TERT promoter mutations which 
is consistent with increased telomerase activity found in bladder tumors (Sanchini 
et al., 2005) but those mutations were not found in our series of kidney cancer, 
neuroendocrine tumors (phaeochromocytoma) or gastrointestinal stromal tumor 
(GIST). 
In thyroid cancer, TERT mutations were found in follicular cell-derived cancers 
(PTC, FTC, poorly differentiated and anaplastic thyroid carcinomas) but not in 
medullary thyroid carcinomas, which was consistent with other studies (Killela et 
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al., 2013; Landa et al., 2013) nor in goiter, adenomas or in thyroiditis. These 
findings are in accordance with telomerase expression that is less frequent in 
normal tissue and in hyperplastic lesions than in malignant thyroid lesions 
(Capezzone et al., 2011).  
In classical PTCs, TERT promoter mutations were associated with BRAFV600E 
mutation, as observed in melanomas, and coexistence of mutations in both genes 
was associated with increased expression of the TERT mRNA in thyroid cancer. 
These findings suggest a cooperative effect of BRAFV600E and TERT promoter 
mutations. In one hand, cells acquiring genetic alterations such as the BRAFV600E 
mutation begin to reply to the oncogenic stimuli by inducing proliferation. Very 
short telomeres upon several cell divisions may trigger telomere dysfunction which 
may be compensated by telomerase reactivation via TERT promoter mutations 
(Londoño-Vallejo JA 2008, Muzza M 2015). In the other hand, activation of the 
mitogen-activated protein kinase (MAPK) pathway by BRAFV600E is known to 
upregulate the erythroblast transformation-specific (ETS) system (Janknecht et al., 
1995; Whitmarsh et al., 1995; Strahl et al., 1996). Having de novo consensus 
binding sites for ETS factors promoted by TERT promoter mutations, the lifespan 
of BRAF-driven clones is extended. Further accumulation of additional genetic 
defects is suported which in turn allows progression to advanced tumor stages 
(Pratilas CA 2009, Huang FW 2013, Horn S 2013, Liu X 2013). Thus, the coexistence 
of BRAFV600E and TERTC228T must form a unique mechanism upregulating the 
expression of TERT. This oncogenic cooperation of TERT with BRAF mutation is 
interestingly similar to the findings in a transgenic mouse model in which TP53 
mutation and induced overexpression of TERT cooperatively promoted cancer 
development (González-Suárez et al., 2002).  
The presence of TERT promoter mutations in thyroid cancer led to further studies 
by our group. TERT promoter mutations were found to be an indicator of clinical 
aggressiveness of follicular cell-derived thyroid carcinomas, being associated with 
distant metastases, worse response to treatment, and poor outcome. The detection 
of TERT promoter mutations appears to be, per se, a promising prognostic 
indicator in DTCs and PTCs (Melo et al., 2014; Melo et al., 2015).  
Our series were small to draw a definitive conclusion but recently a large-scale 
study of multiple tumor types supported the evidence that TERT promoter 
mutations differentially enhanced the transcriptional activity of the TERT core 
promoter (Huang et al., 2015). At the time of our study, many speculated that 
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mutations in the TERT promoter, rather than the coding region of the gene, were 
creating additional binding sites for ETS transcription factors. A recent study 
implicated GA-Binding Protein (GABP) as a relevant ETS factor (Bell et al., 2015) as 
it was identified the recruitment of the multimeric GABP transcription factor 
specifically to the mutant TERT promoter. Although many ETS factors can bind 
similar deoxyribonucleic acid (DNA) sequence motifs, the GABP is a unique factor 
that binds to neighboring ETS motifs as a heterotetrameric complex.  
In summary, our work identified TERT mutations as common events in human 
cancers and supported the assumption that TERT promoter mutations may be one 
of the mechanisms that underlies telomerase reactivation in several types of human 
tumours. However, the pathway by which an epigenetically silenced TERT gene is 
activated by one of two cancer-specific somatic mutations on its promoter remains 
largely unknown.  
 
IV.2 Targeted expression of BRAFV600E in thyroid cells of 
transgenic zebrafish induces hyperplasia reverted by loss of 
WT p53 
Oncogenic BRAF plays an important role in maintaining the transformed and 
progressive state of neoplastic thyroid cells (Liu et al., 2007). 
Targeted expression of BRAFV600E in thyroid cells of a living animal allows to model 
thyroid cancer and it is a novel approach to study the relationship between BRAF 
mutation and those found in the TERT promoter. 
The development of two fluorescent reporter lines, tg(tg:mCh) and tg(tg:mCh-T2A-
BRAFV600E), has given an opportunity to visualize and study the effect of BRAFV600E in 
early thyroid growth and organization in zebrafish. These transgenic lines combine 
an early onset of transgene expression specific to the thyroid, with live imaging of 
thyroid growth, from thyroid budding to formation of follicles. 
Apart from the demonstration of the effect of BRAFV600E expression in cell lines and 
thyroid gland of mice, very little is known about its role in other organisms. Our 
observation that BRAFV600E expression does not result in thyroid cancer in zebrafish, 
even in the absence of WT p53, highlights a unique capacity of this line to serve as 
an in vivo tool to screen thyroid dysfunction mediated by BRAFV600E and to identify 
potential mechanisms that do not allow the development of cancer. In this regard, 
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our observations argue that BRAFV600E expression in the context of tp53M214K might 
be particularly interesting for further studies. 
Concerning the BRAFV600E expression in the developing thyroid of larvae, our results 
demonstrated an abnormal thyroid morphogenesis and accelerated larval growth 
as early as 7dpf. The first observation is particularly relevant as it shows that 
BRAFV600E expression affects the spatial organization and migration of developing 
follicles in zebrafish.  
We did not study this effect in detail, however we propose that BRAFV600E-induced 
phenotype in the first days of development may have contributed to a 
downregulation of thyroid-specific genes that mediate thyroid differentiation and 
growth. In zebrafish, these processes are mediated by NK2 homeobox 1a (nk2.1a), 
paired box gene 2.1 (pax 2.1) and hematopoietically expressed homeobox (hhex) 
(Wendl et al., 2002; Alt et al., 2006). In one particular study, reduction in pax2a 
and loss of nkx2.1a expression in zebrafish was concomitant with a reduction of 
thyroid primordium volume and a decreased number of thyroid cells as a result of 
overexpression of Notch intracellular domain (NICD) in embryos (Porazzi et al., 
2012). Although we did not explore the Notch signaling, we propose that 
downregulation of thyroid-specific genes might have been mediated by BRAFV600E 
via activation of MAPK pathway which in turn might have upregulated Notch 
signaling (Ferretti et al., 2008; Yamashita et al., 2013). Nevertheless, this 
hypothesis needs further investigation. Because the phenotype prevailed during the 
larval development, it also indicated that BRAFV600E expression may have enabled 
downregulation of solute carrier family 5 (sodium/iodide cotransporter), Member 
5 (slc5a5) and cathepsin B (ctsb), two important proteins in thyroid hormone (TH) 
biosynthesis (Bizhanova et al., 2009). These hypothesis are in accordance with data 
showing that BRAFV600E is associated with silencing of multiple thyroid-specific 
iodine-metabolizing genes in vitro and in human tumors (Erhardt et al., 1999; 
Riesco-Eizaguirre et al., 2006; Liu et al., 2007b; Tang et al., 2010; Cantwell-Dorris 
et al., 2011). In our transgenic model, downregulation of these genes may have 
allowed a delay in embryonic thyroid growth which is consistent with the observed 
phenotype. We can not conclude whether protein synthesis of thyroglobulin (tg) 
was affected but, because there was no retardation of body growth, it suggested 
that thyroid function was not severly disturbed at this stage. Also, maternal 
contribution of the TH might have compensated for a possible compromised 
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thyroid function during the first days of development (Brown., 1997; Elsaline et al., 
2003b). 
Regarding the BRAFV600E-induced phenotype in the thyroid of juvenile fish, our 
results showed thyroid hyperplasia and retardation of fish growth by 2-3 months 
of age (see below). The first observation suggested a contribution to thyroid cell 
proliferation by BRAFV600E (Liu et al., 2007). When examining thyroid tissue, it was 
found an overexpression of BRAFV600E concomitant with an overexpression of pERKs 
and pAKTs, representing an activation of the MAPK and PI3K-AKT pathways, 
respectively. This observation corroborate with the fact that (1) BRAFV600E can gain 
up to 500-fold increased activation stimulating the MAPK pathways in cells that 
harbor the BRAF mutation, even in the absence of any extracellular stimuli, allowing 
those cells to become self-sufficient in growth signals within the pathway 
(Cantwell-Doris et al., 2011) and (2) constitutive activation of effectors along the 
MAPK and PI3K-AKT pathways are essential in thyroid cancer (Mitsutake et al., 
2005; Palona et al., 2006; Faustino et al., 2012; Xing., 2013). Our data also showed 
an upregulation of proliferation which we believe was due to phosphorylation and 
stabilization of genes responsible for cell-cycle entry and repressing genes 
responsible for inhibiting proliferation promoted by a sustained ERK signaling 
(Chambard et al., 2007). This was key to a successful development of hyperplasia. 
Also high levels of ERKs could have possibly induced cell-cycle arrest by expression 
of cylin-dependent kinases (CDK)-inhibitor proteins such as p21 and p27 
(Chambard et al., 2007), however activation of AKT suggested that the arrest was 
counteracted enabling cells to engage in active proliferation.  
In melanocytes, senescence has been proposed to play a major role in preventing 
malignant transformation of melanocytic nevi. Evidence pointed out that BRAFV600E 
expression in mouse models resulted in induction of senescence in melanocytes 
and senescent markers are highly expressed in human melanocytic nevi (Collado 
et al., 2010; Dhomen et al., 2009). Our data showed a downregulation of 
senescence which must have contributed to prevent growth arrest by BRAF 
oncogene-induced senescence (Vizioli et al., 2011). We believe that in our model 
senescence did not play a role in preventing malignant transformation of thyroid 
cells due to mechanisms that overcame arrest of cell proliferation. 
We found in the juvenile thyroid high levels of p53 and activated caspase 3 which 
can indicated that an apoptotic machinery was behind tumor suppression at this 
stage. This observation is consistent with Mitsutake et al., 2005 that reported that 
146 
 
BRAFV600E expression allowed activation of apoptosis (Mitsutake et al., 2005). Also, 
Wapapeyee et al., 2008 reported that expression of BRAFV600E in primary cells lead 
to synthesis and secretion of insulin-like growth factor-binding protein 7 (IGFBP7) 
which, by acting through autocrine/paracrine pathways to inhibit BRAF-MEK-ERK 
signaling, induced apoptosis by upregulating pro-apoptotic B-cell lymphoma 2 
(BCL2) family proteins (Wapapeyee et al., 2008). We propose that apoptosis 
possibly reduced the number of cells that were dependent on the RAF signaling 
and likely to acquire genomic instability which in turn significantly decreased the 
likehood of tumor development in those fish by 3 months of age. 
It should be noted that at this stage, hyperplasia was a possible phenotype in the 
thyroid of transgenic fish. Appreciating other models in mice, human 
neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) with a mutation at 
codon 61, which is an upstream activator of RAF, targeted to thyroid cells lead to 
the development of thyroid hyperplasia characterized by large, indistinct areas of 
small follicles with scant colloid and tall epithelial cells by 6 months of age 
(Vitagliano et al., 2006). Targeting the Paired Box 8 (PAX8)/Peroxisome 
Proliferator-Activated Receptor (PPAR Gamma) rearrangement to mice thyroid cells 
also led to thyroid hyperplasia and enlarged follicles at 1 year of age (Diallo-Krou 
et al., 2009).  
Regarding the BRAFV600E-induced phenotype in the thyroid of 12-month old fish, 
our results have shown that these fish displayed signs resembling colloid goiter 
and kept the growth retardation observed while juveniles. We propose that thyroid-
specific expression of BRAFV600E induced dysfunction in this tissue possibly due to 
repression of sodium iodide symporter (NIS) expression which is tighly regulated 
by the thyroid-stimulating hormone (TSH)- thyroid stimulating hormone receptor 
(THSR)-cyclic adenosine monophosphate (AMP)-protein kinase A (PKA) signaling 
pathway. This hypothesis is supported by a study that reported that BRAFV600E 
induced transforming growth factor beta (TGFβ) secretion leading to NIS repression 
in a MEK-ERK-independent manner but cooperating with the pathway (Riesco-
Eizaguirre et al., 2009).  
We also propose that upon NIS repression, the iodide uptake mediated by this 
symporter was compromised and so was the TH synthesis. In turn, homeostatic 
compensation could have been achieved through increased TSH released by the 
pituitary. TSH levels enabled thyroid to reach a steady state through development 
of colloid goiter. This possible compensation was only possible if TSH receptor 
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expression was not affected by BRAFV600E, allowing adequate TSH responsiveness. 
Our hypothesis is consistent with the mice models of thyroid cancer. Thyroid-
specific expression of BRAFV600E induced thyroid dysfunction which was 
compensated through increased TSH levels and goiter development at 5 weeks of 
age (Knauf et al., 2005). Tamoxifen treated Thyro::CreERT2;BRAFCA mice also 
developed enlarged, goiterous, hypercellular thyroid that was up to 10 times larger 
than controls one month only after BRAFV600E expression was induced and up to 300 
times larger after 12 months (Charles et al., 2011). In these models activated 
BRAFV600E ultimately elicited PTCs in the adult mouse (Knauf et al., 2005; Charles et 
al., 2011). Also, compensation mediated by TSH is indeed a plausible hypothesis 
as TSH signaling pathway cooperate with oncogenic-BRAF, in part by cAMP 
signaling. A study showed that deletions in Gsα, a protein which couples hormonal 
stimulation of several cell membrane receptors to the activation of adenylyl cyclase, 
did not prevent formation of thyroid tumors in LSL-BrafV600E/TPO-Cre/Gnas-E1fl/fl 
mice (Franco et al., 2011).  
We propose that retardation in growth found from 3 to 12 months of age in 
tg(tg:mCh-T2A-BRAFV600E) fish is likely to be a consequence of thyroid dysfunction. 
This suggests that fish could have been hypothyroid at some point during 
development and eventually compensated by becoming euthyroid. Knauf et al., 
2005 showed that one particular mice line with thyroid-specific expression of 
BRAFV600E initially grew marginally slower than nontransgenic littermates but proved 
to be transient as it was not observed after eight weeks (Knauf et al., 2005). 
Nevertheless, we cannot exclude the maintenance of a hypothyroid state in 
transgenic fish as judged by the phenotype found in a model of tg mutants of 
zebrafish (Jao et al., 2008). These fish were reported to be homozygous insertional 
mutants for the putative tg gene and as they entered adulthood, they developed a 
goiter-like phenotype in the absence of tg and THs synthesis (Jao et al., 2008). 
Further mechanistic and functional studies are clearly needed to clarify the nature 
of the BRAFV600E interaction in zebrafish thyroid. 
Besides the plausible explanations from molecular and functional perspectives, we 
understand that thyroid-specific expression of BRAFV600E in thyroid cells was due to 
a transgene and its expression and regulation were certainly dependent on many 
genetic factors. We do not exclude the hypothesis that tumor development was not 
successful in tg(tg:mCh-T2A-BRAFV600E) fish because (1) the oncogene dosase was 
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not sufficient to full transformation of thyroid cells and/or (2) downregulation of 
the tg promoter upon BRAF-induced silencing of thyroid-specific genes. 
The first assumption is supported by observations in transgenic mice. In 
doxycycline-inducible transgenic mice, that allowed RAS activation to be titrated, 
high-level but not low-level of RAS activation induced tumor suppressor pathways 
and triggers an irreversible senescent growth arrest in vivo (Sarkisian et al., 2007). 
In one of the two mice transgenic lines with targeted expression of the BRAFV600E in 
thyroid cells, BRAFV600E levels were low enough to induce a very weak increase in 
pERK levels in mice thyroids (Knauf et al., 2005). Oncogene dosage in our 
transgenic model may have been dependent on the transgene copy number. 
The second point is not less important. If the tg promoter was downregulated at 
some level by the mutant form of BRAF or downstream effectors, it might have 
restrained BRAFV600E levels enough to induce cell proliferation to a limited extent. 
Indeed, a study found that expression of thyroid-specific genes and their 
transcription factors is lost in thyroid cells derived from follicular, papillary and 
anaplastic human carcinomas and in these cells, thyroid-specific promoter 
activities such as the tg promoter were absent. Only re-expression of transcription 
factors was able to stimulate transcription from the promoters at some extent (Ros 
et al., 1999).  
One intriguing observation was that neoplasia was not observed in tg(tg:mCh-T2A-
BRAFV600E) fish until 12 months of age, instead these fish developed colloid goiter. 
In the light of these findings, we hypothesize that in our model BRAFV600E would only 
elicit neoplasia if the p53 pathway was downregulated. Melanocyte-specific 
expression of BRAFV600E in zebrafish induced a dramatic change in fish pigmentation 
patterns and it was found to be sufficient to promote fish nevi development but 
not melanomas. Indeed, melanoma only developed in a tp53M214K background 
(Patton et al., 2005). This observation is of particular relevance because TP53 
mutations are not frequently found in well-differentiated thyroid carcinomas and 
are associated with tumor progression to anaplastic forms of cancer (Soares et al., 
1994). Also, using a thyroid-specific Cre recombinase-estrogen receptor (CreER) 
transgenic mouse with a Cre-regulated BRAFV600E and a conditional Trp53 it was 
found that p53 loss enabled progression to aggressive anaplastic thyroid cancer 
but additional events were required for full anaplastic conversion (McFadden et al., 
2014) 
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Suprisingly, tp53M214K tg(tg:mCh-T2A-BRAFV600E) fish showed normal thyroid 
morphogenesis during larval growth with proper follicle migration and 
invididualization. Hyperplasia and/or growth retardation was not observed in 
juveniles and neoplasia was also not found by 12 months of age.  When examining 
thyroid tissue at 3 months of age, it was found a decrease in BRAFV600E expression 
concomitant with downregulation of pERKs and pAKTs, representing lack of 
activation of the MAPK and PI3K-AKT pathways, respectively. Also, proliferation 
was not extensively promoted as judged by a comparison with the controls. We 
propose that in this transgenic model, inneficient activation of the MAPK and PI3K-
AKT pathways may have supported a normal thyroid phenotype even in absence of 
a tumor suppressor gene and/or activation of apoptosis. Studies have shown that 
activation of the MAPK pathway leads to increased levels of p53 and subsequent 
stimulation of p53-dependent physiological responses including apoptosis and 
cell-cycle arrest (Agarwal et al., 2001; Wu et al., 2004). Also, the MAPK pathway is 
regulated in response to p53, as p53 is believed to stimulate the secretion of 
growth factors that activate the pathway (Lee et al., 2000; Wu et al., 2004).  
Without understanding the final mechanisms, we propose that loss of WT p53 has 
prevented BRAFV600E-induced thyroid dysfunction by an unclarified mechanism, 
possibly implicating the MAPK pathway. This might have resulted in reexpression 
and/or restablishment of thyroid-specific genes favoring normal thyroid growth 
and function in zebrafish. In turn, fish did not develop neoplasia by lack or 
insufficient pro-oncogenic signals.  
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Figure 1. Working hypothesis. In the tg(tg:mCh-T2A-BRAFV600E) line, BRAFV600E induced 
abnormal thyroid morphogenesis and thyroid hyperplasia as a result of upregulation of the 
MAPK and PI3K-AKT signaling pathways. Upregulation of WT p53 restrained cancer and 
BRAF-induced dysfunction was compensated by increased levels of TSH leading to the 
development of goiter. In the tp53M214K tg(tg:mCh-T2A-BRAFV600E) line, BRAFV600E was not able 
to upregulate the MAPK and PI3K-AKT signaling pathways and in the absence of WT p53, 
thyroid developed similarly to WT. 
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Conclusion 
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For the past half century, research have led us to believe that cancer has its origin 
in a single cell that acquire mutation(s) and this paradigm was established by the 
fact that cancers often harbor a large number of mutations and also chromosomal 
abnormalities and many carcinogens are indeed mutagens (Prehn, 2005). 
Numerous genetic alterations have an important role in the tumorigenesis of 
thyroid tumors and a prominent example is the T1799A point mutation on the B-
type Raf kinase (BRAF) gene. BRAF mutations along with other classical mutations 
have been extensively studied for many years including the cellular processes that 
these proteins, when mutated, mediated (Woodman et al., 2010). 
The human genome is far richer and complex than once thought and it is not 
surprising that it is not just the gene but the network that makes the genome so 
dynamic. Translating to cancer, this dynamics creates too many opportunities for 
tumorigenesis initiation that go beyond a simple mutation. No wonder cancer is 
more diverse that its genetics and this explains why researchers are still committed 
in understanding and control cancer.  
In contrast to coding regions, the functional impact of noncoding regions is more 
difficult to evaluate, due to the lack of knowledge those regions from the genome. 
Indeed, the non-protein-coding sequences, which accounts for over 98% of the 
human genome, remain widely unexplored in cancer. 
Human model-oriented, my thesis has shown for the first time the presence of 
mutations in the promoter region of telomerase reverse transcriptase (TERT) in 
different histotypes of thyroid cancer (Vinagre et al., 2013) and the results validated 
the findings reported by others in melanoma, bladder and gliomas (Horn et al., 
2013; Huang et al., 2013; Killela et al., 2013). Also, it seemed that activated BRAF 
enhanced the effects of TERT promoter mutations. Evidence showed that TERT 
promoter mutations were significantly associated with increased TERT mRNA 
expression in thyroid cancers and that TERT mRNA was particularly high in cases 
harbouring both TERT and BRAF mutations (Vinagre et al., 2013). The location of 
these mutations in the TERT promoter, rather than in the coding region of the gene, 
creates additional binding sites for transcription factors and represents also a novel 
mechanism of genetic activation in cancer. Further observational and mechanistic 
studies are needed to clarify these points. 
Animal model-oriented, my thesis has shown that targeted BRAFV600E expression in 
thyroid cells of transgenic zebrafish induced abnormal thyroid morphogenesis 
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followed by hyperplasia and colloid goiter but not neoplasia (Almeida et al., 
submitted). BRAF-induced thyroid dysfunction could be related to repression of 
sodium iodide symporter (NIS) and homeostatic compensation was achieved 
through increased thyroid-stimulating hormone (TSH) levels (Almeida et al., 
submitted). High TSH levels must have been required to reach a new steady state 
which was arrived in part through development of colloid goiter and not 
carcinomas. Remarkably, activated BRAF alone or in p53-deficient zebrafish did 
not induce formation of cancer during the set of experiments (Almeida et al., 
submitted). Loss of the wild-type (WT) p53 possibly prevented BRAF-induced 
thyroid dysfunction by restoring at some level thyroid function and restraining 
cancer development by controlling the propagation of genetically-unstable cells. 
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Thyroid cancer is the most common endocrine malignancy, 
with more deaths annually than all of the other endocrine 
cancers combined [1]. In the last few years, its frequency 
has been rising, with the highest rate of increase for small 
and localized thyroid cancers. This led many authors to 
suggest that this increase is attributable to better cancer 
detection and early diagnosis through ultrasonography and 
fine-needle aspiration biopsies [1,2]. However, it is most 
likely that this is not the sole reason and other factors 
probably play a role, namely radiation exposure 
(therapeutic and fallout) [1,2], chemical environment 
carcinogens, autoimmune phenomena and alterations in 
iodine intake [1]. In this chapter, environmental risk factors 
for thyroid cancer will be addressed, giving a particular 
emphasis on ionizing radiation and endocrine disruptors. 
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Ionizing radiation
Ionizing radiation is a major risk factor for 
thyroid cancer and particularly for papillary 
thyroid cancer (PTC), the most common 
type of thyroid cancer [2]. The thyroid is 
unusually sensitive to external and internal 
radiation, and it is, in fact, an organ with a documented rise in cancer 
incidence after radiation exposure, especially during childhood [1]. The 
pathophysiology of radiation-induced thyroid damage includes: 
n	Short-term effects, related to direct damage of the parenchymal cells 
that causes an inhibition of follicular epithelial function; 
n	Late sequelae caused by cell death, autoimmune reactions, chronic 
inflammation, vascular toxicity, fibrous organization and partial epithelial 
regeneration [3,4]. Thyroid cancer can be a long-term consequence of 
radiation. This risk is modulated by other factors, such as age, gender, 
dose and type of radiation.
Thyroid exposure to irradiation (internal vs external radiation)
Exposure of the thyroid to radiation can result from exposure to an external 
source (external radiation) or to radioactive material that enters the body 
(internal radiation).
Internal radiation exposure results from radioactive isotopes that enter 
the body by ingestion, inhalation or absorption. The radioactive isotopes 
recognized as the most important in this context are iodine isotypes, 
namely Iodine-131 and Iodine-133. 
Most of the information on thyroid cancer risk and internal radiation came 
from studies on the health effects of nuclear power tests/accidents, 
notably the Chernobyl accident; before this evidence, internal radiation 
was believed to have relatively low potential risk [5]. The first years after 
the Chernobyl accident allowed several striking epidemiological 
observations, namely an increased incidence in thyroid cancer, particularly 
pronounced among the youngest at the time of exposure (0–4 years of 
age). Given the huge amount of radioiodine isotopes released, the radiation 
dose to the thyroid gland was estimated to be 1000–10,000-times higher 
than to any other organ [6], and the thyroid of young children was revealed 
to be extremely sensitive to those radioiodines [5]. Moreover, it was 
possible to detect that iodine deficiency 
and radiation dose from the Chernobyl 
fallout acted jointly, with a twofold higher 
excess relative risk observed in areas of 
Ionizing radiation: type of radiation (e.g., x-rays 
or g-rays) that has the ability to penetrate 
material inducing a process called ionization (any 
process by which a neutral atom or molecule gains or 
loses electrons, acquiring a net charge). It comes from 
radioactive materials or radiation generators.
Gray (Gy) is the unit of the International Unit 
System. Radiation dose absorbed by a specific 
organ or tissue per unit of mass.
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severe iodine deficiency compared with iodine-sufficient areas [5]. Thirty-
six years after the accident, thyroid cancer risk in exposed young people 
continues to be significantly elevated.
Curiously, diagnostic or therapeutic use of radioiodine did not show 
evidence of increased risk of thyroid cancer; this may simply be related to 
radiation exposure at an older age when the thyroid has a lower sensitivity 
to the carcinogenic effects of radiation [6,7], or to the dose applied, which 
results mainly in a cytotoxic effect.
Evidence for the etiopathogenic role of external radiation for thyroid 
cancer came from studies of atomic bomb survivors and from cohorts 
of individuals subjected to therapeutic or esthetic external radiation. 
Between 1920 and 1960, external radiation was used for a variety of 
head and neck benign conditions, namely x-ray scalp epilation for tinea 
capitis treatment. This kind of procedure has been shown to increase 
the risk for thyroid cancer [8,9]. By conducting a retrospective and 
prospective study in a Portuguese cohort subjected to x-ray scalp 
epilation for tinea capitis treatment, we observed an increased prevalence 
(2.6%) of thyroid cancer [9]. Sadetzki et al., in a retrospective study 
performed in a similar cohort from Israel, found a thyroid cancer 
prevalence of 0.95% in the irradiated individuals compared with 0.35% 
in two matched nonirradiated groups [8]. 
Presently, people still can be exposed to (external or internal) radiation, 
namely in the setting of incidental nuclear accidents (as recently verified 
in Fukushima, Japan), radiotherapy, diagnostic examinations and selected 
occupations (e.g., radiologists). 
Among the atomic bomb survivors, thyroid cancer was one of the earliest 
solid cancers linked to external radiation exposure [1,10]. Radiotherapy for 
head and neck cancers, thorax cancers, lymphomas, breast cancers and 
whole-body irradiation may expose the thyroid to radiation due to its 
anatomical position [4]. Treatment-related secondary cancers are becoming 
a disturbing problem as survival from the majority of childhood cancers is 
relatively high and is continuing to improve [11]. An update from the 
Childhood Cancer Survivor Study confirmed the previously established 
dose–response relationships and estimated odds ratios for the development 
of thyroid cancer after high-dose therapy in childhood (odds ratio: 9.8; 
95% CI: 3.2–34.8), as well as the fall-off risk at doses exceeding 20–25 Gy, 
thought to be attributable to cell killing [12].
Presently, diagnostic computed tomography (CT) scanning is the major 
source of x-ray exposure by medical means [13]. CT involves much larger 
radiation doses compared with conventional x-ray imaging procedures; 
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the typical organ dose from a CT scan is 0.01–0.02 Gy [11]. There is increasing 
concern regarding radiation exposure to the thyroid gland from pediatric 
CT scans, especially if an iodinated contrast is used. It appears that many 
physicians are ill-informed about the risks of diagnostic examinations using 
radiation, so there is a clear need to educate the medical profession and 
the general public about the risks regarding CT imaging [11].
Although there are some differences between internal and external 
radiation exposure, the magnitude of excess cancer risk and the findings 
for effect modification by age at exposure and gender are generally 
compatible.
Risk factors for irradiation-induced thyroid cancer: age, gender 
& dose
A major risk factor for radiation-induced thyroid cancer is young age at 
exposure – the maximum risk is when the exposure occurs below the age 
of 5 years; above the age of 15–25 years the risk is only slightly increased 
compared with adults [6]. Importantly, the excess risk persists for at least 
40 years after exposure [8,14].
It has been suggested that children develop radiation-related cancer more 
often than adults because their tissues are actively growing and cells are 
dividing more rapidly, so they are more susceptible to the mutagenic 
effects of radiation [1,11]. Moreover, children have a longer life expectancy 
compared with adults, therefore presenting a longer period for the 
expression of radiation-induced cancers. Consequently, the adverse effects 
of radiation are much greater in children than in adults. Keeping this line 
of thought, one could expect the fetus to be highly vulnerable to radiation 
exposure. However, information about thyroid cancer risks associated with 
in utero exposure to Chernobyl fallout is very limited [5]. Clearly, this issue 
will need additional research to establish the relative radiosensitivity of 
the prenatal versus the postnatal versus the adult thyroid gland [11].
PTC affects women more than men, although until puberty the sex ratio 
is relatively equal [1]. It is predicted that, in the near future, thyroid cancer 
will be one of the five leading causes of new cancers in women, representing 
5% of all cancers [15], and the fastest growing cancer in this gender [2]. The 
additional risk of thyroid cancer in radiation-exposed individuals was 
estimated to be 4–12-times higher in females than in males [6]. A higher 
radiosensitivity in women has been discussed but the mechanisms 
underlying that radiosensivity are not yet established. 
The question of gender as a risk factor for thyroid cancer has been puzzling 
since, in spite of the clearly increased risk in women, it seems that the 
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disease may be more aggressive in men [1]. It is also important to refer to 
the fact that prepubertal and postmenopausal incidence rates are no 
greater in women than in men, so it has been repeatedly suggested that 
the female preponderance may be due to estrogen or other gender-related 
hormonal factors. 
Any irradiation to the thyroid involving more than 0.5 Gy, in particular during 
childhood, should be viewed with concern [3]; for some authors, doses as 
low as 0.05–0.1 Gy may cause apprehension [8,14]. With the data presently 
reported in the literature, there remains uncertainty about the doses of 
irradiation that the thyroid tolerates, as well as about the dose–volume and 
dose–time relationships [4]. Therefore, it is recommended that the radiation 
dose that the thyroid will receive in the diagnostic and/or therapeutic 
context is limited.
Radiation-induced thyroid cancer: biological & genetic aspects
The mechanisms through which radiation induces thyroid tumors are still 
poorly understood [6]. Moreover, it is not known with certainty whether 
radiation-related thyroid cancer has the same clinical behavior as sporadic 
thyroid cancer [11]. Some studies find radiation-related thyroid tumors as 
being frequently multifocal, although they do not demonstrate that these 
differences imply a different tumor behavior; on the contrary, other studies 
suggest that these tumors present a more aggressive clinical course [11].
Histological differences have also been reported. PTC was the most 
common histological type found among post-Chernobyl cases and the 
tumors were more often of the solid/follicular subtype than of the classical 
papillary type [5]. The solid architecture, exclusively or admixed with other 
architectural patterns, commonly observed in the post-Chernobyl cases, 
is less frequent in thyroid tumors without history of radiation exposure [2].
Concerning molecular alterations, the most common mutational mechanism 
in radiation-induced thyroid tumors consists of chromosomal 
rearrangements, notably the RET/PTC rearrangements, which can be found, 
in some series, in up to 80% of these tumors (Table 4.1) [2,6]. In sporadic 
nonirradiated thyroid tumors, the frequency of these rearrangements can 
be as low as 5–15% [6]. In sporadic tumors, the most prevalent mutation 
mechanism is point mutation, typically involving the BRAF and RAS genes [2]. 
BRAF mutations are infrequent events in thyroid cancers from subjects 
exposed to radiation, both internal and external [16,17]. BRAF mutations and 
RET/PTC rearrangements are usually alternative events in the etiopathogenesis 
of PTC [18], but recently Dinets et al. found the co-occurrence of RET/PTC and 
BRAF mutation in four PTCs from post-Chernobyl cases [19].
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Efforts are being made to develop strategies that would distinguish a 
thyroid carcinoma caused by radiation from one that is not, as neither the 
histological features nor the genetic alterations observed in these tumors 
have shown to be specific fingerprints of exposure to radiation [20]. Ory 
et al., using microarray transcriptome profiles, identified a signature of 
322 genes that allowed the discrimination of postradiotherapy-induced 
tumors from their sporadic counterparts, with an efficacy of 90% [20]. They 
suggest that the same strategy could be applied to classify post-Chernobyl 
thyroid tumors.
Clinical management of radiation-related thyroid tumors
All subjects exposed to radiation during childhood should be submitted to 
a life-long follow-up that will take into account the risk factors for 
developing a thyroid carcinoma: female gender, a young age at irradiation, 
high irradiation dose, and personal or family history of radiation-associated 
tumors [6]. In this follow-up, neck palpation and neck ultrasonography 
should be performed every 1–3 years, depending on the risk factors. 
Thyroid nodules ≤1 cm only need to be controlled with ultrasonography 
6–12 months later. Any thyroid nodule ≥1 cm should be submitted to a 
fine-needle aspiration biopsy; the results will decide on the need for 
further treatment (including surgery). 
Imaizumi et al., in a long-term follow-up study, demonstrated a high risk 
for thyroid cancer in atomic bomb survivors with solid thyroid nodules 
compared with nodule-free survivors [21]. Therefore, in accordance with 
what was reported by Rubino et al. [6], they proposed that irradiated 
individuals with thyroid nodules should be followed carefully, not only by 
ultrasonography but also by biopsy, irrespective of age, sex, thyroglobulin 
level, thyroid-stimulating hormone (TSH) level, thyroid radiation dose or 
nodule volume, because none of these factors predicted the development 
of cancer. They recommend at least biennial follow-up, even if the nodules 
are diagnosed as benign [21].
Table 4.1. The most frequent genetic alterations in sporadic versus radiation-
associated thyroid cancer.
Cancer type BRAF mutations 
(%)
NRAS mutations 
(%)
RET/PTC rearrangements 
(%)
Sporadic thyroid cancer 30–69 10–20 5–40
Radiation-associated 
thyroid cancer
4–24 ND 50–80
ND: Not defined.
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Endocrine disruptors
The relationship between thyroid 
dysfunction and cancer has been studied 
for years and there is now evidence that 
points to a bilateral association linking 
both. Thyroid dysfunction triggered by factors such as endocrine disruptors 
may ultimately contribute to cancer, whereas thyroid cancer may induce 
dysfunction of the thyroid gland.
The endocrine disruptor hypothesis was postulated in the early 1990s, 
when a report linked fetal exposure to the synthetic estrogen 
diethylstilbestrol with the development of a very rare clear-cell carcinoma 
of the vagina. It did not take long to realize the complexity of the effects 
upon exposure to endocrine disruptors.
The group of molecules identified as endocrine disruptors is very 
heterogeneous and can adversely impact a number of hormonal 
systems. In a scientific statement published by The Endocrine Society, 
the endocrine disruptors are defined as “compounds natural or synthetic 
which through environmental or inappropriate developmental 
exposures alter the hormonal and homeostatic systems that enable the 
organism to communicate with and respond to its environment” [22]. 
The statement supports the relationship connecting environmental 
exposure to the disruptors with effects not only on the endocrine but 
also on the nervous system.
Concerning the thyroid, it has been shown that thyroid disruptors (TDs), 
ranging from industrial chemicals to natural substances, may interfere with 
the complex regulatory system of the thyroid. Broadly defined, TDs are 
capable of altering the structure and function of the thyroid gland and of 
the regulatory enzymes associated with thyroid homeostasis, or changing 
the circulating and tissue concentrations of thyroid hormones [22]. 
Howdeshell [23] and Bruker-Davis [24] extensively reviewed many TDs and 
summarized the effects of these chemicals on thyroid metabolism by citing 
wildlife and experimental animal and human studies. We will next focus 
on the more relevant TDs.
Perchlorates & polychlorinated biphenyls as TDs
Perchlorate is a chemical found naturally in the soil that has been used as 
an oxidant in solid rocket propellants, ordnance, fireworks and airbag 
systems, for example. Its environmental stability has led to contamination 
in drinking and irrigation waters and in food [25]. The effects of perchlorate 
as a TD were extensively studied in animal models, and the main effect is 
Endocrine disruptors: substances in the 
environment, food and consumer products 
that interfere with the synthesis, secretion, transport, 
metabolism, binding action or elimination of the 
hormones responsible for homeostasis.
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competitive inhibition of the sodium iodide symporter (NIS), leading to 
triiodothyronine (T3) and thyroxine (T4) suppression [24,26]. In fact, 
perchlorate has been used in the treatment of hyperthyroidism. Blount 
et al. reported that increased levels of urinary perchlorate were found to 
be predictive of significantly lower levels of serum T4 and significantly 
higher levels of serum TSH in women with urine iodine concentrations 
below 100 µg/l (median level that indicates a prevalence of goiter in a 
population due to dietary iodine insufficiency). Nevertheless, urine 
perchlorate was only a significant positive predictor of serum TSH, but not 
serum T4, in females with urinary iodine above 100 µg/l. The same study 
observed a significantly greater effect of perchlorate on serum T4 in 
smokers, which may reflect a cumulative effect of perchlorate and 
thiocyanate, the latter being a metabolite of the goitrogen substance 
cyanide found in cigarettes [27]. Of note, increased levels of thiocyanate 
are associated with an increased thyroid volume and a higher risk for goiter 
development [28].
Exposure to perchlorate and other NIS competitors including nitrate and 
thiocyanate may have a significant effect on thyroid hormones, particularly 
in an iodine-insufficient dietary environment. Since infants are vulnerable 
to thyroid hormone insufficiency, and because breast milk is believed to 
have high levels of perchlorate, it was of concern that this chemical may 
affect thyroid hormone signaling in early developmental stages, although 
consistent studies failed to show such a relationship [22]. Other studies were 
less successful in finding a significant relationship between perchlorate 
exposure and thyroid parameters.
Polychlorinated biphenyls (PCBs) are industrial organochlorine compounds 
that exist in a variety of congeners, paired phenyl rings with various 
degrees of chlorination; their effect is congener-specific (dependent on 
the number and structural relation of chlorine atoms in the molecule). 
PCBs were phased out in the mid 1970s owing to their carcinogenic 
potential but these chemicals still persist in the environment by resisting 
to molecular degradation. The most threatening PCBs are those with a 
higher degree of chlorination at meta- and para-positions, owing to its 
structural resemblance to T4 and its persistence in human and animal 
tissues [29]. PCBs were shown to affect thyroid function on many levels: 
reduce the ability of thyroid hormones to bind to transthyretin (TTR), 
since they are a potent competitive inhibitor; upregulate liver enzymes 
that metabolize thyroid hormones; inhibit or upregulate the production 
of deiodinases, which convert T4 to T3; and act as an agonist or antagonist 
on the thyroid receptor site [30]. Most studies have shown an inverse 
relationship between PCB exposure levels and serum levels of total T3, 
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total T4 and TSH; however, not all studies have agreed on the extent of 
the effects of thyroid disruption by PCBs. Unquestionably, PCBs are 
directly implicated in lower circulating levels of thyroid hormones, 
especially T4, and in thyroid toxicity [29], but the consequences of PCB 
exposure appear to be more complex given the 209 possible different 
chlorine substitution patterns on the bisphenyl backbone and derived 
metabolites [22].
PCB congeners can also affect gene expression in the brain by mimicking 
the effect of thyroid hormone, and can exert neurotoxic effects on the 
developing brain by causing a state of relative hypothyroidism [22]. Thus, 
the PCB effect is not directly restricted to the thyroid gland.
2,3,7,8-tetra-chloro-dibenzo-p-dioxin (TCDD) is thought to be the most 
toxic polychlorinated dibenzo-para-dioxin congener. In mice and rats, TCDD 
decreases T4 and increases TSH, and causes follicular cell adenomas of the 
thyroid gland, as well as carcinomas and fibrosarcomas in different 
sites [26,31]. Data from humans are scarce and come from cohort studies of 
populations exposed to industrial exposures and accidents, but the 
evidence is still limited. A cohort study revealed two cases of thyroid cancer 
out of 104 cancer cases, on an area contaminated with less than 5 µg/m2 
of 2,3,7,8-TCDD, due to an industrial accident. Other studies showed a 
significant increase of thyroid cancer in workers exposed to 2,3,7,8-TCDD 
compared with those nonexposed [31] and a significant increase in TSH 
levels for the group of war veterans with the highest exposure to 
2,3,7,8-TCDD [26].
Impact of TDs on the thyroid axis
TDs may interfere with the regulatory network of thyroid hormone 
synthesis, metabolism and distribution, and affect various levels of 
endocrine regulation and feedback control (Table 4.2), namely by:
n	Inhibiting the iodide uptake at the follicular cell membrane
n	Compromising the production and interconversion of thyroid hormones 
n	Disturbing the transport of thyroid hormones in the bloodstream 
n	Altering the enzyme-regulated metabolism of thyroid hormones 
n	Changing the thyroid receptor activity
Therefore, major targets of endocrine disruptors within the thyroid axis 
are the NIS, hemoprotein thyroperoxidase (TPO), the T4 distributor pro-
tein TTR, the deiodinases, the thyroid hormone-conjugating enzymes and 
the thyroid hormone receptor family (Figure 4.1).
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The first step in thyroid hormone biosynthesis is the uptake of iodide into 
the follicular cell, which is mediated by the plasma membrane transport 
protein, the NIS. NIS (and possibly other auxiliary proteins responsible for 
building up the sodium gradient across the cell membrane) can be affected 
by TDs such as perchlorate, thiocyanate, bromate and nitrate, which, by 
competing with iodine for binding to the NIS, inhibit the uptake of iodide. 
It is likely that their disruptor effect on iodide uptake is dependent on the 
presence and concentration of other NIS inhibitors as well as iodine itself, 
Table 4.2. The most important thyroid disruptors, their mechanisms of 
action and effects on thyroid hormones.
Thyroid disruptor Mechanism Effect on THs
Perchlorate, thiocyanate, 
bromate, nitrate
Competition with 
NIS
Decreased T3 and T4 
synthesis
Methilmazole, amitrole, 
ehylenothiourea, mancozeb, 
benzophenone-2 and 
methylmercaptoimidazole, 
isoflavones and flavonoids
Blocking production 
and inhibition of 
TPO
Decreased T3 and T4 
synthesis
PCBs, flame retardants, 
phthalates, the pesticide 
metabolite pentachlorophenol, 
synthetic flavonoids and 
plasticizers including bisphenol A
Competitive binding 
to TTR
Decreased T4 levels and 
compromise of fetal 
brain T4 production
Hydroxyl PCBs, flame retardants, 
tetrabromobisphenol A and 
bisphenol A and dioxins
Altering binding to 
thyroid receptor
Altered activation of 
thyroid hormone-
dependent gene 
transcription
PCBs, FD&C red dye #3, octyl-
methoxycinnamate, the pesticide 
methoxychlor and the toxic 
metals cadmium and lead
Inhibition of 
deiodinase activity
Decreased peripherical 
T3 synthesis
Hydroxylated PCBs, triclosan, 
pentachlorophenol, dioxins, 
acetochlor, phenobarbital, 
3-methylcoanthrene and 
bisphenol A
Inhibition of 
diphosphoryl-
glucuronosyl- and 
sulfo-transferases 
and enhanced 
hepatic metabolism
Deregulation of 
peripherical levels of T3 
and increased biliary 
excretion of T3 and T4
Dichlorodiphenyltrichloroethane, 
PCBs
Inhibition of TSH 
receptor
Decreased T3 and T4 
production
FD&C: Food, Drug and Cosmetics; NIS: Sodium iodide symporter; PCB: Polychlorinated 
biphenyl; T3: Triiodothyronine; T4: Thyroxine; TH: Thyroid hormone; TPO: Thyroperoxidase; 
TSH: Thyroid-stimulating hormone; TTR: Transthyretin.
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as it has been observed for perchlorate [32]. The effect of NIS disruptors is 
a decrease of T3 and T4 synthesis and they may exacerbate problems of 
iodine deficiency [25]. Of note, iodine deficiency, which has been associated 
with the risk of thyroid cancer and downregulation of NIS expression 
(observed in thyroid adenomas and carcinomas), when combined with the 
effect of disruptors of NIS activity can also be relevant in the carcinogenesis 
process.
TPO is an enzyme that plays a central role during thyroid hormone (T3 and 
T4) synthesis and is stimulated by the presence of TSH. Some TDs, namely 
Figure 4.1. Major targets of disruption by endocrine disruptors within the thyroid hormone axis.
Hypothalamus
Pituitary
Thyroid cell
NIS
T3 and T4
Tyrosine
TRH
+
TRH
TH TH
TH
TTR
Deiodinases
TSH
+
-
- +
Thyroid-sensitive cell
UGT and SULT
Liver
Blood
Peripheral tissues
Biliary excretion
I I
TPO
The NIS, the hemoprotein TPO, the T4 distributor protein TTR, the deiodinases, thyroid hormone-conjugating 
enzymes UGT and SULT, and the thyroid hormone receptor family are major targets of endocrine disruptors. 
I: Iodine; NIS: Sodium iodide symporter; SULT: Sulfotransferase; T3: Triiodothyronine; T4: Thyroxine; 
TH: Thyroid hormone; TPO: Thyroperoxidase; TRH: Thyrotropin-releasing hormone; TSH: Thyroid-stimulating 
hormone; TTR: Transthyretin; UGT: Uridine 5’-diphospho-glucuronosyltransferase.
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methilmazole, amitrole, ehylenothiourea, 
mancozeb, benzophenone-2 and 
methylmercaptoimidazole, appear to be 
able to inactivate TPO in one of at least 
three ways: 
n	By a reversible interaction that does not involve covalent binding; 
n	By an irreversible interaction requiring de novo synthesis of enzyme to 
restore its activity; 
n	By inhibiting the production of TPO. Thus, the synthesis of thyroglobulin 
and the production of T3 and T4 are compromised [33,34]. 
Furthermore, TPO seems to be a target of goitrogens, which are present 
in nutritive sources such as isoflavones, especially those found in soy 
protein, and also flavonoids. There is evidence of a mutual enhancement 
of the effects of iodine deficiency and nutritional or environmental 
goitrogens, probably via the inhibition of TPO, thus promoting goiter 
development, which has been related to thyroid neoplasia [28,30].
To maintain an extrathyroidal pool of thyroid hormones available for 
cellular use, transporter proteins bind to the T4 released in the bloodstream 
by the follicular cells. One of the transporter proteins is TTR. TTR binds to 
only 15–20% of the circulating T4 but it is crucial to deliver T4 across the 
blood–brain barrier and through the placenta. T4 binding to TTR is known 
to be very sensitive to the interference of endocrine disruptors, such as 
PCBs, flame retardants, phthalates, the pesticide metabolite 
pentachlorophenol, synthetic flavonoids and plasticizers including 
bisphenol A (some have higher affinity to TTR than T4 does itself). Disruptors 
binding to TTR may not only decrease the levels of T4 and the availability 
of thyroid hormones to various tissues, but also be targeted for transport 
and uptake [26]. As for TPO, flavonoids are also known to be potent 
competitors for T3 and T4 binding to TTR [28].
To exert its biological function, T3 binds to nuclear thyroid receptors inside 
the target cells, and those receptors act as signal transducers to initiate 
intranuclear changes in the metabolism of the cell. Hydroxyl PCBs, flame 
retardants (tetrabromobisphenol A and bisphenol A) and dioxin can 
activate or inhibit the cellular uptake of thyroid hormones, therefore 
altering the nuclear thyroid receptor activity and gene transcription. Biliary 
excretion of both T3 and T4 could also possibly be increased [26,30].
Deiodinase enzymes, which control the production and recycling of thyroid 
hormones, are sensitive to the interference of PCBs, Food, Drug and 
Cosmetics (FD&C) red dye #3, octyl-methoxycinnamate, the pesticide 
Goitrogens: substances that inhibit the 
synthesis of the thyroid hormones. This results 
in increased levels of thyrotropin, which excessively 
stimulates thyroid cell growth, thereby causing goiter. 
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methoxychlor and the toxic metals cadmium and lead. By altering the 
enzymatic activity, these disruptors lead to a decrease of peripheral 
synthesis of T3 [26].
Besides deiodinases, a number of diphosphoryl-glucuronosyl transferase 
or sulfotransferase isoenzymes are responsible for the metabolism of 
thyroid hormones in the liver, enabling the biliary clearance of glucuronide 
or sulfate conjugates of T4 or T3 [30]. Once again, hydroxylated PCBs, 
triclosan, pentachlorophenol, dioxins, acetochlor, phenobarbital, 
3-methylcoanthrene and bisphenol A inhibit the enzymes responsible for 
detoxification reactions of thyroid hormones, thus deregulating the 
peripheral levels of T3 and T4 and increasing their biliary excretion [26,30]. 
An increase in both the metabolism and clearance of T3 could also result 
in a goiter, as the thyroid gland compensates to maintain proper hormone 
levels [24].
Finally, both TSH and thyrotropin-releasing hormone were found to be 
affected by TDs, mainly through receptor-binding inhibition mechanisms, 
compromising the upregulation of metabolism and T3 and T4 production [26]. 
Of note, one of the most sensitive determinants of thyroid dysfunction is 
the measurement of serum TSH. Triggered by TDs, elevated TSH levels, as 
well as iodine deficiency, may induce both goiter growth and the 
development of thyroid nodules [35]. To date, some epidemiological studies 
have reported a strong association between serum TSH levels and the risk 
of malignancy in thyroid nodules and have shown that serum TSH 
concentration, even within the normal range, is an independent predictor 
of the presence of thyroid malignancy [36–38]. This could be explained by 
the trophic effect of TSH on thyroid cancer growth, which is likely to be 
mediated by the TSH receptors present on tumor cells [36]. Moreover, a 
lesser degree of TSH suppression is associated with an increased incidence 
of relapse of differentiated thyroid tumors since these usually retain 
responsiveness to TSH [39,40]. Therefore, TSH suppression is also an 
independent predictor of relapse-free survival, and the prognosis is 
improved with a greater level of TSH suppression on well-differentiated 
tumors [39,40], which seems to slow down tumor progression.
To summarize, TDs can elicit their own spectrum of alterations on nearly 
every step of the production and metabolism of thyroid hormones by 
altering the gland function and regulation (Table 4.2) [24]. A prolonged 
disruption of the pituitary–thyroid axis may be linked to thyroid 
neoplasia [34]. However, not every TD promotes the development of thyroid 
neoplasia, as some compensatory mechanisms may ensure a still normal 
thyroid function, probably as long as the iodine supply is adequate [28].
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